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Classical Hodgkin lymphoma (cHL) is assumed to be a curable tumor, but an important 
fraction of patients with advanced disease do not respond favorably to the standard 
chemotherapy regimens based on adriamycin and current predictive systems, based on clinical 
and analytical parameters, fail to accurately identify these high risk patients. Thus, the 
identification of biomarkers associated with treatment response remains a critical challenge in 
this lymphoid malignancy.  
cHL represents a distinctive model of histological complexity, with a minor population 
of the characteristic tumor cells, the Hodgkin and Reed Sternberg cells (HRS) diluted in a 
complex reactive inflammatory background. The intrinsic relationship between the HRS cells 
and their microenvironment is only partially understood but important advances in the 
understanding of the cHL pathophysiology are being made. Indeed, microarray expression 
studies of tumor samples have led to the identification of signatures and biological processes 
associated to Hodgkin´s lymphoma pathogenesis and treatment response, showing that 
outcome in cHL patients could be related with both biological characteristic components of 
cHL tumors. However, no steps towards the translation of gene profiling results into routine 
clinical practice have been made. 
This study identified gene subsets expressed either by the tumoral HRS cells and the 
Hodgkin´s microenvironment showing that robust methodologies based on quantitative real-
time-PCR- (RT-PCR) assays are suitable for expression profiling of tumors and can be easily 
applied to paraffin-embedded samples. By a sequential analysis process, functional gene 
signatures associated with treatment response were first identified and finally a quantitative 
RT-PCR assay for patients with advanced cHL was described, incorporating a limited number of 
genes and pathways from tumor and microenvironment cell components, designed for 
application to routine formalin-fixed paraffin-embedded samples. This model was able to 
identify patient subgroups with highly different probabilities of treatment failure. Additionally, 
it was able to incorporate one of the well established clinical variables (Stage IV), thus 
integrating the main biological and molecular characteristics of the tumors related with 
treatment response and the tumor burden estimation in a single scoring system.  
MicroRNAs (miRNAs) have been described to be essential regulators of cell 
differentiation and biological processes, emerging as robust predictor and prognostic markers. 
Specific signatures from the HRS cells and their microenvironment have been proposed, but 
the potential prognostic role of them remains unclear. Thus, this study additionally 
investigated whether miRNA signatures could allow to a better understanding of cHL 
pathogenesis and identified a cHL miRNA signature related to treatment response.  
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El linfoma de Hodgkin clásico presenta en general una alta tasa de curación, sin 
embargo una importante proporción de pacientes con estadios avanzados presentan 
quimiorresistencia a los protocolos quimioterapéuticos actuales basados en adriamicina (ABVD 
y variantes). Los sistemas pronósticos disponibles en la actualidad, basados en parámetros 
clínicos y analíticos como el IPS (International Prognostic Score, Índice Pronóstico 
Internacional), fallan a la hora de identificar una importante fracción de estos pacientes. Así, el 
empleo de técnicas moleculares robustas y la identificación de marcadores asociados con fallo 
terapéutico es esencial para el desarrollo de nuevas herramientas que permitan un diagnóstico 
de mayor precisión. 
Asimismo, esta neoplasia linfoide representa un modelo único de complejidad 
histológica, se diferencia de la mayoría de las neoplasias malignas en su especial composición 
celular, de forma que en la masa tumoral las células neoplásicas (células de Hodgkin y Reed-
Sternberg, HRS) son minoritarias mientras que el componente mayoritario está constituido por 
células inflamatorias .La compleja interacción existente entre las células neoplásicas y el 
microambiente tumoral no ha sido del todo elucidada si bien importantes avances en su 
conocimiento han sido realizados recientemente. De hecho, estudios de expresión génica han 
permitido la identificación de firmas moleculares asociadas a los fenómenos biológicos 
característicos de su patogenia y respuesta terapéutica, señalando la importancia de ambos 
componentes tumorales en la respuesta a terapia. Sin embargo, estos descubrimientos no han 
sido trasladados a la práctica clínica.  
En el presente estudio, se identificaron firmas moleculares atribuibles tanto a las 
propias células tumorales como a su correspondiente microambiente, demostrando la 
idoneidad y potencial aplicación de ensayos basados en PCR cuantitativa para el análisis de 
muestras parafinadas. Se identificaron las rutas biológicas y genes característicos de cada uno 
de los componentes tumorales asociados a fallo terapéutico, y se desarrolló un ensayo de PCR 
cuantitativa capaz de identificar grupos de pacientes con distintas probabilidades de fallo. 
Asimismo, la inclusión de variables clínicas (Estadio IV) permitió el desarrollo de un modelo 
predictivo final combinando en un único sistema tanto características moleculares propias del 
tumor (genes) como factores relacionados con la masa tumoral.  
Por otro lado, el estudio de microRNAs dentro del linfoma del Hodgkin ha permitido la 
identificación de firmas de microRNAs característicos sin estudiar su potencial predictivo. Dado 
su crucial papel en regulación se estudió la relevancia de su expresión dentro del contexto de 
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la enfermedad y su potencial poder predictivo identificándose finalmente una firma de 
microRNAS asociados a fallo terapéutico. 
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1.1 Lymphomas. 
Lymphomas are neoplasms derived from either B or T lymphocytes. They represent around 
4-5 % of all diagnosed cancer cases in industrialized countries with an annual incidence rate of 
120,000 new cases in Europe (7.000 in Spain) and 70.000 in United States of America (USA) 
based on data from the Surveillance Research Program of the National Cancer Institute of 
United States (NCI). Noteworthy, this incidence has grown since the last decades and 
according to the SEER (Surveillance, Epidemiology and End Results, http://seer.cancer.gov/ ), 
it´s estimated that 74.030 men and women (40.050 men and 33.980 women) were diagnosed 
and 21.530 men and women died of lymphoma in 2010 in USA. 
The term “lymphoma” comprises a complex group of malignancies that includes more 
than 40 subtypes classified by the World Health Organization (WHO) attending to their 
morphology, immunophenotype and genetic characteristics. This distinction is not only 
relevant in terms of lymphoma pathogenesis; it also defines different clinical behaviors 
therefore determining treatment strategies. Although lymphoma classification is dynamic and 
frequent revisions are published, there are two major categories recognized: 
A. Non-Hodgkin lymphoma (NHL), that constitute around 87.5% of all lymphomas and 
include neoplasms derived from either B or T/Natural killers cells (T/NK); with B-cell 
lymphomas representing around 90% of the total NHL cases. 
B. Hodgkin lymphoma (HL), the first type of lymphoma described (Thomas Hodgkin, 
1832) in which this thesis work has been focused. 
Lymphoma classification is complex with an extension out from the scope of this work. 
This doctoral thesis is focused on HL. Thus, its main biological and clinical characteristics are 
described along this chapter. 
1.2 Hodgkin Lymphoma. 
Hodgkin lymphoma (HL) is a lymphoid neoplasm first described in patients in 1832 by 
Thomas Hodgkin. It´s relatively rare and according to the Leukemia and Lymphoma Society, 
Hodgkin Lymphoma represents about 11% of all lymphoma diagnoses. Approximately 8.000 
cases (4.400 males and 3.820 females) of Hodgkin's Lymphoma are detected per year, thus 
representing less than 1% of all cancers. Nevertheless, this is a still a significant disease 
worldwide and around 1.000 new cases per year are diagnosed in Spain (National Spanish 
Statistic Institute data, www.ine.com ).  
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The WHO Classification of HL (Table 1.1) defines two clinical, pathological and biological 
disease entities: classical Hodgkin lymphoma (cHL) (representing 95% of all cases) and nodular 
lymphocyte predominant Hodgkin lymphoma (NLPHL). So-called classical HL is the one further 
studied in this work and includes different histological subtypes: Nodular sclerosis (NS), mixed 
cellularity (MC), Lymphocyte rich (LR) and Lymphocyte depleted (LD) with nodular sclerosis 
and mixed cellularity accounting for the majority of classical HL cases. 
Table 1.1 WHO 2008 classification of Hodgkin lymphoma 
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) 
Classical Hodgkin lymphoma (cHL) 
              Nodular sclerosis  (NS) 
              Mixed cellularity  (MC) 
              Lymphocyte rich  (LR) 
              Lymphocyte depleted  (LD) 
 
1.2.1 Epidemiology 
The distinguishing epidemiological feature of Hodgkin lymphoma is its bimodal age 
incidence curve characteristically seen in economically advantaged populations such as in 
United States, where the majority of patients are young adults. With a relatively few number 
of cases in children, there is a rapid increase of incidence rates among teenagers peaking at 
about 25 years. Incidence rates decline through middle age, after which they increase again 
with advancing age. However, in developing countries this bimodality disappears and a high 
incidence rate during childhood is observed. 
A large number of studies point out a possible viral infectious etiology for HL.  Several 
clinical features of the disease, such as fever, night sweats, and lymphoadenopathy, have 
suggested an infectious etiology to investigators from the time of its first description 
(Gutensohn, 1982; Mueller, 1992). However, most of them are not conclusive with exception 
of Epstein-Bar virus (EBV). Great interest in the disease has been generated by the use of 
molecular methods to identify the frequent presence of the Epstein-Barr virus genetic material 
in tumor specimens (Weiss et al., 1987).  The Epstein-Barr virus, a human herpesvirus that is 
the cause of infectious mononucleosis, was first isolated from a Burkitt lymphoma tumor 
specimen. Scientific data linking this virus with Hodgkin lymphoma have become strong 
enough for the International Agency for Research on Cancer (IARC) in 1997 to classify the 
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Epstein- Barr virus as a group 1 carcinogen ( that is, “ the agent is carcinogenic to humans” ) for 
HL, thus validating the intuition of previous generations of scientific investigators.  
Other data suggest genetic epidemiological factors. Although not recurrent genetic 
abnormalities have been described, familial aggregation and genetic susceptibility play 
important roles in the causation of Hodgkin lymphoma. Thus, it´s well established that first-
degree relatives of patients with HL have about three fold increased risk of developing the 
disease (with a higher risk in identical twins, 100 fold higher (Mack et al., 1995)) 
1.2.2 Classical Hodgkin lymphoma. Histopathology and immunophenotype 
cHL is a tumor composed by a heterogeneous cell composition with characteristic 
neoplastic cells (so called Hodgkin and Red Sternberg cells, HRS ) diluted in a reactive 
inflammatory background composed of non-neoplastic B and T cells, macrophages, 
eosinophils,  neutrophils, plasma cells and fibroblasts (Jaffe et al., 2001; Pileri et al., 
2002).These tumoral cells are present in a low percentage (5-10%) within the reactive 
inflammatory background. 
The diagnosis of cHL is established with the identification of these characteristic HRS 
cells (large cells, either with a large poliploid nucleus or multinucleated) in the appropriate 
cellular milieu. At the current time, definitive diagnosis can be made either by morphologic 
assessment alone, or by morphologic assessment combined with immunohistochemical 
studies, thus diminishing the importance of the definitive identification of diagnostic HRS cells. 
From an immunohistochemical point of view, HRS cells harbor an immunophenotype 
not similar to any kind of normal hematopoietic cells. They express proteins that are 
characteristic to several cell types, such us granulocytes (CD15), T lymphocytes (perforin, 
Notch-1), memory B cells (syndecan) and dendritic cells (fascin, CCL17) whereas typical 
markers of B cell lineage are not observed with the exception of PAX5 (paired box 5, B cell 
specific trasncription factor )  which is expressed in almost all cases. Most of the cases (around 
89%) overexpress CD30 which is commonly used as a diagnostic marker (Figure1.1). In 
contrast, tumoral cells for the NLPHL type express specific B cells markers (immunoglobulin, 
CD19, CD20, CD79A and the B cell specific transcription factors PAX5, OCT2 and BOB1), 
including some for the germinal center markers ( BCL6,  AICDA).(Jaffe et al., 2001; Pileri et al., 
2002). 
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Figure 1.1 Immunophenotype of HRS cells. Hematoxilin-eosin stained paraffin sections (H/E; either 
mononucleated or multinucleated cells) and immunohistochemical markers for CD30, CD15 and B cell 
markers (CD20 and CD79A).As commented, HRS cells don’t express B specific markers (CD20 and CD79). 
1.2.3 Biology of classical Hodgkin lymphoma. 
This lymphoid malignancy is considered to be a monoclonal proliferation of the 
characteristic HRS cells. It has a defective B-cell inmunophenotype and a characteristic paucity 
of the HRS cells within the tumor. The scarcity of HRS cells (5-10%) accounting for the majority 
of cases has limited molecular studies by conventional techniques, thus being cellular origin of 
HRS cells an intriguing issue during a long time. However, the B-cell origin and the 
monoclonality of the HRS cells have been clearly established in the last two decades by several 
studies (Kanzler et al., 1996a; Kuppers et al., 1994; Marafioti et al., 2000) 
1.2.3.1 Cellular origin of HRS cells. 
The origin of the HRS cells was finally clarified when microdisecction and single-cell 
PCR methods were applied to individual HRS cells to analyze them for immunoglobulin or TCR 
rearrangements. This rearrangements are highly diverse and specific for either B or T cells, 
thus being ideal markers for the elucidation of either  B- or T-cell origin (Rajewsky, 1996). HRS- 
Single cells studies allowed the identification of clonal immunoglobulin gene rearrangements 
in nearly all cHL cases, thus establishing their clonality and B-cell lineage origin(Kanzler et al., 
1996b; Kuppers et al., 1994; Marafioti et al., 2000). Nearly all cases carried somatically 
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mutated immunoglobulin variable (V) gene rearrangements whereas just a few cases 
presented clonal TCR rearrangements (Muschen et al., 2000). 
Also, in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) a B-cell origin 
was demonstrated by the presence of clonal immunoglobulin gene rearrangements. In many 
of the cases, intraclonal V-gene diversification was observed, indicating ongoing 
hypermutation activity during clonal expansion. As active hypermutation is a hallmark of 
germinal center B-cells (Kuppers et al., 1993), this fact indicated a germinal-center B-cell origin 
of the tumoral cells in NLPHL. 
1.2.3.2 Loss of the B-cell phenotype of HRS cells. 
Despite the presence of a B cell genotype in HRS cells (immunoglobulin 
rearrangements and hypermutations), immunohistochemical studies showed down-regulation 
of B cell transcriptional program (numerous B-cell markers ,such as CD20,CD79, Oct-2,Bo and 
Pu.1). The lack of expression of transcription factors regulating immunoglobulin gene 
transcription seen in almost all of cHL cases (Oct-2, Bo and Pu.1) could explain the absence or 
the very low level of immunoglobulin gene transcription observed in HRS cells.(Re et al., 2001; 
Stein et al., 2001; Torlakovic et al., 2001) 
However, there is now an indication that the immunoglobulin loci could also be 
silenced by epigenetic mechanisms (DNA methylation) (Ushmorov et al., 2006; Ushmorov et 
al., 2004). In fact, this epigenetic silencing by promoter methylation not only affects the 
immunoglobulin genes but also other B-cell specific genes, such as Pu.1, CD19, CD79b, and 
Bob1. Other mechanisms may contribute to the loss of B-cell phenotype: immunoglobulin 
rearrangements in the VDJ region, thus resulting in truncated proteins (25% out of the total 
cases)(Kanzler et al., 1996b); and mutations in regulatory area of the genes (despite being 
rare). 
Interestingly, gene expression profiling studies of HL derived cell lines ( HDLM2, L1236, 
L428, KMH2) and normal mature B cells revealed that B-cell-specific genes downregulation is 
more general than previously thought(Schwering et al., 2003b). Decreased mRNA levels from 
the vast majority of known B-cell lineage-specific genes were identified, including components 
of the BCR pathway (Blk, Syk, and SLP-65), transcription factors ( Pu.B, A-myb, Spi-B),and 
surface markers (CD37, CD53). Taking into account that normal B cells are selected for 
expression of a BCR throughout their life, it might be a connection between the proposed 
origin of HRS cells from crippled germinal-center B cells and their global loss of B-cell 
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phenotype (Kuppers et al, 1998).  A germinal-center B cell that, because of unfavorable 
immunoglobulin V-gene mutations fails to express a high–affinity BCR and would undergo 
apoptosis in normal conditions, could escape the selection for expression of a (high affinity) 
BCR by losing its B-cell identity. However, this loss of identity could also reflect an involvement 
of transforming events in the cHL pathogenesis rendering cells independent from the normal 
survival signals of B-cells and enabling them to adopt another phenotype. 
Table 1.2  Genetic and phenotypic characteristics of HRS cells in relation to their cellular origin 
Feature  
Somatically mutated Ig V genes Yes 
Destructive somatic mutations*
 
Yes (25%) 
Ongoing somatic mutations No 
Proposed cellular origin Pre-apoptotic germinal-center B cell 
Expression of a BCR No 
Expression of B-cell-specific transcription factors  
( Oct-2,Bob1, Pu1) 
Very rarely 
Expression of B-lineage commitment factor Pax-5 Yes ( low level) 
Expression of B-cell surface molecules (CD20, CD79) No or rarely 
Expression of germinal center B-cell markers ( BCL6, AID) Rarely 
Expression of plasma cell markers (Mum1, CD38) Often 
Expression of molecules involved in antigen presentation 
( MHC class II, CD40, CD80, CD86)  
Yes 
Expression of markers for non B-cells ( TARC, granzyme B, 
CD15, CD3 ) 
Occasionally/ frequently 
Rare cases with T-cell origin Yes (<2%) 
Note : Ig_ immunoglobulin; BCR_ B cell receptor;MHC_ Major histocompatibility complex  
*crippling mutations that can be easily identified ( nonsense mutations) 
 
Finally, it must be pointed out that plasma cell origin of HRS cells has been already 
proposed (Carbone et al., 1998; Carbone et al., 1999) because down-regulation of many B-cell 
markers is also a feature of post-germinal-center (plasma) cells and expression of the plasma 
cell marker CD138 was reported in HRS cells. However, CD138-positivity of HRS cells could not 
be confirmed in other studies and there are major differences in key features of their gene 
expression patterns (lack of expression of immunoglobulin and plasma cell marker BLIMP1 and 
retained expression of Pax-5 and MHC Class II). In conclusion, despite derived from germinal 
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center B lymphocytes, HRS cells present a defective B cell transcription program (Hertel et al., 
2002; Jundt et al., 2002; Schwering et al., 2003b) (Table 1.2). 
1.2.3.3. Apoptosis  
In B normal lymphocytes, the absence of functional immunoglobulins would make 
them to undergo apoptosis (FAS mediated) in germinal center; however in HRS cells multiple 
signaling pathways are aberrantly activated and many other alterations have been described 
to contribute to their proliferation and survival. 
A. FAS gene mutations; either somatic mutations (Muschen et al., 2000) (less frequent than in 
other germinal center derived lymphomas)or germ line mutations(Straus et al., 2001). 
B.c-FLIP expression;(observed in most cases)(Thomas et al., 2002). There is now a strong 
evidence that the resistance of HRS cells against CD95-mediated apoptosis induction is indeed 
due to strong expression of cFLIP, a negative regulator of CD95 signaling (Mathas et al., 2004). 
C. Deregulated expression levels of the apoptosis protein regulators: IAPs (XIAP, cIAP1, cIAP2, 
survivin) and BCL2 proteins. (Garcia et al., 2003; Kashkar et al., 2003). 
D. Constitutive activation of signaling pathways in HRS cells: 
- NF-κB, a heterodimeric key transcription factor involved in many inflammatory and 
immunologic processes, was first described in 1996 to be constitutively active in Hodgkin 
lymphoma cell lines (Bargou et al., 1996). It has been shown to mediate both proliferative and 
antiapoptotic gene transcription programmes in HRS cells.  
There are various explanations for NF-κB upregulation in HRS cells: c-REL amplification 
(Martin-Subero et al., 2002); activation of cell-surface receptors such us CD30, CD40, RANK or 
Notch1 (Cabannes et al., 1999; Horie et al., 2002; Joos et al., 2002); expression of viral latent 
membrane proteins LMP1 and LMP2a in EBV-positive cases; or loss of function mutations of 
the NF-κB suppressor IκBα or IκBε. 
 
- JAK/STAT. In HRS cells STAT3, STAT5 and STAT6 are expressed and constitutively activated. 
Upon cytokine activation, Jak kinases become activated, and these can then phosporilate 
members of the Stat family transcription factors. Phosphorylated STATs can enter the nucleus 
and activate transcription of target genes. Among factors contributing to this activation, 
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recurrent amplifications of JAK2 locus and autocrine stimulation loop through IL-13 and IL-13R 
can be mentioned.(Joos et al., 2000; Kapp et al., 1999). 
 
-There are also other signaling pathways frequently activated in HRS cells such as PI3K/AKT, 
MEK/ERK  and  AP1 pathways(Dutton et al., 2005; Mathas et al., 2002; Zheng et al., 2003). 
 
1.2.3.4. Role of Epstein Barr Virus (EBV) in Hodgkin lymphoma. 
In about 40-50% of cHL cases EBV genome has been detected (Weiss et al., 1987), with 
a higher incidence in mixed cellularity histological subtype, elderly patients , childhood and 
cases diagnosed in developing countries. HRS cells from EBV positive cases show a viral gene 
expression pattern (LMP1, LMP2A y EBNA1) that persists throughout the course of the disease 
and is characteristic of a latent infection (“type2 latency”) (Herbst et al., 1991). EBV plays a 
central role in cHL pathogenesis by rescuing BCR deficient, pre-apoptotic germinal center B 
cells from apoptosis, thus rendering to the HRS cells independence of survival signals normally 
supplied by the BCR (Bechtel et al., 2005). LMP1 and LMP2A contribute to the constitutive 
activation of CD40/NF-κB and B cell receptor signaling pathways and thereby mimic survival 
signals provided by either T lymphocytes or follicular dendritic cells. 
1.2.3.5 Other genes  
It has not been identified a consistent mutation pattern neither in oncogenes nor in 
tumor suppressor genes, being mutations in p53, NRAS or BCL10 very rare or inexistent. 
Numerical and structural chromosome abnormalities are detected in most cases of cHL in the 
HRS cell population (Falzetti et al., 1999; Joos et al., 2000; Martin-Subero et al., 2003). Thus, it 
is known from classical cytogenetic studies the presence of several recurrent chromosomal 
breakpoints affecting the immunoglobin loci (Martin-Subero et al., 2006). Additionally, known 
translocation partners such as BCL2 (Szymanowska et al., 2008), BCL6, MYC and MALT1 can be 
also found in HRS cells.  
Applying comparative genomic hybridization (CGH), recurrent genomic imbalances 
were found. Among them, 2p13-16 (REL); 9p23-24 (JAK) and 12q14 (MDM2) were involved 
most frequently (Joos et al., 2000; Joos et al., 2002; Kupper et al., 2001). In a high percentage 
of cases, HRS cells are characterized by deregulation or abnormal expression of multiple 
proteins implicated in the regulation of cell cycle, such as CDK1, CDK2, cyclin A, B1 and E and 
MDM2 (Figure 1.2). In addition, it is frequently found the lost of expression of tumor 
  
suppressor genes (p16, p15, p27) thus leading to an abnormal integrity of S, G1 and G2/M 
mitotic checkpoints (Garcia et al., 2003
Figure 1.2 Molecular alterations in cHL (
 
1.2.4 Hodgkin lymphoma microenvironment.
Most of the tissue affected 
Multiple evidences suggest an active role of this “microenvironment” in the tumor biology, 
through a bidirectional signaling 
and survival of neoplastic cells being also reciprocally attracted and modulated by tumoral 
cells. A complex network of cytokines and cell contact
and inflammatory cells are thought to be implicated. It may also rescue HRS cells from the 
proapoptotic state arising from their characteristic BCR deficiency by providing alternative 
survival signals. 
The cellular composition and biological role of tumoral microenviron
determined by the already mentioned complex crosstalk between HRS cells and the infiltrating 
cells (Fig 1.3). Although much remains unsolved, some clear interactions have been observed 
with cytokines, and cell adhesion molecules largely accounting 
infiltrating cells. Several chemokines secreted either for HRS cells (CCL17, CCL22) or 
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inflammatory cells (CXCL10, CCL3, CCL4, CCL5) induce migration and activation of T 
lymphocytes, monocytes and other cell populations. Likew
(CCR7, CXCR4) for chemokines already secreted by cells from the microenvironment (CCL19/21 
and CXCL12) (Skinnider and Mak, 2002
HRS cells constitute a small percentage of the tumoral mass, which presents a 
characteristic infiltrate of inflammatory cells
like lymphocytes, although these neither produce the Th2 cytokines IL
functional IL-2 receptor. However, they express CTLA
in regulatory T cells), are anergic (hyporesponsive to stimulation by mitogens and antigens) 
and can inhibit Th-cell responses
T cells, predominantly CD4
regulatory T cells (Marshall et al., 2004
may be recruited non-specifically by C
secrete cytokines like IL 10 and 
explains the lack of an effective anti
EBV proteins). CD8+ cells represent a small proportion of the T
not in close contact with HRS cells and, similarly to CD4
against a common antigen.  These T cells express ligand receptors ( CD40L, CD27, CD4, LFA
for a variety of surface molecules expressed by HRS cells  (CD40, CD70, HLA
(Poppema and van den Berg, 2000
between HL and T cells. 
Other cell populations present are histiocytes, plasma cells, esosinophils, mast ce
neutrophils, fibroblasts and other stroma cells such as macrophages (currently becoming as a 
hot topic in cHL biology, as it will be discussed in this work).
• Mast cells are present in mostly 
proliferation in vitro (Molin et al., 2001
• Eosinophils also express ligands for 
proliferative and antiapoptotic signals for HRS cells. Furthermore, eosinophils produce TGF
and may therefore be involved in fibroblast activation and fibrosis.
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• Fibrosis is mainly observed in nodular sclerosis subtype and can be due to the unbalanced 
production of pro-fibrogenic cytokines like IL13, TGF-β, b-FGF and CD40. Primary fibroblasts 
from HL also produce growth factors for HRS cells, such as IL6 and IL7(Aldinucci et al., 2004). 
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Fig 1.3 Chemical crosstalk between HRS cells and the microenvironment. B_ Bcell; T_T-cells; Th2_T 
helper 2  cells, MΦ_ Macrophage; Eo_ eosinophil. 
 A detailed description of all the interactions found is out of the scope of this thesis 
work , thus just a general overview has been given in order to remark the complexity and thus 
important role of the cHL microenvironment for the biology and pathogenesis of the cHL. 
Interestingly, now there are so many evidences pointing out that the microenvironment is also 
playing an important role in the clinical outcome of cHL and some findings regarding the 
function of macrophages and different T-cell subsets are proving to be of interest. In this 
context, a complete analysis of cHL should pay attention to both cellular components. 
1.2.5 In vitro models of HL. 
The scarcity of HRS cells within the infiltrate tissue has limited molecular studies and 
the progress of Hodgkin´s lymphoma research for a long time. The establishment of HL derived 
cell lines represented a very important step, as these cell lines were used for the successful 
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discovery of HRS cell-associated antigens (CD30, CD70) as well as for the analysis of multiple 
signaling pathways in HRS cells. Most remarkably, the wide use of gene expression techniques 
for cHL cell lines profiling provided new clues regarding pathogenic mechanisms of the 
disease,(Kuppers et al., 2003; Schwering et al., 2003a);(Cossman et al., 1999; Kapp et al., 
1999). 
Most attempts to establish permanently growing cell lines derived from a pure HRS cell 
population failed, but finally more than 10 bona fide Hodgkin lymphoma cell lines have been 
established, being 5 of them the most widely used and accepted for molecular studies in cHL 
(Table 1.3). 
Table 1.3  Immunophenotype and genotype of the most widely used Hodgkin lymphoma cell lines 
Cell line CD30 CD15 B Ag T-Ag Rearranged Ig 
or TCR gene 
BCR or TCR 
expression 
EBV 
L428 + + - - IgH,L - - 
L540 + + - - TCRαβδ - - 
L1236 + + - - IgH,L - - 
HDLM2 + + - - TCRαβδ - - 
KMH2 + + - - IgH,L - - 
B-Ag, B Antigens; T-Ag, T Antigens 
 
cHL derived cell lines constitute a good approach for cHL in vitro studies and elucidation 
of HRS cells biology as presenting a close resemblance to tumoral cells in immunophenotype. 
In fact, L1236 cell line has been proven to derive directly from HRS cells. 
1.3 Current challenges in classical Hodgkin lymphoma 
Although cHL is a curable tumor, an important fraction of patients in advanced stages are 
refractory to standard chemotherapy regimens based on adryamicin and other variants. 
Despite major advances, treatment approaches for cHL patients are rather uniform without 
taking into account this clinical problem and approximately 20-30% may relapse or eventually 
die due to progressive disease or complications of the therapy (Bonadonna et al., 2005; 
Canellos and Niedzwiecki, 2002).  Patients with advanced disease and clinical indicators of 
poor prognosis, and those with disease that persists despite optimized primary treatment, may 
need intensified chemotherapy (Connors, 2005) while others could benefit from reduced 
treatment approaches (Hasenclever and Diehl, 1998). 
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1.3.1 Prognostic factors, definition and end-points. 
Prognostic factors are variables measured in individual patients that offer a partial 
explanation of the heterogeneity observed in the outcome of a given disease, important in 
patient care for selecting management. Although we cannot prognosticate exactly for 
individual patients, we can make statements of probability that will be more accurate for 
groups of patients than for individuals. 
Prognostic factors can be divided into tumor-related factors (directly related to tumor 
characteristics such as tumor pathology, biology, extension); host related factors (age and 
gender) and environmental-related factors (factors outside the patient). 
Different outcomes may be of interest in analyses of prognostic factors, including 
overall survival (OS), Disease specific survival (DSS), Progression free survival (PFS), Failure free 
survival (FFS) and duration of response. For each of these end-points it must be clearly 
specified the starting point in time for the analysis and the clinical characteristics of events and 
censoring. Regarding this work, it has been mainly focused on directly tumor related factors 
(either related to HRS cells or microenvironment), looking for new clues and biological 
processes underlying cHL pathogenesis (with special attention of treatment response, FFS and 
OS events). 
1.3.2 Clinical aspects and prognostic factors in Hodgkin lymphoma. 
The most common clinical presentation of Hodgkin lymphoma is the presence of an 
enlarged lymph node in cervical region. Another common presentation is the discovery of a 
mediastinal mass on imaging, and approximately 60% of patients have mediastinal 
involvement at diagnosis with 50% of the patients presenting localized disease (early stages I-
II). Mediastinal tumor masses are frequent, especially in Nodular sclerosis subtype (NS) and 
around 25-40% of patients present systemic symptoms such as fever, night sweats and weight 
loss (known as “B symptoms”). Staging of the disease is based on the Ann Harbor staging 
system modified by Costwolds (Table 1.4). 
Current predictive systems are based on clinical and analytical parameters such as the 
International Prognostic Score (IPS) (Hasenclever and Diehl, 1998) that still fails to accurately 
identify a significant fraction of patients with very short failure free survival (FFS) (Gobbi et al., 
2001). Thus, outcomes in cHL patients have been classically prognosticate using recognized 
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clinical variables like bulk of the disease , patient age, number of nodal sites and erythrocyte 
sedimentation or the ones present in the IPS . 
Table 1.4 Ann Arbor staging classification for Hodgkin lymphomas 
Stage I Involvement of a single lymph node region (I) or a single extra lymphatic organ or site (IE) 
Stage II Involvement of two or more lymph node regions or lymphatic structures on the same side 
of the diaphragm alone (II) or with involvement of limited, contiguous extralymphatic 
organ or tissue (IIE) 
Stage III Involvement of lymph node regions on both sides of the diaphragm (III) which may include 
the spleen (IIIS) or limited, contiguous extralymphatic organ or site (IIIE) or both (IIES) 
Stage IV Diffuse or disseminated foci of involvement of one or more extralymphatic organs or 
tissues, with or without associated lymphatic involvement. 
 
This prognostic mode (IPS), the most classic and widely used prognostic index for 
advanced cHL, consists of seven clinical variables, including serum albumin less than 4g/dL, 
hemoglobin less than 10.5 g/dL, male gender, age 45 years or higher, stage IV disease, white 
blood cell count at least 15,000/mm3, and absolute lymphocyte count less than 600/mm3 (or 
less than 8% of the total white cell count).  With improvements in therapy, increasing dose 
intensity, early recognition of toxicity, and enhanced supportive care, current outcomes in 
patients may be superior to the ones predicted by IPS. In fact, recent studies show that IPS 
doesn´t adequately risk-stratify subgroups of patients with excellent, intermediate or poor 
outcomes, because patients with 0 to 3 risk factors demonstrated similar 5-year FFS rates 
ranging from 80% to 86% and patients with 4 or more risk factors had similar outcomes ( 
(Blum, 2010). 
Therefore, a re-evaluation of the IPS in a larger population of patients treated at 
multiple centers is needed to confirm these findings and to determine if the IPS in the current 
era segregates patients into clearly defined risk groups suitable for risk-adapted therapeutic 
strategies designed to minimize treatment for patients with the most favorable outcomes and 
intensify or utilize novel therapy for those ones that most likely will relapse. 
1.3.2. Biological prognostic factors. 
In the background previously described, we could hopefully think in the future; in a 
greater understanding of cHL´s biology that could determine and individualize patient therapy. 
Biologic factors underlying this malignancy may serve as prognostic markers and therapeutic 
targets. Nevertheless, numerous biologic markers have been recently identified including 
surface receptors, intracellular proteins, cytokines, and genetic abnormalities comprised of 
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amplifications, deletions, epigenetic silencing, or alterations in microRNA in the tumoral HRS 
cells or their surrounding reactive infiltrate.  
However, the identification of biological markers has been problematic due to several reasons: 
- 1. Lack of large and confirmatory prospective trials. 
- 2. Failure in the reproducibility and feasibility of the assays.  Many of the techniques 
used to detect the markers are not easily reproducible in other laboratories. 
- 3. Failure to improve upon already clinical risk factors (IPS or others). 
Technical advances such us DNA microarray-based gene and microRNA expression 
profiling, RT-PCR platforms, comparative genomic hibridyization (CGH) , SNPs arrays, 
microdisecction and  immunohistochemical indexes have led to new discoveries and there is 
no doubt that their integration with the classical parameters will further improve the 
understanding of disease, and likely the management of patients. Recently, some markers 
have been recognized as putatively useful prognostic factors in HL as described below. 
 
- MMP11 
MMP1 is a marker of matrix metallopeptidases expressed by tumor-associated 
macrophages, found to be associated with treatment failure by both gene expression profiling 
and immunohistochemistry. This gene had a good discriminate power with respect to patient 
outcome and, more than 1% MMP1 staining by immunohistochemistry predicted a reduced 
progression-free survival in both univariate (p=0.008) and multivariate (p=0.009) analyses. 
However, this marker stains many type cells in classical HL specimens (endothelial cells, 
macrophages) thus being very difficult to determine the biologic mechanism responsible for 
this protein´s association with outcome. 
- CD20 
CD20 is a gene that encodes a B-lymphocyte cell-surface antigen has been evaluated by 
immunohistochemistry in several studies (Chetaille et al., 2009; Steidl et al.) finding a positive 
association of an increased number of tumor-infiltrating CD20+ cells with either prolonged 
progression-free (p=0.02) and disease-free (p=0.02) survivals. Similar findings, in which a high 
number of CD20+ cells in the inflammatory infiltrated correlated with improved event-free and 
OS have been reported by Chetaille (Chetaille et al., 2009). No correlation with the number of 
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CD20+ HRS cells and patient outcome was found neither by the previous cited Steidl´s study 
nor other one of 598 patients(Rassidakis et al., 2002b). However, a small study performed by 
Portlock et al (Portlock et al., 2004)in a set of 248 samples showed that both time to treatment 
and OS were significantly lower in patients treated with ABVD with CD20+ cells. Interestingly, 
in a fourth study, greater than 10% CD20+ HRS cells was associated with inferior patient 
outcomes in patients treated from 1974 to 1980 whereas failed to impact failure-free survival 
in patients treated from 1981 to 1999(Tzankov et al., 2003). Thus, the prognostic relevance of 
CD20 in HL might depend on its location and other factors (such as therapeutic modality, and 
the criteria used to define CD20 positivity). As it happens to many other identified markers, 
these results need further validation in prospective studies to determine their reproducibility. 
- CD68 
CD68 is a macrophage marker. This gene encodes a 110-kD trans-membrane glycoprotein 
that is highly expressed by human monocytes and tissue macrophages. It is a member of the 
lysosomal/endosomal-associated membrane glycoprotein (LAMP) family. In the previously 
mentioned study ( Steidl et al, 2010) the initial finding of a tumor infiltrating  macrophages 
gene signature associated with treatment failure prompted to an additional 
immunohistochemical validation of CD68 to assess if this marker could be easily studied and 
expression levels correlated with outcome.  In univariate analysis, the presence of a high 
number of infiltrating CD68+ cells was correlated with reduced progression free (p=0.003) and 
disease-free (p=0.003) survivals. Noteworthy, this marker was superior to the IPS in predicting 
disease free-survival in multivariate analysis (p=0.003 vs p=0.03) and indeed is being currently 
discussed in so many works validating its predictive value (Kamper et al.). 
Similar findings correlating the presence of tumor-infiltrating macrophages with adverse 
patient outcomes have been also been described in follicular non-Hodgkin’s lymphoma(Dave 
et al., 2004; Farinha et al., 2005) , suggesting that interactions between the malignant 
lymphoma cells and the microenvironment are critical to the pathogenesis and progression of 
these diseases. However, the use of CD68 alone as a marker is being currently discussed in so 
many works some of them with contradictory results (Azambuja et al., 2011) 
- CD163.   
CD163 is a monocyte/macrophage specific protein that seems to be involved in anti-
inflammatory functions marker that has been found to have similar correlations with outcome 
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as for CD68 in several studies (Steidl et al., 2010) (Kamper et al., 2011) and is considered to  be 
more specific  and thus more accurate for macrophage identification than CD68.  
- Others.  A variety of other prognostic markers have been described in HL. 
Increased serum levels of soluble CD30 (sCD30)(Zanotti et al., 2002), interleukin (IL)-10, B-
cell-activating factor (BAFF), tumor necrosis factor-alpha (TNFα), thymus and activation 
regulated chemokine (TARC) and vascular endothelial growth factor (VEGF) have all been 
correlated with adverse patient outcomes (Casasnovas et al., 2007). In several studies, 
combining sCD30 level with the IPS improved its predictive value (Ma et al., 2009; Renna et al., 
2009). 
-BCL2. The relationship between BCL2 expression and patient outcome in HL is a 
controversial issue with studies reporting that BCL2 expression was independently associated 
with reduced failure free survival in addition to other clinical prognostic variables ( age over 
45, stage IV disease, low albumin and elevated lactate dehydrogenase)(Rassidakis et al., 
2002a) whereas other have not demonstrated the same correlation (Montalban et al., 2004). 
Similarly to BCL2, other markers like p21 and p53 have been associated with treatment 
outcomes (Sup et al., 2005) with controversial results, although more studies suggest a 
prognostic role for BCL2 than for p53 and p21. 
-T- cells. The presence of T cells in the inflammatory infiltrate also seems to influence 
patient outcomes and several studies have examined the ratio of regulatory T cells (CD4+ CD25+ 
and FOXP3 expression) and cytotoxic T cells (TIA-1+ or granzyme B expression) in relationship 
to overall and disease free survival rates (Alvaro et al., 2005).  The ratio of regulatory FOXP3+ T 
cells to cytotoxic T/NK (natural killer cells) with granzyme B expression independently 
predicted patient survival.  
Noteworthy, these results showed that not only biological markers from the HRS cells are 
prognostic in HL; also the composition of the surrounding cellular matrix and 
microenvironment is playing a key role in the treatment outcome process, thus setting the 
basis for the interest of this thesis work:  
Elucidation of biological processes underlying treatment outcome in both tumoral 
components. 
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1.4 Hodgkin Lymphoma, expression analyses of whole tissue sections. Rationale. 
Scientific advances in the field of genetics, gene and micro-RNA expression profiling have 
revolutionized the concept of molecular biology, patient management and treatment. Analysis 
of differential gene-expression patterns across thousands of biological samples in a single 
experiment, and extrapolation of these data to answer pertinent questions such as those 
relating to tumor classification, metastatic potential and treatment outcome , can help define 
clinical decisions and the best therapeutic regimens for particular subgroups of patients. 
Gene-expression profiling has been used to study all kind of diseases but they have been 
predominantly focused on the study of cancer. Microarray analysis has made possible to 
identify groups of genes according to their expression pattern or “genetic signature” for the 
most common types of neoplastic malignancies including lymphomas. These studies have 
demonstrated the ability to identify pathogenic mechanisms, new molecular targets and 
biological processes involved in lymphomagenesis. 
The main strategies to identify categories of tumors by gene-expression profiling are 
unsupervised and supervised classification methods.  The main difference between these two 
methods is that for supervised classification clinical or pathological information is used to find 
correlations with gene expression patterns, whereas with supervised methods tumors are 
grouped on the basis of gene expression pattern independently of the clinicopathological 
status. Thus, unsupervised methods are useful when looking for genes responsible for cellular 
processes and specific properties from tumor and non-tumor cells. However, to find gene 
expression patterns that can predict the clinical behavior of tumors, it is more appropriate to 
use a supervised classification able to distinguish on the basis of predefined clinical and 
pathological information, because classes are already known (T-test, Anova and other 
traditional statistical test can be used for this aim). 
1.4.1 Gene signatures in classical Hodgkin lymphoma 
In Hodgkin lymphoma, gene expression profiling of cHL cell lines has given new clues for 
the pathogenic mechanisms underlying this malignancy, such as the complex crosstalk 
between HRS cells and microenvironment previously mentioned and other important 
discoveries such as the inactivation of B-cell receptor and differentiation program (Kuppers et 
al., 1994).   
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In addition, gene expression analyses using whole tumor sections helped into the 
identification of different molecular subtypes of cHL disease (Devilard et al., 2002) and the 
elucidation of gene patterns and processes associated to treatment response (outcome). 
Interestingly, by unsupervised methods, Devilard identified three main molecular subgroups of 
cHL tumors with respect to histology and clinical outcome (response to therapy and survival), 
thus establishing the first molecular taxonomy of cHL in correlation with clinical variables and 
suggesting the possibility of improving the current prognostic signification. This study found 
that samples from all bad outcome patients clustered in one group whereas the two other 
groups contained most good outcome ( related to NS subtype) cases and revealed the 
upregulation of genes implicated in fibroblast activation, angiogenesis, extracellular matrix 
remodeling, cell proliferation and downregulation of tumor suppressor genes. 
Other works have also identified specific gene patterns by comparing data from two 
completely opposed biological situations (treatment responders vs non-responders) (Sanchez-
Aguilera et al., 2006) all of them pointing out the important role of genes involved in cell 
proliferation, cellular matrix remodeling and apoptosis in treatment outcome of patients.  
These initial studies based on DNA microarrays demonstrated their ability to define the 
interaction pathways between neoplastic and nonmalignant cells in cancer tissues. Taking into 
account the special composition of cHL, expression profiling on whole tissue sections can 
detect specific transcriptional patterns from both the tumoral cells and the non-tumoral 
microenvironment. During the past ten years, a number of approaches including 
microdissection have tried to resolve the variability in measurements derived from this 
heterogeneity. Another approach that has also been used in thesis work and is designated as 
virtual or in silico microdissection (Alizadeh et al., 2001), avoids the laborious and time-
consuming step of anatomic microdisecction and consists of confronting the gene expression 
profiles of whole tissue samples to those of cell lines representative of different cell lineages, 
differentiation stages, or different signaling pathways. This strategy has been used in recent 
studies, thus aiming the analysis of whole tissue sections as a good alternative to identify 
genes that could ideally reveal as useful prognostic markers and be added to the already 
known prognostic factors. 
1.4.2 MicroRNA signatures in classical Hodgkin lymphoma. 
MicroRNAs (miRNA) are small (approximately 22 nucleotides length) non-coding RNA 
molecules that regulate gene expression at post-transcriptional level through messenger RNA 
interference by binding to complementary sequence at 3´ untranslated region (UTR) of target 
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genes. These molecules were described first time in 1993 by Ambros and colleagues in 
Caenorhabditis elegans and to date hundreds of miRNAs have been identified in other species, 
including viruses (such as EBV and others).  They are encoded by intronic or intergenic DNA 
regions, first as large molecules that are cleaved and processed by an RNAase complex called 
Dicer to generate the finally mature miRNA that binds a protein complex called the RNA-
induced silencing complex (RISC). Nucleotides 2 to 7 from the 5´ end of the miRNA, the seed 
region, are crucial for miRNA-target gene interaction (Grimson et al., 2007). If the miRNA has 
perfect or nearly perfect complementarity to the 3´UTR region, induces messenger RNA 
cleavage (Llave et al., 2002; Yekta et al., 2004) whereas when complementarity is not perfect 
translational silencing of the target gene occurs(Barrington et al., 2009). 
MiRNA expression has been shown to be tissue specific as well as temporally 
regulated. They are emerging as important regulators of biological processes such as 
proliferation, differentiation , and they also act as oncogenes or tumor suppressor genes 
(Hammond, 2006, 2007; Kent and Mendell, 2006), thus suggesting an important role for 
miRNAs in human tumorigenesis. In fact, their role in cancer pathogenesis has been 
demonstrated in several malignancies, including lymphomas (Calin et al., 2004). Remarkably, 
the majority of miRNAs are found in cancer –associated genomic regions or in chromosome-
fragile sites. 
Some attempts have been made to elucidate specific miRNA signatures for the 
characteristic HRS cells and their microenvironment. Overexpression of miR-155 has been 
found in cHL cell lines by qRT-PCR analysis (Kluiver et al., 2005), being also differentially 
expressed between HL and Burkit lymphoma. MiRNA profiling of cHL derived cell lines has 
revealed HL-specific miRNAs that includes miR-17-92 cluster members which is frequently 
amplified in B cell lymphomas(Ota et al., 2004), and others miRNAs such as miR-16, miR-21, 
miR-24 and miR-155.  A significant downregulation in HL compared to non - Hodgkin 
lymphoma has been observed only for miR-150 (Wong and Altekruse, 2009). At the same time, 
comparison of miRNA profiles of microdiseccted HRS cells from nine cHL patients , four 
common cell lines (HDLM2, L540, KMH2 and L1236) and CD77+ germinal center B-cells ( used 
as normal counterparts) yielded a distinct cHL signature of 12 over- and three underexpressed 
miRNAs (Van Vlierberghe et al., 2009). 
Despite these studies, the potential prognostic role of miRNA signatures in cHL 
remains unclear. Overexpression of miR-328 has been found in advanced cHL stages (III-IV 
stages) (Navarro et al., 2007)and low miR-135 levels are associated with higher relapse rates 
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and shorter disease free survival (DFS). Thus, it has not been yet well investigated the 
relevance of microRNA expression in cHL and their putative value for patient outcome 
prediction. 
1.4.3 MicroRNA signatures and EBV 
Additionally, several oncogenic viruses also express miRNAs although the function of 
most of these miRNAs is largely unknown. This is especially important in oncogenic viruses like 
EBV that expresses more than 20 miRNAs organized in two clusters within the EBV genome: 
one in the intronic region of the BART (BamH1-A Rightward transcript) gene and another in the 
untranslated regions (UTRs) of the BHRF1 ( BamHI-H right reading frame) gene (Cai et al., 
2006). These miRNAs are important for the biological cycle of the virus and control several viral 
genes such as BALF5, LMP1 and LMP2a (Barth et al., 2008; Lo et al., 2007; Lung et al., 2009). 
Some of these viral miRNAs promote survival of the host cell by targeting cellular transcripts. 
An example is ebv- BART5 which targets p53 up-regulated modulator of apoptosis (PUMA), 
thus rendering the infected cells less sensitivity to apoptosis (Choy et al., 2008). However, the 
exact role that EBV encoded miRNAs are playing in cHL is still and intriguing issue. 
1.5 Translating gene and microRNA signatures to the clinical care. 
Currently, microarray technology is in a transition phase where scientific information is 
beginning to guide clinical care decisions although they still need to demonstrate reliability and 
reproducibility. In this context, techniques such as real time quantitative polymerase chain 
reaction (qPCR, RT-qPCR) and immunohistochemistry are becoming necessary and widely used 
to validate hypothesis generated by microarray analysis. In addition, it is important to remark 
that microarray techniques present today important limitations, such as the complexity of the 
biostatistical analysis methods used, the high cost of technique and the sample acquisition 
among others. 
1.5.1 The sample problem. 
Microarray technology needs from frozen available samples that are not easily to find. In 
contrast, formalin fixed paraffin embedded samples (FFPE) are extensively available and easily 
accessible. Thus, a technique that could be applied to FFPE tissues would be ideal for profiling 
of genes without limitations of sample availability.  
 Quality of RNA from formalin fixed paraffin embedded tissues is not usually good due 
to the fixation and paraffination process (that causes severe degradation of the RNA). This RNA 
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is shorter (primarily with fragments of less than 300 bases in length), and extraction yields in 
general are lower in comparison with the ones from frozen tissues. However, RNA from FFPE 
tissues is still suitable for some applications. Interestingly, microarray hybridization of FFPE 
tissue samples has been already performed by some groups, although the reliability is still not 
enough clear (April et al., 2009; Grenert et al., 2011). 
However, several studies have shown that RT-qPCR, the gold standard technique for 
microarray hits validation, can be used to quantify gene expression of RNA isolated from FFPE 
tissues even after laser capture microdisecction (LCM) (Koch et al., 2006; Specht et al., 2001) 
obtaining  good quality data results. Moreover, in the past several years great advances have 
been made in the development of sensitive and quantitative gene expression assays using RT-
PCR and FFPE tissue. Limitations due to the sample origin (low quality and amount of the 
extracted RNA) can be overcome in order to set assays based on this technique either for 
validation of microarray hits or the development of tests able to be applied to clinical routine. 
1.5.2 Low density arrays (TLDAs) 
As mentioned, researchers have been frustrated in the past by attempts to profile 
gene expression in archived cancer tissue because almost all archived samples were embedded 
in paraffin. In these samples RNA is degraded and cross-linked, thus significantly limiting the 
ability to examine changes in gene expression.  
A technology PCR-based, sensitive enough, and reproducible enough was needed. 
Recently, a commercially available platform known as Taqman® Low density arrays (TLDAS, 
from Applied Biosystems AB) has been developed.  They are 384-well micro fluidic cards that 
allow performing simultaneous RT-PCR reactions for sample without the need of robots of 
multi-channel pipettes to load samples. Taqman® Gene Expression Assays are preloaded into 
these low to medium-throughput arrays and consist on an ideal screening technology and a 
perfect tool for validating hits that come from microarrays. (See Material and Methods for 
further description and details). Their accuracy and reliability has been already demonstrated 
and are able to be applied to FFPE tissues as done in the first part of this work. 
 Additionally, the inclusion of novel pre-amplification systems (Taqman® PreAmp) 
designed to enhance expression analysis from limited amounts of RNA has successfully 
overcome the difficulties usually caused by FFPE tissue samples (Ciotti et al., 2009).
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Classical Hodgkin lymphoma (cHL) is assumed to be a curable tumor, but an important 
fraction of patients with advanced disease don´t respond favorably to the current standard 
chemotherapy regimens based on Adriamycin. The most widely used prognostic score is based 
on clinical and analytical parameters integrated in the International Prognostic Score (IPS), but 
this still fails to accurately identify at the moment of diagnosis, a significant fraction of patients 
with very poor prognosis. (Canellos GP, et al.1992). 
Therefore, the identification of biomarkers that may consistently predict failure at 
diagnosis is essential for the recognition of patients at high risk of treatment failure, thereby to 
establish a more rational risk-adapted treatment strategy. In addition, gene expression studies 
of tumoral samples have led to the identification of gene signatures and biological processes 
associated to Hodgkin´s lymphoma pathogenesis and treatment response showing that 
outcome in cHL patients could be related with the both biological characteristic components of 
cHL tumors. However, no steps toward the application of this increasing knowledge in the 
development of assay tests feasible to be applied at the moment of diagnosis in a routine 
setting have been made. Hence, the objectives of this work were the following: 
a. To identify gene expression signatures from tumoral (HRS cells) and their non-
neoplastic microenvironment. 
b. To elucidate biological processes and pathways related to patient outcomes. 
c. To design an RT-PCR assay and derive a Molecular Risk Score using formalin fixed 
paraffin embedded (FFPE) cHL samples able to identify subgroups of patients with 
different risk of treatment failure.  
In a similar manner, due to the emerging role of miRNAs in cancer, the objectives of the 
second part of this work were the following: 
d. To investigate the relevance of microRNA expression in cHL and identify specific 
miRNA profiles from the tumoral cells and their non-neoplastic microenvironment. 
e. To derive a miRNA signature associated to patient outcome, identifying miRNAs 
potentially useful for prognosis.  
f. To explore the relationship among genes and microRNAs implicated in cHL 
pathogenesis and chemosensitivity.    
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2.1 Patients and samples 
2.1.1 Patient selection criteria 
All patients samples included in this work fulfilled the same following stringent criteria: 
ages higher than 15 years, advanced cHL (Ann Harbor stage IV, III or IIB with Bulky masses), 
proven HIV-negative status, who had received a first line standard chemotherapy regimen that 
included ABVD (doxorubicin/ adryamicin, bleomycin, vinblastine and dacarbazine ) or ABVD 
variants and with clinical information available about the achievement of complete remission 
(CR) and a follow-up of at least 12 months thereafter. 
The protocol used to data collection comprised the following clinical and analytical 
parameters: birth date; gender; hospital of origin; diagnosis date; histological subtype; bone 
marrow infiltration; presence of Bulky masses; extra nodal and ganglionar affectation, B 
symptoms, lung involvement, stage, hemoglobin, albumin, white blood cell count, 
lymphopenia (lymphocytes<600), leukocytosis ( leukocytes >15000), IPS, chemotherapy 
,radiotherapy ,type of response ( complete response (CR) , partial response (PR) or progression 
(P)) ,and data regarding last follow up (dead, alive with disease or without disease). 
Additionally, IPS was codified according to low versus High: IPS codified (low (< 3) versus 
High(≥ 3) . 
All tissue samples consisted of representative specimens of pretreatment lymph node 
biopsies and were collected after revision by the institutional review board (IRB) of the 
participant’s institutions from the Spanish Hodgkin Lymphoma Study Group and the MD 
Anderson Cancer Centre (Houston, Texas). 
2.1.2 Patient sample series / Datasets 
Different patient series were used in this work and consisted as follows: 
2.1.2.1 Gene expression project 
For the first project, an initial gene dataset previously generated in our laboratory by 
gene-expression profiling of frozen tumor samples from 29 patients was used. This dataset 
included 14 responders and 15 non-responders to the standard ABVD treatment and 5 cHL-
derived cell lines (L428, L540, L1236, HDLM2 and HDMYZ). These data were used to define 
tumor and microenvironment databases and in subsequently bioinformatic analyses, looking 
for genes and pathways associated to treatment failure. 
  Material and Methods 
 
 
32 
To validate specific genes identified by microarray data that were subsequently 
analyzed in FFPE samples, an independent series of 52 advanced cHL cases without 
overlapping with other datasets was used. Finally, the study leading to the Molecular Risk 
score (MRS) development enrolled 282 FFPE patient samples obtaining suitable analyzable 
data for 262 cases ( 92.90 percent)  that were randomly split and assigned to either estimation 
or validation sets. A summary of the clinical characteristics of patients can be found in Table 
2.1.   
Differences in distribution of standard clinical parameters (age, gender, stage, IPS and 
outcome) between estimation and validation datasets were tested by Pearson chi-square test 
(χ2 test) without any observed statistically significance (IPS values < 3 classified as low IPS; IPS 
values ≥ 3 classified as high IPS). 
Table 2. 1.  Clinical characteristics of patients with adequate RT-PCR profiles used for MRS development. 
Characteristic   Estimation   % Validation   % Total % p value (χ
2
 test) 
Age (yr)    (N = 183)  (N = 79)  (N = 262)     
  < 45 133  (72.67)  56  (70.88) 189 (72.14) 0.883 
  ≥ 45 50    (27.32)   23  (29.11)  73  (27.86)    
Gender     (N = 183)  (N = 79)  (N = 262)     
  Male 99    (54.10) 51  (64.55) 150 (57.25) 0.151 
Female 84    (45.90) 28  (35.44) 112 (42.75)   
Stage IV      (N = 182)  (N = 79)   (N = 261)     
  No 132  (72.52)   47  (59.49) 179 0.053 
Yes 50    (37.87) 32  (40.50) 82   
IPS    (N = 182) (N = 79)  (N = 261)    
  < 3 109  (59.89) 41  (51.90) 150 (57.47) 0.288 
≥ 3 73    (40.11) 38  (48.10) 111 (42.53)   
Outcome      (N = 183)  (N = 79)  (N = 262)     
  F 132  (72.14) 57  (72.16) 189 (72.14) 1.000 
U 51    (27.86) 22  (27.84) 73  (27.86)   
 
2.1.2.2. MicroRNA expression project 
Following a similar schema as the one described for gene expression project , for 
miRNA study an initial dataset was used for miRNA microarray hybridization and included 
frozen samples from 29 patients with advanced cHL, 24 responders (F) and 6 non-responders 
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(U) to ABVD treatment and 5 derived cell lines ( L428, L540, L1236 , HDLM2 and HDMYZ). This 
set of samples had not overlap with the previous one used for the gene expression project and 
was used first to define tumor and microenvironment miRNA signatures and secondly to 
identify a set of miRNAS for further study in FFPE samples. As controls, 4 fresh frozen lymph 
nodes and 4 fresh frozen reactive tonsillectomy specimens were included. 
A summary of the clinical characteristics of patients can be found in Table 2.2. 
Table 2.2.Clinical characteristic of patients used for microRNA microarray hybridization (N=29) 
Characteristic   N % 
Age <45 24 82,76 
  ≥45 5 17,24 
Gender Male 14 48,28 
  Female 15 51,72 
Stage IV No 21 72,41 
 Yes 8 27,59 
IPS code <3 21 72,41 
  ≥3 8 27,59 
Histologic Type Nodular Sclerosis 22 75,86 
  Mixed Cellularity 6 20,69 
 Other 1 3,45 
Outcome F  23 79,31 
  U 6 20,69 
 
Additionally, 4 frozen cHL samples (without available clinical data) were used to 
perform laser capture microdisecction (LCM) in order to validate some miRNAs attributed to 
be expressed by HRS cells. (See Results II) 
Finally, the second part of the study enrolled a set of 220 formalin fixed paraffin 
embedded samples (FFPE)  recruited from  different institutions of the Spanish Hodgkin 
lymphoma group and from MD Anderson Cancer Centre ( Houston, TX )  that were used as an 
entire dataset for further elucidation of miRNA prognostic signatures.  A summary of the 
clinical characteristics of the FFPE series used for miRNA RT-qPCR is represented in Table 2.3. 
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2.1.2.3 TMA analysis 
An independent series of 142 cHL cases available in our lab were analyzed by 
immunohistochemistry using tissue microarrays (TMAs) looking for specific genes identified as 
expressed either for HRS cells and their surrounding microenvironment. 
2.2 Cell lines 
cHL- derived cell lines were used in the different projects looking for specific signatures 
attributable to the HRS cells and are described in Table 2.4 
Table 2.4 Description of cell lines used in this study 
Cell line Species Description Culture medium Origin 
HDLM-2 Human Hodgkin lymphoma (T type) RPMI-1640 + 20% FBS DSMZ 
HD-MYZ Human Hodgkin lymphoma ( B type) RPMI-1640 + 10% FBS DSMZ 
KM-H2 Human Hidgkin lymphoma  (B type) RPMI-1640 + 10% FBS DSMZ 
L1236 Human Hodgkin lymphoma(B type) RPMI-1640 + 10% FBS DSMZ 
L428 Human Hodgkin lymphoma ( B type) RPMI-1640 + 10% FBS DSMZ 
L540 Human Hodgkin lymphoma ( B type) RPMI-1640 + 20% FBS DSMZ 
Table2.3.Clinical characteristic of patients series included in RT_qPCR analyses for miRNA study (N=220) 
Characteristic  N % 
Age <45 163 74,09 
  ≥45 57 25,91 
Gender Male 116 52,73 
  Female 104 47,27 
Stage IV NA 1 0,45 
  No 149 67,73 
  Yes 70 31,82 
IPS code NA 17 7,73 
  <3 140 63,64 
  ≥3 63 28,64 
Histologic Type Nodular Sclerosis 158 71,82 
 Mixed Cellularity 54 24,55 
 Other 8 3,64 
Outcome F  143 65,00 
  U 77 35,00 
NA_ Not available data 
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2.3 RNA extraction 
2.3.1 Cell lines 
2. 3.1.1 mRNA extraction 
 For mRNA extraction, 5 - 10 millions cells were stored in PBS media at -80ºC. After 
defreezing, they were disaggregated using a 1mL of Trizol reagent with the help of a syringe 
and a needle. The suspension was kept 10 minutes at room temperature an then, 200µl of 
chloroform were added. Samples were mixed thoroughly 15 seconds and maintained 10 
additional minutes at room temperature. After 15 minutes of centrifugation at 8000g, the 
aqueous phase was recovered in a fresh tube. The same volume of isopropanol and 2µl of 
lineal acrilamide were added and samples were left at -20ºC overnight. Next day, samples 
were centrifuged at 12.000 g for 15 minutes at 4ºC. Pellets were washed twice with 70% cold 
ethanol and resuspended in RNAase free water. For a higher purity, the RNAeasy® Mini Kit 
from Qiagen (Hilden, Germany) was used following manufacturer instructions, including the 
DNAase treatment. Finally RNA was resuspended in 20-30µl of RNAase free water. 
If RNA concentration or quality was not optimal, RNA was precipitated by addition of 1 
µl of lineal acrylamide, 0.5 volumes of AcNH4 (ammonium acetate) 7.5 M and 2.5 volumes of 
ethanol overnight. After 20 minutes centrifugation, the pellet was washed twice with 70% cold 
ethanol, air-dried and resuspended in 20-30 µl of RNAse-free water. RNA was quantified using 
the Nanodrop 1000 device (ND-1000) (Nanodrop Technologies, Wilmington, DE, USA). 
2.3.1.2 MiRNA extraction 
 RNA extraction protocol described in previous section is not suitable for small RNAs 
because small fractions are lost through the RNAeasy column. Thus, for analysis of miRNA 
expression, a different protocol was used. Since the detection of microRNA expression was 
performed using Taqman miRNA probes (Applied Biosystems) able to discriminate mature 
from inmature miRNAs without binding the microRNA gene, no DNA removal step was done. 
First, 1- 2 millions cells were washed twice with 1X PBS and the pellet was disrupted by 
addition of 1 mL of Trizol reagent (Invitrogen) and 5 minutes incubation at room temperature. 
Trizol is a monophasic solution of phenol and guanidine isothiocyanate that maintains the 
integrity of the RNA, while disrupting cells and dissolving cell components. Then, 200 µl of 
chloroform were added, mixed and the sample was centrifuged at 1.200 rpm for 15 minutes at 
4ºC. Aqueous phase was recovered and the same volume of isopropanol added for RNA 
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precipitation. The sample was then centrifuged and washed with 70% ethanol. Finally, pellets 
were dried and resuspended in 50 µL of RNAse-free water. 
2.3.2 Tissues 
2.3. 2.1 Frozen tissues. 
Frozen tissues were cut with a cryostat to get 20-30 slides depending on the size of the 
frozen piece. The slides were homogenized using a Polytron homogenizer (Capitol scientific, 
Inc, Austin, TX).The homogenized samples were lyzed by addition of 1 mL of Trizol. Following 
steps are common to the protocol described in section 2.3.1.1 including column purification. 
2.3.2. 2 FFPE tissues 
Total mRNA was extracted from 3-10 FFPE sections of 10 µm thickness (depending on 
the size of the fixed piece).Paraffin sections were deparaffinized by incubation with 1 ml of 
xylene for 10 minutes at 65ºC. Samples were then centrifuged at 10,000 rpm for 10 minutes 
and the supernatant was removed. After an ethanol wash, tissue pellets were dried and 
resuspended in 200 µl of RNA lysis buffer containing 50 mM Tris, 0.5 mM EDTA (pH 8.0) and 
10% sodium dodecylsulfate and incubated overnight at 65ºC with 10 µl of proteinase K (20 
mg/ml, Qiagen Inc., Hilden, Germany). RNA was purified by phenol-chloroform extraction 
followed by precipitation in an equal volume of isopropanol in the presence of 1 µl of lineal 
acrylamide (Ambion, Austin, TX) at –20ºC. The RNA pellet was washed once in 70% ethanol, 
dried, and resuspended in 30 µl of of RNAse-free water. For genomic DNA removal, DNAse 
digestion was carried out by treating the total RNA with 5 µl DNaseI (1 U/µl, Epicentre® 
Biotechnologies, Madison, WI). 
 The final RNA concentration (A260:0.025) and purity (A260:A280 ratio) was measured 
using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, 
USA). 
2.3.2.3 Microdissected tissues 
 RNA from microdiseccted samples was extracted from 800 - 1000 cells. Briefly, 350ul 
of RLT buffer from Quiagen (Hilden, Germany) and 3,5ul of ß -mercaptoetanol were added to 
the samples that were homogenized with a syringe.  After, 150 µl of chloroform was added 
and samples were then centrifuged at 13,200 rpm for 10 minutes taking supernatant into a 
new eppendorf tube for RNA precipitation in 400 µl of isopropanol in the presence of 4 µl of 
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lineal acrylamide (Ambion, Austin, TX) at -20ºC overnight. The RNA pellet was washed twice in 
70% ethanol, dried, and resuspended in 10-15 µl of RNAse-free water. 
2.4 Retrotranscription (RT) 
2.4.1 mRNA  
First-strand cDNA was synthesized from total RNA using the High Capacity cDNA 
archive kit (Applied Biosystems, Foster City, CA), in 50 µl reactions using these cDNA samples 
for qPCR analyses by TLDA platforms according to the manufacturer’s instructions. Briefly, 
500ng of RNA were mixed with 25µl of RT Master Mix containing 5µl of 10x RT buffer and 10x 
Random Primers, 2 µl 25x dNTPs, 2.5 µl of 50U/µl MultiScribe RT, 9.5 µl of RNAse free water 
and 1 µl of RNAse inhibitor. The samples were put in a thermocycler with the following 
program: 
Table 2.5  RT program conditions used for cDNA synthesis 
Program Temperature Time (min) 
HOLD 25ºC 10 
HOLD 37ºC 120 
HOLD 85ºC 5 
HOLD 4ºC ∞ 
RT_ Retrotransciption;    min_minutes 
 
2.4.2 miRNA 
Taqman® microRNA assays were used to specifically measure the mature form of the 
miRNAs.  cDNA synthesis step was carried out with a specific primer for e This primer contains 
a specific sequence that anneals on the miRNA in the 3´end and a general sequence in the 
5´end. This general sequence impedes the annealing of the immature forms. In the other hand,  
the primer yields a product much larger than the original miRNA allowing for an easier design 
of the PCR primers. 
Retrotranscription was carried out using the TaqMan® MicroRNA Reverse 
Transcription Kit (Applied Biosystems). Briefly, 5µl of 250ng/µl RNA solution was mixed with 
0.25 µl of 100mM dNTPs, 2µl of 50U/µ MultiScribe Reverse Transciptase, 3 µl of Reverse 
Transciption Buffer, 025 µl of 20 U/µl of RNAase inhibitor and 1µl of each one of the specific RT 
  Material and Methods 
 
 
38 
primers (mixed in a pool) in a final reaction volume of 25µl. The samples were put in a 
thermocycler with the following program. 
Table 2.6 RT conditions used for cDNA miRNA synthesis 
Program Temperature Time (min) 
HOLD 25ºC 10 
HOLD 42ºC 50 
HOLD 70ºC 15 
HOLD 4ºC ∞ 
RT_ Retrotransciption;    min_minutes 
 
 
2.5 Preamplification  
Taqman® RT-qPCR technique is based on the 5´nuclease activity of Taq DNA 
polymerase and involves cleavage of a specific fluorigenic hybridization probe that is flanked 
nby the PCR primers. Limited amounts of tissue and RNA and cDNA were available from FFPE 
samples, thus restricting the number of genes and cases that could be analyzed in some 
samples. In order to ensure high data quality a preamplification step was added to the sample 
processing.  
The principle of TaqMan® PreAmp technique is to amplify target cDNA prior to RT-
qPCR analysis. Briefly, cDNA is synthesized from total RNA using random priming; The cDNA for 
the specific target assays is then amplified by pre-amplification reaction using pooled gene-
specific primers to increase the number of targeted copies. The pre-amplification product is 
diluted and finally analyzed by RT-qPCR using single assay  
   TaqMan® PreAmp Master Mix (T-PreAmp) (Applied Biosystems, Foster City, CA) that 
preamplifies small amounts of cDNA without introducing amplification bias to the sample was 
used. By incorporating a preamplification step into the sample preparation workflow, adverse 
sample effects due to the low quality of the RNA material were significantly reduced. 
First, it was tested in an initial small set of 13 cases and 32 genes. Briefly, the pooled 
assays were diluted to a final concentration of one-fifth that of the PreAmp primer/assay pool. 
Initial experiments comparing the volume of PreAmp reaction recommended by the 
manufacturer (total PreAmp reaction volume: 50 µl) and a tenth of that volume (5 µl PreAmp 
reaction volume) gave identical PreAmp results, so we subsequently used the latter volume 
due to reasons of cost-effectiveness. The chosen PreAmp reaction involved 14 cycles of 
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preamplification with 15 s at 95ºC, and 4 min at 60ºC. Preamplified products were diluted at a 
ratio 1:10 and then used as templates for RT-PCR analysis. Due to the good results obtained, 
preamplification was included as a standard step prior to qPCR in the FFPE samples used in the 
gene expression study. No preamplification step was added into miRNA processing. 
2.6 Real-time quantitative PCR  
2.6.1 TaqMan low-density array assays (TLDAS). 
To explore the different pathways and genes, a series of quantitative RT-PCR assays 
based on TaqMan® low-density array (TLDA) technology (Applied Biosystems, Foster City, CA), 
were designed , and measured the expression of each selected gene in triplicate. TLDAs are a 
very useful tool for gene expression studies. They are based on RT-qPCR technology using the 
relative quantification method ( DeltaCt) .Depending of the chosen configuration, they  allow 
to study from 12 to 384 genes in 1 to 8 samples,. In this work we used 2 different TLDA formats 
(64, 32) in a sequential gene selection process. 
 
 
 
Figure 2.1 Taqman® Low Density array platform and formats. First column indicates number of assays 
included in each platform; following columns show number of samples analyzed depending on 
replicates. 
2.6.1.1 TLDA models and gene study selection. 
A multistep approach was applied to design the subsequent TLDA platforms used in this work, 
integrating genes known to be expressed either by the tumor HRS cells and their reactive 
microenvironment, and related with clinical response to adriamycin-based chemotherapy. A 
total of 2 different TLDA platforms were used. Their different gene composition of each 
      umber of samples per TaqMan Array  
Format  umber of  
assays* 
1 
replicate** 
2 replicates 3 replicates 4 
replicates 
Format 12 11    8 
Format 16 15   8 
Format 24 23  8  4 
Format 32 31   4 
Format 48 27  4  2 
Format 64 63   2 
Format 96a 95  2  1 
Format 96b 95  2  1 
Format 384 380 1   
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platform is described in this section. All assay details of genes included in the different TLDA 
platforms are described in Table 2.8. 
a. TLDA model _ Format 64 _ 2 samples per card, 60 genes study. This initial model included 
60 genes from pathways related to cHL outcome that had been previously identified by 
bioinformatic analysis from gene expression data. It allowed the analysis of 2 samples per 
array and was applied to an initial set of 52 samples. The main aim of this platform was the 
technical validation of RT-qPCR technology on FFPE tissue samples. It included 60 study genes 
and 4 control endogenous genes (HMBS, GUSB, TBP and GADPH). 
 
Figure 2.2 TLDA Format 64.  
b. TLDA model _ Format 32_ 4 samples per card, 30 genes study. Second, the best candidate 
genes from the initial TLDA 64 assay were selected based on their amplification efficiency, 
biological significance and treatment response correlation to design and set up a novel assay 
of genes. This platform was applied to a larger series of 282 samples and used to develop the 
final predictive model (MRS_ Molecular Risk Score). 2 endogenous control genes (HMBS and 
GUSB) were present and chosen from the 4 initial ones. 
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Figure 2.3 TLDA Format 32  
2.6.1.2 Reference gene selection 
The TLDA format 64 included HMBS, GUSB, TBP and 18S as reference genes to 
normalize the data on the basis on their proven role as housekeeping genes and their uniform 
expression tested in a small set of FFPE tumor samples from the studied series.  Expression 
stability of the selected endogenous genes was determined by the geNORM Visual Basic 
application from Real Time StatMinerTM software (Integromics, Madrid,Spain), also known as 
the pairwise approach(Vandesompele et al., 2002). This analysis relies on the principle that the 
expression ratio of two perfect endogenous genes should be identical in all samples. GeNorm 
program calculates a gene stability measure termed as M by determining the average pairwase 
variation between a particular reference gene and the other studied genes. A higher value of 
M means greater variation in RNA expression. By stepwise exclusion of the least stable gene 
and recalculation of the M values, most stable reference genes are identified and a final 
normalization factor (NF) is calculated (based on the geometric mean of the expression levels 
of the best reference genes).The best two candidates were HMBS and GUSB (NF = 0.0902), 
thus being chosen to be included in the other TLDA platforms (Format 32 and 16) and for 
normalization of the gene expression levels in all the analysis.  
Table 2.7 GeNorm Analysis candidate endogenous genes TLDA assays  
Gene 18S TBP HMBS/GUSB 
NF 0.206508201 0.104911765 0.090217764 
NF- Normalization factor 
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Table 2.8 Assays details included in the RT-qPCR TLDA platforms used in the study  
Control 
genes 
Description Assay ID bp   Format 
64 
Format 
32 
GUSB glucuronidase, beta Hs99999908_m1 81  x  x 
18S Eukaryotic 18S rRNA Hs99999901_s1 187  x 
 x 
TBP TATA box binding protein Hs00427620_m1 91  x 
 
HMBS hydroxymethylbilane synthase Hs00609297_m1 64  x 
 
Study 
Genes 
Description Assay ID bp   Format 
64 
Format 
32 
BCL2 B-cell CLL/ lymphoma2 Hs00608023_m1 81 t x 
 x 
BCL2L1 BCL2-like 1 Hs00236329_m1 65 t x 
 x 
CASP3 caspase 3, apoptosis-related cysteine protease Hs00234385_m1 66 t x 
 x 
CCNA2 cyclin A2 Hs00153138_m1 110 t x 
 x 
CCNE2 cyclin E2 Hs00180319_m1 92 t x 
 x 
CDC2 cell division cycle 2, G1 to S and G2 to M Hs00176469_m1 101 t x 
 x 
CENPF centromere protein F, 350/400ka (mitosin) Hs00193201_m1 99 t x 
 x 
GADPH glyceraldehyde-3-phosphate dehydrogenase  Hs99999905_m1 125  x 
 x 
HMMR hyaluronan-mediated motility receptor (RHAMM) Hs00234864_m1 98 t x 
 x 
IRF4 Interferon regulatory factor 4 Hs00180031_m1 81 m x 
 x 
LYZ lysozyme (renal amyloidosis) Hs00426231_m1 84 m x 
 x 
STAT1 signal transducer and activator of transcription 1, 91kDa Hs00234829_m1 79 m x 
 x 
TYMS thymidylate synthetase Hs00426591_m1 87 t x 
 x 
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) Hs00829154_g1 161 t x 
 x 
CD3D CD3D antigen, delta polypeptide (TiT3 complex) Hs00174158_m1 92 m x 
 x 
SH2D1A SH2 domain protein 1A, Duncan's disease (lymphoproliferative syndrome) Hs00158978_m1 93 m x 
 x 
CD8B1 CD8 antigen, beta polypeptide 1 (p37) Hs00174762_m1 95 m x 
 x 
FOXP3 forkhead box P3  Hs00203958_m1 64 t/m x 
 x 
ALDH1A1 aldehyde dehydrogenase 1 family, member A1 Hs00167445_m1 97 m x 
 x 
BCCIP BRCA2 and CDKN1A interacting protein Hs00255585_m1 104 t x 
 x 
BUB3 BUB3 budding uninhibited by benzimidazoles 3 homolog  Hs00190920_m1 78 t x 
 x 
DNAJA2 DnaJ (Hsp40) homolog, subfamily A, member 2 Hs00195365_m1 76 t x 
 x 
GRB2 growth factor receptor-bound protein 2 Hs00257910_s1 68 t x 
 x 
H2AFX H2A histone family, member X Hs00266783_s1 48 t x 
 x 
HIST1H3D histone 1, H3d Hs00371415_s1 62 t x 
 x 
HSPCA heat shock 90kDa protein 1, alpha Hs00743767_sH 133 t x 
 x 
IFI16 interferon, gamma-inducible protein 16 Hs00194261_m1 83 m x 
 x 
MAPK6 mitogen-activated protein kinase 6 Hs00833126_g1 100 t x 
 x 
TOP2A topoisomerase (DNA) II alpha 170kDa Hs00172214_m1 125 t x 
 x 
RRM2 ribonucleotide reductase M2 polypeptide Hs00357247_g1 79 t x 
 x 
MAPK9 mitogen-activated protein kinase 9 Hs00177102_m1 102 t x 
 
MLH1 mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) Hs00179866_m1 103 t x 
 
NUMA1 nuclear mitotic apparatus protein 1 Hs00272062_m1 94 t x 
 
RSN restin (Reed-Steinberg cell-expressed intermediate filament-associated 
protein) 
Hs00161477_m1 65 m x
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2.6.1.3 Experimental procedure and data analysis 
Each cDNA sample (30 µl) was added to 20 µl of RNase-free water and 50 µl of 2 x 
TaqMan® Universal PCR Master Mix (No AmpErase UNG) (Applied Biosystems, Foster City, CA). 
The mixture was then transferred into a loading port on a TLDA card. The card was centrifuged 
twice, sealed, and PCR amplification was performed using Applied Biosystems Prism 7900HT 
Sequence Detection System under the following thermal cycler conditions:  
 
Study 
Genes 
Description Assay ID bp   Format 
64 
Format 
32 
AGC1 aggrecan 1 (chondroitin sulfate proteoglycan 1, large aggregating 
proteoglycan, antigen identified by monoclonal antibody A0122) 
Hs00202971_m1 93 m x
 
 
BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) Hs00176169_m1 90 t x 
 
CCNH cyclin H Hs00236923_m1 127 t x 
 
CD30 
(TNFRSF8) 
tumor necrosis factor receptor superfamily, member 8 Hs00174277_m1 94 t x
 
 
CDC6 CDC6 cell division cycle 6 homolog Hs00154374_m1 77 t x 
 
CDK7 cyclin-dependent kinase 7 Hs00361486_m1 68 t x 
 
CDKN2C cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) Hs00176227_m1 86 t x 
 
CENPE centromere protein E, 312kDa Hs00156507_m1 88 t x 
 
CHEK1 CHK1 checkpoint homolog (S. pombe) Hs00176236_m1 112 t x 
 
CSE1L CSE1 chromosome segregation 1-like (yeast) Hs00354853_m1 123 t x 
 
CYCS cytochrome c, somatic Hs01588974_g1 85 t x 
 
CTSL cathepsin L Hs00377632_m1 85 m x 
 
DCK deoxycytidine kinase Hs00176127_m1 93 t x 
 
DPP4 dipeptidylpeptidase 4 (CD26, adenosine deaminase complexing protein 2) Hs00175210_m1 90 m x 
 
EMR3 egf-like module containing, mucin-like, hormone receptor-like 3 Hs00261470_m1 72 m x 
 
H1F0 H1 histone family, member 0 Hs00271174_s1 107 t x 
 
HSPA4 heat shock 70kDa protein 4 Hs00382884_m1 62 t x 
 
HSPA9B heat shock 70kDa protein 9B (mortalin-2) Hs00269818_m1 92 t x 
 
ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) Hs00168433_m1 61 m x 
 
LCP1 lymphocyte cytosolic protein 1 (L-plastin) Hs00158701_m1 72 m x 
 
MAP3K7 mitogen-activated protein kinase kinase kinase 7 Hs00177373_m1 95 m x 
 
MAPK14 mitogen-activated protein kinase 14 Hs00176247_m1 62 m x 
 
MAPRE1 microtubule-associated protein, RP/EB family, member 1 Hs00606526_mH 93 t x 
 
NBS1 Nibrin Hs00159537_m1 75 t x 
 
PTPN11 protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 1) Hs00275784_m1 83 t x 
 
RAMP null Hs00212788_m1 91 t x 
 
STK6 serine/threonine kinase 6 (AuroraA) Hs00269212_m1 85 t x 
 
bp_ base pairs ; m_ microenvironment; t_tumor cells 
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Table 2.9  PCR conditions used for TLDA platforms 
Program Temperature Time (min) 
HOLD 50ºC 2 
CYCLE (x 40) 94,5ºC 10 
 97ºC 0.5 
 59,7ºC 1 
As previously explained, a preamplification step (PreAmp, Applied Biosystems, CA) was 
used to improve the sensitivity of the assays for low-abundance target genes available from 
FFPE samples. Ct values were exported using SDS software (SDS 2.3), and the data were 
analyzed with Real-Time StatMiner software (INTEGROMICS TM; www.Integromics.com) for 
normalization. -ΔCT values (-(Ct value of gene – median Ct value for HMBS and GUSB) were 
considered for further statistical analysis if they meet quality criteria ( Ct<35 ). 
 
RNA Extraction 
 
Quality and Quantity determination ( NanoDrop) 
Quality criteria (A 260/280 and A 260/230 >1.5) 
 
Retrotranscription  ( 10µl)( High Capaciy Archive Kit, Applied Biosystems) 
10ul RNA+ 15 ul H20 RNAasa free + 25 RT Master Mix 
 
Preamplification  _ 2,5 ul cDNA + 2,5 Pool de Assays ( 0,2x ) + 5 ul PreAMP Master Mix 
Dil 1 : 10 ___ 5 ul + 45 ul H20 RNAasa free water 
 
25 ul sample + 25 ul H2O+ 50 ul Taqmam  Master Mix 
 
TLDA ( Taqman Low Density array) 
 
    Figure 2.4. Protocol summary TLDAs 
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2.6.2 Real-time PCR for relative miRNA quantification using RNA from FFPE tissue. 
For FFPE samples, miRNA RT-qPCR was performed for the 34 selected miRNAs ( Table 
2.10) following manufacturer protocol (Applied Biosystems, Foster City, CA, USA) by the 
Applied Biosystems 384-well multiplexed real-time PCR assay using 250 ng of total miRNA.  
Table 2.10 Assay Details miRNAs analyzed in the study m_microenvironment; t_tumor cells 
Name Assay ID Description Signal miRBase accession 
RNU44 001094  Endogenous Control  
RNU48 001006 Endogenous Control  
hsa-miR-15b* 002173 Mature miRNA t MIMAT0004586  
hsa-miR-17* 002421 Mature miRNA t MIMAT0000071  
hsa-miR-216a 002220 Mature miRNA t MIMAT0000273 
hsa-miR-23a 000399 Mature miRNA t MIMAT0000078  
hsa-miR-25 000403 Mature miRNA t MIMAT0000081  
hsa-miR-30d 000420 Mature miRNA t MIMAT0000245  
Hsa-miR-30e 002223 Mature miRNA t MIMAT0000692 
hsa-miR-320 002277 Mature miRNA t MIMAT0000510  
hsa-miR-93 000432 Mature miRNA t MIMAT0002762  
hsa-miR-21 000397 Mature miRNA t MIMAT0000076  
hsa-miR-21* 002438 Mature miRNA t MIMAT0004494  
hsa-miR-92a 000431 Mature miRNA t MIMAT0000092  
hsa-miR-130b 000456 Mature miRNA t MIMAT0000691  
hsa-miR-378 002243 Mature miRNA t MIMAT0000732  
hsa-miR-551a 001519 Mature miRNA t MIMAT0003214  
hsa-miR-708* 002342 Mature miRNA t MIMAT0004927  
hsa-miR-92b* 002343 Mature miRNA m MIMAT0004792  
hsa-miR-26a 000405 Mature miRNA m MIMAT0000082  
hsa-miR-27b* 002174 Mature miRNA m MIMAT0004588  
hsa-miR-132 000457 Mature miRNA m MIMAT0000426  
hsa-miR-148b* 000471 Mature miRNA m MIMAT0000759  
hsa-miR-204 000508 Mature miRNA m MIMAT0000265  
hsa-miR-300 241035_mat Mature miRNA m MIMAT0004903  
hsa-miR-31* 002279 Mature miRNA m MIMAT0004504  
hsa-miR-423-5p 002340 Mature miRNA m MIMAT0004748  
hsa-miR-503 001048 Mature miRNA m MIMAT0002874  
hsa-miR-539 001286 Mature miRNA m MIMAT0003163 
hsa-miR-559 001527 Mature miRNA m MIMAT0003223  
hsa-miR-609 001573 Mature miRNA m MIMAT0003277  
hsa-miR-621 001598 Mature miRNA m MIMAT0003290  
hsa-miR-628-3p 002434 Mature miRNA m MIMAT0003297  
hsa-miR-637 001581 Mature miRNA m MIMAT0003307  
hsa-miR-888 002212 Mature miRNA m MIMAT0004916  
hsa-miR-937 002180 Mature miRNA m MIMAT0004980  
  Material and Methods 
 
 
46 
Briefly, miRNA from each case was reversed-transcribed as previously explained in 
triplicate using a multiplex looped primer pool with the selected miRNA probes for the study.. 
Each completed reaction was loaded onto the 384-well plate and real-time PCR was done on 
the ABI 7900HT Prism using RNU44 and RNU48 as the endogenous normalization controls. Ct 
values were exported using SDS software (SDS 2.3), and data were analyzed with Real-Time 
StatMiner software (INTEGROMICS TM; www.Integromics.com) using the ΔCT method. All 
assays were performed in triplicate and results which did not meet methodological quality 
control criteria were omitted considering a miRNA to be present if the Ct was less than 36 in all 
three biological replicates; -ΔCT values (-(Ct value of miRNA of interest – median Ct value for 
RNU44 and RNU48) were considered for further statistical analysis. 
2.7 Gene expression microarrays 
In this work the Whole Human Genome Microarray kit v2 (1x44K, Agilent Technologies) was 
used. 
2.7.1 cDNA synthesis from total RNA 
2µg of total RNA were mixed with 2µl of a 5,000-fold dilution of Agilent´s Two-Color 
Spike-in RNA control and amplified using Agilent Low RNA Input Fluorescent Amplification Kit 
(Agilent Technologies, Inc., Santa Clara, CA). A final mixture volume of 6,5 µl ( total 
concentration at least 5ng/µl) was mixed with 5µl of T7 promoter primer. The primer and the 
template were denatured by incubating the reaction at 65ºC for 10min and placing on ice for 
5min. Following, 8.5µl of cDNA Master Mix was added and the samples were incubated first at 
400C in a circulating water bath for 2h and then at 65ºC in a heating block for 15 min to 
inactivate MMLV-RT. After this time, samples were incubated on ice for 5 min. 
cDNA Master Mix composition: 4µl of 5X First strand buffer, 0.1M DTT 2µl, 10mM 
dNTP mix 1µl of MMLV-RT and 0.5µl of RNase OUT. 
2.7.2 Fluorescent cRNA synthesis: In Vitro Transcription and incorporation of fluorochromes. 
To each sample tube, either 2.4µl of 10mM cyanine 3-CTP (sample) or 2.4µl of 10mM 
cyanine 5-CTP (Stratagene Universal Human Reference RNA) were added and mixed. 
Following, to each sample, 57.6µl of Transcription Master Mix was added and incubated in a 
circulated water bath at 40ºC for 2h. Following amplification and labeling, each sample was 
assessed on the Nanodrop ND-1000 to measure yield and specific activity. 
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Transcription Master Mix composition: 15.3µl of Nuclease-free water, 20µl of 4X 
Transcription buffer, 0.1 M DTT 6µl, 8µl of NTP mix, 50% PEG 6.4µl, 0.5 µl of RNase OUT, 0.6µl 
of Inorganic pyrophosphatase and 0.8µl T7 RNA Polymerase. 
2.7.3 Hybridization 
cRNA target was prepared as follows: 0.75µg cyanine 3-labeled, linearly amplified 
sample cRNA was mixed with 0.75µg cyanine 5-labeled, linearly amplified reference pool 
cRNA, 50µl of 10X control targets and Nuclease-free water to final volume of 240µl. The 
hybridization solution was prepared by adding 240µl of 2X target solution to 10µl of 25X 
fragmentation buffer. The mixture was incubated at 60ºC in the heating block for 30 min. 
Following, 250µl of 2X hybridization buffer (from In situ Hybridization kit) to the final volume 
of 500µl, mixed,  spinned and 490µl of the hybridization solution was applied to 60-mer 
Agilent 44 K (or 4X 44K) Human Whole Genome oligonucleotide microarrays and assembled in 
microarray hybridization chamber (G2534A). Once fully assembled, the chambers were loaded 
into the hybridization rotator rack and set to rotate at 4rpm. The hybridization was performed 
in a rotating oven at 60ºC for 17h. All the washing steps were performed at room temperature. 
First the sandwiched slides were submerged in Wash Solution 1 to remove oligo microarray 
slide. The slides were washed for 1min in the Wash Solution 1 with the magnetic stir and 
transferred to the staining dish containing Wash Solution 2 and washed for 1min. Following, 
the slides were transferred to the staining dish containing the Wash Solution 3 and washed for 
30 seconds. All steps were performed in darkness. The dried slides were scanned with a 
G2565BA Microarray Scanner System (Agilent Technologies, Palo Alto, CA). 
Wash solution 1 composition: 6X SSPE, 0.005% N- Lauroylsarcosine, deionized nuclease free water. 
Wash solution 2 composition: 0.06X SSPE, 0.005% N- Lauroylsarcosine, deionized nuclease free water. 
The buffers 1 and 2 are passed through a 0.2µm sterile filtration unit before use. 
Wash solution 3 composition: Agilent Stabilization and Drying Solution containing an ozone scavenging 
compound dissolved in acetonitrile. 
 
2.8 MicroRNA expression microarrays 
2.8.1 Labeling 
100 ng of total RNA were hybridized onto Agilent 8x15 Human microRNA Microarray 
kit version2 containing probes from 723 human and 76 viral microRNAs based on Sanger 
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miRbase, following the manufacturer´s instructions (Agilent Technologies). Briefly, this 
procedure consisted of a RNA dephosphorylation step where the mixture of 100 ng RNA, 10X 
CIP Buffer and CIP (16 U/µl) was incubated at 37ºC for 30 min. Following, a denaturation step 
was performed through addition of DMSO to samples and carried out at 100ºC for 5min. 
Samples were then treated with T4 ligase (15 U/µl )and labeled with Cy3 at 16ºC for 2 hours. 
The reaction was performed in a total volume of 20µl. Subsequently, RNA was purified with 
Bio-spin 6 columns (BioRad, Hercules, CA) and dried in a speed vacuum (45ºC, 45 minutes). 
2.8.2 Hybridization 
 Labeled RNA was resuspended in the appropriate volume of hybridization mix ( H2O 
18µl, blocking agent 4.5µl and hybridization buffer 22.5µl) to a final volume of 45µl and 
incubated at 100ºC for 5 minutes, quickly cooled and pippeted into the 8X gasket, closed with 
the Agilent 8x15K Human miRNA v2 platform, and locked with the appropriate support. 
Hybridization was carried out at 55ºC at 20rpm. After that time the slides were washed first 
with WB1 buffer and then with WB2 buffer. Both washing steps were performed at 37ºC for 7 
minutes each, with shaking. Finally, the array was submerged in acetonitrile for 1 minute and 
dried. The arrays were scanned for Cy3 fluorescence with a G2565BA Microarray Scanner 
System (Agilent Technologies, Palo Alto, CA). 
2.9 Tissue Microarrays 
Tissue Microarrays (TMA) technology allows for the simultaneous analysis of multiple 
individual tissue samples on a single slide through immunohistochemistry, in situ hybridization 
and fluorescence in situ hybridization techniques (Kallioniemi et al., 2001);(Kononen et al., 
1998) and consist on the arrayed disposition of a variable number of circular biopsies (0.6-
2mm diameter) originated from different FFPE blocks into a unique block. This technology 
takes advantage of the possibility of analyzing a big number of samples in homogeneous 
experimental conditions with a minimum destruction of the original tissue sample and a low 
time and money consumption. The possibility of bias due to non-representative tissue sections 
is overcome by the number of tumors analyzed as demonstrated by several studies. 
The expression of a selected number of markers was assessed in a set of 142 FFPE 
samples Primary chosen antibodies were as follows: anti-BCL2 and anti-LYZ (DAKO), anti-BCLXL 
(anti-BCL2L1) (Zymed Laboratories); anti-CASP3 and anti-CCNA2 (Novocastra Laboratories); 
anti-CTSL (Alexis Biochemicals); anti-STAT1, anti-SH2D1A, anti-CDK7, anti-HSP70 and anti-
  
MUM1 (IRF4; Santa Cruz Biotechnology) ; anti
and anti-HISTH2A ( Upstate Biotechnology).
Figure 2.5 TMA´s constructio
microscope and quantification
The TMAs were scanned using a computerized microscope (Olimpus BX61) and stored 
as digital images. Protein levels were subsequent
thresholds for each marker using the TMA score software package (Ariol SL
2.10 Analysis of the presence of the Epstein
The presence of EBV in cHL lymph nodes was examined by in situ
RNA (EBER 1 and 2, Dako) and LMP1 immunohistochemistry (CS1
procedures on TMAs constructed with paraffin
was carried out in FFPE tissue by the Histology and Immunohis
Spanish National Cancer Research Center (CNIO). 
2.11 Laser capture microdisecction
Laser Capture microdis
of 4 frozen tissue samples to validate the expression of s
A 
B
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Briefly, five-micrometer serial sections from the frozen tissue blocks were cut, fixed with 
acetone at 4 °C, and incubated at 1:250 with anti-human CD30 monoclonal antibody (clone 
Ber-H2, DAKO) at 1:1,000 to identify the HRS cells, using a standard indirect avidin-biotin 
horseradish peroxidase method and diaminobenzidine color development.  
After immunostainig, 600 to 800 CD30-positive HRS cells were microdissected using 
the PALM UV Laser Microbeam system (Carl Zeiss Inc., Germany). In each experiment, equal 
number of CD30-negative cells was randomly picked from the reactive microenvironment.  
After microdissection, miRNA expression was analyzed by RT-qPCR as previously 
explained. Quantitative RT-PCR for miR-21 and miR30d was performed with microdissected 
samples testing also the levels of the same miRNAs in microdissected fragments obtained from 
the reactive surrounding infiltrate of each case. Ct values using RNU44 and RNU48 as 
endogenous controls were used for analysis. 
2.12 Microarray data analysis  
2.12.1 Gene expression and miRNA microarrays preprocessing 
Data were processed and extracted by Feature Extraction software  (v.9.5.3.1) (Agilent 
Technologies) being afterwards combined and filtered for saturated and non-uniformly stained 
flags using the combine program (http://combine.bioinfo.cnio.es/). Between-array median 
normalization was carried out. 
2.12.2  Bioinformatic methods 
2.12.2.1 Supervised analysis. Pomelo II Tool. 
The analyses of the initial gene expression datasets (either Gene Expression or miRNA 
expression dataset) were performed using Pomelo II tool(Morrissey and Diaz-Uriarte, 2009), 
available free at http://pomelo2.bioinfo.cnio.es . To identify genes and miRNAs differentially 
expressed between tumoral samples and cHL cell lines we used a supervised method based on 
Student´s t test with a correction of multiple testing. Unadjusted P values were obtained from 
100,000 permutations of the dataset and false discovery rates (FDRs) were calculated by the 
method of Benjamini and Hochberg(Green and Diggle, 2007) considering genes with an 
FDR<0.15 as differentially expressed. Genes and miRNAs with FDR<0.15 were considered to be 
differentially expressed and used to construct the Tumoral and Microenvironmental signatures 
from both gene ( Tumoral Database (TDB;  Microenvironmental  Database (MDB) ) and 
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microRNA studies. This first analysis was done without consideration of clinical outcomes of 
the patients. 
2.12 .2.2 Gene Set Enrichment Analysis 
Gene Set Enrichment Analysis (GSEA) (http://www.broad.mit.edu/gsea ) (Subramanian 
et al., 2005)  is a computational method that determines whether an a priori predefined set of 
genes (pathways) shows statistically significant differences among two biological states. In this 
work GSEA tool was used  in the Gene Expression study ( Results I) to identify sets of related 
genes that might correlate to therapy resistance (Favorable versus Unfavorable Outcome) in 
the previously identified TDB and MDB databases testing each one separately . GSEA´s method 
uses t statistics to search for predefined list of gene sets that were in this work selected taking 
into consideration the particular heterogeneity of cHL tumors including all public pathways 
associated with immune response and cell-cell interactions.  
Biocarta (www.biocarta.com ) and other public sources available through the 
Molecular Signature Database (MSigDB: http://www.broad.mit.edu/gsea/msigdb/index.jsp) 
were used to generate the gene-set databases. Final gene sets used were manually curated 
and enriched in pathways also known to be involved in lymphoma pathogenesis and immune 
response. The rank of all genes in the sets were determined and an enrichment score (ES) was 
calculated for each pathway as a measure of its relevance. This enrichment score (ES) value 
was afterwards normalized in order to calculate the Normalized enrichment score (NES) used 
for pathway evaluation (See Results I).  
The analysis was performed with 1,000 random class permutations. Genes with more 
than 30% of missing values were excluded , and only gene sets meeting the gene set size 
criteria (min=10, max=500 genes) were analyzed. Thus, final analysis of TDB included 46 
pathways whereas 21 pathways were taken into account for MDB analysis. 
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Figure 2.6 GSEA workflow scheme analyses. 
 
2.13 Bioinformatics Target miRNA prediction. 
 miRBase (miRBase v11.0, MICROCOSM)(Griffiths-Jones, 2004; Griffiths-Jones et al., 
2006; Griffiths-Jones et al., 2008)and TargetScan (TargetScan release 5.1, Whitehead Institute 
for Biomedical Research)(Friedman et al., 2009; Grimson et al., 2007; Lewis et al., 2005) 
databases were interrogated to identify the genes that might be regulated by the 4- miRNAs 
identified with outcome in this series of cHL cases. Details of algorithms used by this 
bioinformatic tools can be found on their respective web sites (http://www.mirbase.org/ and 
http://www.targetscan.org/). Additionally, TarBase  (Sethupathy et al., 2006) ( 
http://diana.cslab.ece.ntua.gr/tarbase/), a database which houses a manually curated 
collection of experimentally supported microRNA targets was included in the analysis. 
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 Finally, with the aim of incorporating microRNAs in pathways DIANA-mirPath 
(http://diana.cslab.ece.ntua.gr/pathways/index_multiple.php ) (Papadopoulos et al., 2009) 
was used.  It consists on a web-based computational tool developed to identify molecular 
pathways potentially altered by the expression of single or multiple microRNAs. The software 
performs an enrichment analysis of multiple microRNA target genes comparing each set of 
microRNA targets to all known KEGG pathways (http://www.genome.jp/kegg/pathway.html). 
The combinatorial effect of co-expressed microRNAs in the modulation of a given pathway is 
taken into account by the simultaneous analysis of multiple microRNAs. The graphical output 
of the program provides an overview of the parts of the pathway modulated by microRNAs, 
facilitating the interpretation and presentation of the analysis results.  
2.14 Statistical data analysis 
All statistical analyses were two-sided, taking values of p < 0.05 to be significant. These 
were performed with SPSS 15.0 (SPSS Inc., Chicago, IL). Survival curves were assessed by the 
Kaplan-Meier method and risk groups were compared by the log-rank test. Plots were 
generated using GraphPadPrism v.5 (GraphPad Software, Inc.). 
 
2.14.1 Clinical endpoints 
Differences in the distributions of standard clinical parameters (age, gender, stage, IPS 
and outcome) in all patient series used in the different analyses were tested by the Pearson 
chi-square test When patient series were split into estimation and validation sets, it was 
randomly done in order to avoid any bias into the event distribution, thus with a balanced 
proportion in favorable versus unfavorable outcomes. 
The major aim of this study was the analysis of biological parameters associated with 
response to the initial therapy and treatment failure, thus data from second-line and salvage 
therapies and/or bone-marrow transplantation were not considered.  
 
2.14.1.1 Treatment outcome (Favorable versus Unfavorable)  
The first endpoint of all studies used for initial gene and miRNA selection was 
maintained response to therapy (treatment outcome). 
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- Favorable outcome (F) .Good response was considered in patients with sustained complete 
response (18 months). 
- Unfavorable outcome (U). Bad response was considered in cases without complete response 
or patients with early relapses to therapy following previously published criteria(Carde et al., 
2002). 
2.14.1koSurvival analysis (FFS and OS)  
 
-Failure-free survival (FFS) was used as the fundamental endpoint for survival analysis, defined 
as the time interval between treatment initiation and treatment failure or last follow-up. 
Failure was defined as either the failure to achieve complete remission (CR), or the occurrence 
of progressive disease, irrespective of whether there had been an initial CR. 
 
-Overall survival (OS) was included as a secondary end point in the survival analyses, defined 
as the time interval between diagnosis and death due to the lymphoma or any other causes.  
However, its significance in the study was imperfect since it is conditioned by the effect of 
subsequent eventual treatments and complication of treatment. 
 
2.14.2 Logistic Regression analysis 
Associations between gene expression levels and the probability of treatment 
response and outcome were studied by logistic regression analyses. Normalized expression 
levels were used as independent continuous variables and either treatment outcome (F vs. U) 
or FFS event (relapse versus non relapse) as the dependent variable. Univariate and 
multivariate backward stepwise logistic regression analyses were used to elucidate and 
develop the different predictive signatures. 
2.14.3 ROC curves 
Receiver operating characteristic (ROC), or simply ROC curve, is a graphical plot of the 
sensitivity, or true positive rate, versus false positive rate (1 – specificity or 1 − true negative 
rate), for a binary classifier system as its discrimination threshold is varied. ROC analysis 
provides a tool to select possibly optimal models and to discard suboptimal ones 
independently from (and prior to specifying) the cost context or the class distribution. 
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Thus, ROC curves were used in the present work to select the best markers (genes and 
miRNAs) and to evaluate the predictive sensitivity and specificity of the different elucidated 
signatures and derived scores (Integrated Risk, Molecular Risk Score and miRNA score) using 
outcome (F versus U) as binary classifier variable. Additionally, the MRS and miRNA score cut-
off points were prespecified by using area ROC analysis to define different risk groups (low risk 
versus high risk) choosing those cut-off points with highest compromise between sensitivity 
and specificity. In clinical practice, it is exceedingly rare that a chosen cut point will achieve 
perfect discrimination between cases. Thus, the best compromise between sensitivity and 
specificity has to be selected as  done in this thesis work (Zweig and Campbell, 1993). 
2.14.4 Survival analysis (Cox regression analysis and Kaplan-Meier Test) 
Survival was estimated using the Kaplan-Meier method and compared by log-rank 
tests either in the Gene expression or miRNA project. For graphical representation, survival 
analyses were done by the Kaplan-Meier method and long-rank test separately in the training 
and validation series for MRS development, and in the entire series for both the MRS and 
miRNA signatures respectively. In addition, multivariate Cox proportional hazards models were 
used to determine and test the joint associations of factors initially found to have potential 
association with outcome and  derive final models to be applied for the entire series: 
Integrative Model (N=262) ( Results I) and miRNA score (N=220) (Results II). 
 
2.15 The derived scores.  
2.15.1Gene Expression project  
2.15.1.1 Integrated Risk Score 
To illustrate the relationship among gene expression data from TLDA Format 64 and 
treatment response an integrated risk score was derived, defined as the logarithmic mean of 
the expression levels of all the genes included in the analysis.   This approach combined with 
ROC analysis of the individual genes from TLDA Format 64 was also used to select the genes 
with the better prognostic ability in order to design the TLDA Format 32 that was  applied to a  
larger series of patients (N=282). 
2.15.1.2 Molecular Risk Score 
The Molecular Risk Score (MRS) algorithm was defined as a continuous function 
obtained by logistic regression analysis and comprised expression levels of 11 genes 
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significantly found to predict failure that were grouped into their corresponding biological 
functional pathways. 
The MRS was developed using gene expression data from the estimation set (N=183) 
and further validated in the validation set (N=79). Briefly, univariate regression analysis was 
first performed with treatment response (F versus U) as the dependent variable to identify 
genes associated with outcome. Genes were ranked on basis on their p value and those ones 
found to be significant were further studied by cross-validation.  
A cross-validation step was included to test the classification ability of the initial set of 
significant genes to choose the strongest predictor ones. For this purpose, Tnasas, a web tool 
for building class prediction models available at (http://tnasas.bioinfo.cnio.es/) was used  and 
three prediction algorithms available were applied: Diagonal linear discriminant 
analysis(DLDA)(Solberg, 1978), Support vector machines (SVM)(Chu and Wang, 2005) a and K-
nearest neighbor (KNN).  
Using this bioinformatic tool several predictive models including the previously 
identified significant genes were derived. To construct each predictive model the program 
used values of the F statistic (the popular ANOVA F-ratio) to rank genes and each one of the 
above described algorithms were used. The frequency of genes in the different developed 
models were used for ranking, and counted after 150 cross-validation runs of each model. 
Final selected genes to be included in the MRS were those ones with frequencies higher than 
40 percent in all-cross validated runs (CV). 
 Selected genes were classified into functional groups on the basis of their known 
biological relationship and their coregulated expression as estimated by Pearson correlation 
coefficient. Three biological functional groups were defined: Cycle, Apoptosis and macrophage 
with the inclusion of a gene as independent variable not ascribed to any functional group. 
Individual genes from each functional group were weighted using diagonal linear discriminant 
analysis (DLDA). Finally, these functional gene clusters associated with cHL outcome were 
analyzed in a multivariate logistic regression model with response to therapy (F versus U) as a 
dependent variable. In this way, an algorithm was derived that combined these measurements 
into a quantitative “molecular risk score” (MRS), used as a continuous variable to estimate the 
probability of treatment response. Further details of MRS development are explained in 
Results I section. 
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2.15.1.3 Integrative Model. 
Initially, a multivariate Cox’s proportional hazards model, including the data at 
diagnosis, the IPS stratified (low <3 versus high ≥3), and its seven individual variables 
(hemoglobin < 10.5 g/dl; albumin < 4 g/dl; leucocytosis ≥15,000/mm3; lymphopenia < 
600/mm3; age ≥ 45 yr; male gender and stage IV), was applied to the entire series in order to 
test the independence of the MRS with respect to clinical variables. The integrative model was 
defined as a continuous survival function derived by Cox proportional hazard model using 
backward stepwise selection algorithm that was applied to the entire series (N=262). This 
model comprised two variables: the previously described MRS and the clinical variable Stage IV 
found to be the only clinical variable that remained significant after multivariate Cox 
regression analysis (See Results I). 
 
2.15.2 MiRNA expression project 
2.15.2.1 MiRNA score 
For miRNA signature score, Cox regression analysis was performed to determine the 
association of the miRNAs initially found to have potential association with outcome in the 
logistic regression analyses. A final Cox proportional hazard model based on the miRNA 
expression was finally derived for the entire series of FFPE samples analyzed (N=220) using 
backward selection algorithm. The miRNA score was defined as the continuous survival 
function derived from the model, being afterwards validated by leave one out crossvalidation. 
Its predictive performance was tested by ROC analyses and patients were stratified into high 
and low risk Cox groups by the median of the miRNA score in the whole series ( using also ROC 
analysis to check suitability of this cut-off point). 
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RESULTS I- Gene Expression Signatures with Prognostic Significance in Advanced 
Classical Hodgkin Lymphoma. 
 
The purpose of this work was the identification of biological processes 
underlying treatment failure in advanced Hodgkin lymphoma (HL) patients, and the 
subsequent development of a quantitative RT-PCR based assay to be applied to routine 
formalin-fixed paraffin-embedded (FFPE) samples. 
Taking into account the heterogeneity and peculiar composition of cHL tumors, 
this study identified gene subsets expressed either by the tumoral cells and the Hodgkin 
microenvironment, and showed that robust methodologies based on quantitative RT-
PCR are suitable for expression profiling of tumors and can be easily applied to paraffin 
embedded samples allowing to analyze a limited number of selected genes in a single 
sample. 
In addition, it identified functional signatures associated with treatment 
response and demonstrated the potential prognostic capacity of the developed assay 
finding a positive correlation between the expression of the proposed genes and 
treatment response (Molecular Risk Score_ MRS) 
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3.1 Identification of tumor and microenvironment signatures.  TDB and MDB. 
As mentioned, clinical and histological heterogeneity of classical Hodgkin lymphoma 
and the characteristic scarcity of HRS cells have prevented molecular studies. Despite the lack 
of a perfect model of HRS cells, established cHL cell lines are commonly used as a model 
system to characterize HRS cells biology while tumor samples represent a complex mixture of 
tumoral cells and the reactive immune infiltrate. 
Comparison of gene expression profiles from 29 frozen tumoral advanced cHL samples 
and gene profiles from 5 cHL-derived cell lines (L428, L540, L1236, HDLM2 and HDMYZ) by 
supervised methods using T-test revealed 3.463 genes differentially expressed (FDR≤0.15). This 
analysis allowed the recognition of gene signatures attributable to both the neoplastic 
components: 
a) Genes overexpressed in cHL cell lines (1.705 genes) were considered as putatively 
expressed by HRS cells and grouped in a database named Tumor Database (TDB). 
b) Genes overexpressed in the tumor samples (1.758 genes) were considered as 
characteristic from the microenvironment and grouped in another database named 
Microenvironment Database (MDB). 
c) The remaining not differentially expressed genes (FDR>0.15, 1,671 genes) were 
considered to be potentially expressed by both populations and included either in TDB 
and MDB in order to avoid loss of information.  
Composition of TDB and MDB was very complex with a high number of genes that 
informed from functions and processes already known to be implicated in cHL pathogenesis. 
TDB contained genes known to be expressed by HRS cells, including cell cycle regulators, 
signaling, surface receptors and transcription factors. According to previous published 
data(Kuppers et al., 2003), genes such as TNFRSF8 (CD30) , GATA3, the tumor necrosis factor 
receptor family member RANK , and the metalloproteinase TIMP1(Fiumara et al., 2001) were 
present in TDB whereas MDB was mainly composed of genes involved in the immune response 
( STAT1, LYZ, SH2D1A and CTSL ) (Sanchez-Aguilera et al., 2006). 
As described above, the identified gene signatures were used to generate two different 
datasets containing the gene expression data from the 29 advanced cHL patients to be further 
analyzed. 
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3.2 TDB and MDB validation by immunohistochemistry. 
Since the elucidation of the tumoral and microenvironmental signatures (TDB and 
MDB) was based on a bioinformatic approach (virtual or In silico microdissection) (Alizadeh et 
al., 2001) ,we wanted to confirm that obtained results were really informative and consistent. 
Thus, a limited number of genes were selected for validation at protein level using tissue 
microarray-based immunohistochemical techniques (TMAs) on an independent series of 142 
cHL patient samples. 
 Validation markers were chosen based on their representative value for either 
tumoral or microenvironment signature and the availability of reliable antibodies for paraffin-
embedded tissue. According to TDB composition, BCL2, BCL2L1, CASP3, MUM1/IRF4, CDK7 and 
CCNA2 were mainly expressed by the HRS tumoral cells, whereas genes present in MDB 
(STAT1, LYZ, SH2D1Aand CTSL) were expressed by reactive T cells, macrophages, reactive T 
cells and fibroblasts (Figure 3.1). 
 
Figure 3.1 Immunohistochemical analyses of selected markers. Proteins in the six panels on the left 
correspond to genes included in the TDB, and their expression was mainly restricted to tumoral HRS 
cells (BCL2, MUM1, CDK7, BCL2L1, CASP3 and CCNA2). The four panels on the right correspond to genes 
included in the MDB, and the expression of the respective proteins was mainly restricted to fibroblasts, 
macrophages, and reactive T cells (CTSL, STAT1, LYZ, and SH2D1A) whereas tumoral cells are negative. 
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 When the number of positive cHL samples for each marker was evaluated considering 
expression levels showed either by HRS cells or the microenvironment the same trend was 
observed (Figure 3.2). The absence in HRS cells from those markers considered to be expressed 
by microenvironment (CTSL; SH2D1A, STAT1 and LYZ) was clearly seen being negative for 
almost all cases. A more complex expression pattern was found in the reactive immune 
infiltrate component in agreement with the intrinsic complexity of cHL microenvironment. 
 
Figure 3.2 The histograms represent the number of positive cHL samples for each marker expressed by 
the HRS cells or the microenvironment. Expression levels codified as negative, low or high expression 
depending on signal intensity observed in the microscope. Total number of evaluated cases (N=142). 
3.3 Pathway analysis (GSEA) of TDB and MDB 
 In order to clarify the complex composition of TDB and MDB, we reanalyzed both 
databases using a different bioinformatic approach able to look for pathways or corregulated 
genes, taking also into consideration the clinical outcome of patients (Favorable or good 
outcome versus Unfavorable or bad outcome) not considered in the first analysis.  As 
explained in material and methods, favorable outcome (F)  was considered in patients with 
sustained complete response (18 months)  whereas unfavorable outcome (U) was considered 
in cases without complete response or patients with early relapses to therapy following 
previously published criteria(Carde et al., 2002) 
 The hypothesis that treatment response in cHL could be determined by a combination 
of factors related to both the neoplastic cells and their tisular microenvironment and might be 
associated with alterations in biological pathways rather than with randomly identified 
individual genes was tested by using Gene Set Enrichment Analysis (GSEA). Noteworthy, 
N N 
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comparisons just made on the level of individual gene lists clearly diverged when different 
statistical methods were used, thus prompting us to avoid this approach. Two independent 
GSEA analyses to either TDB or MDB with independent gene sets for each database were 
performed, looking for functional pathways overrepresented in the unfavorable outcome 
patient´s group (U). In this way, specific gene patterns by comparing expression data from two 
completely opposed biological situations (treatment responders (F) versus non-responders (U)) 
were identified.  
As the number of analyzed samples was pretty low (29 patients) and taking into 
consideration their uneven phenotypic distribution, GSEA was performed looking for pathways 
associated with lack of maintained response in order to select an initial panel of potentially 
predictive genes to be included in an RT_PCR assay (TLDA assay). Thus, we focused our 
attention to the most relevant pathways within all the studied ones with independence of 
strict statistical significance (based on a biological descriptive interest). 
3.3.1 Tumor TDB  
TDB analysis showed that 15 out of the total 46 pathways evaluated were associated 
with unfavorable outcome (Table 3.1 and Table 3.3). Interestingly, two gene sets (G2/M and 
GS) were significantly associated (p<0.005) to treatment failure containing genes associated 
with the regulation of the spindle checkpoint such us Aurora Kinase A (AURKA), MAD2L1, 
BUB1B, BUB3, CHEK1, and CDK1. These results are in agreement with already previous 
published data regarding the identification of genes related with genome integrity checkpoints 
as involved in cHL progression and the observation of disrupted transition through mitosis in 
cHL Hodgkin cells (Sanchez-Aguilera et al., 2006).Additionally, G1 pathway, histones, 
chaperones , MAP Kinase signaling and mitochondrial signaling pathways (including genes 
implicated in apoptosis regulation like CASP3, BCL2 and BCL2L1)  were enriched in the 
unfavorable group of patients highlighting the complexity and wide variety of processes that 
could be associated to therapy resistance.  
Interestingly, the drug resistance pathway was also enriched in the unfavorable group 
of patients with the important presence of genes such TOP2A and MLH1, genes known to be 
involved in the transport and metabolism of doxorubicin (basis of ABVD standard 
chemotherapy regimen used for cHL patients). 
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Table 3.1. GSEA pathways related to unfavorable in Tumoral Database (TDB) 
Pathway Genes 
G2M CDC27, MDM2,CHES1,RPS6KA1,BRCA1,CCNF,WEE1,GADD45B,EP300,CDKN2D,CDC25A,MAD1L1,CDC14A,CDC20,YWHAH, 
YWHAQ,PRKDC,KIF2C,BIRC5,STK6,CCNH,BUB1,MAPRE1,BUB3,CENPE,CHEK1,CCNA2,CENPA,NBS1,BUB1B,CDC2,CENPF, 
NMUA1, HMMR, NEK2, MAD2L1  
GS PRKACA,GAS2,TFDP2,DDX11,E2F2,GNAS,MYC,POLR3D,CDC20,CDC45L,CDC7,MYBL2,CCNE2,CCNH,CDC6,CDK7,CCNA2,PNA, 
GSPT1,CDC2,RAMP 
G1 CDK6,MDM2,RBL1,TGFB2,CDKN2B,ABL1,CDK2,HDAC1,CDC25A,SKP2,CCND2,DHFR,SKP1A,CKS2,CDK5,GSK3B,CDK4,NPM1, 
TFDP1,BCCIP,CCNH,CDN2C,GSPT1,CDC2 
Histone HDAC4,HDAC5,HDAC11,HIST2H2BE,HIRA,HUS1,HIST1H1C,HIST2H2AA,MYST2,HDAC1,H2AFV,HIST1H2AC,HDAC2,HIST1H4H, 
NASP,H2AFZ,HDAC8,HDAC7A,HIST1H3D,H2AFX,H1F0 
Chaperone CDC37,HSPB3,DNAJB2,HSF1,DNAJB12,DNAJC11,DNAJB1,DNAJC3,DNAJC13,HSPA4L,BAG5,DNAJB6,HSPA2,DNAJA3,DNAJB5, 
HSPCB,HSPA1L,HSBP1,HSPH1,DNAJC8,HSPA8,DNAJA1,DNAJA2,HSPCA,HSPA9B,HSPA4 
Drug resistance  CYP3A4,ABCC5,SMPD1,ABCC1,UHRF1,ERCC2,RALBP1,ABCB1,PSME4,ACO1,RPL11,ABCC2,APEX1,GLRX2,MSH2,SOD1,GSTP1, 
ABCC3,TYMS,H2-ALPHA,PSMC1,MLH1,RRM2,TOP2A,DCK 
Metabolism MAP4K1,HRAS,PTK2,SOS1,MAPK3,PAK1,HGF,ACTA1,MET,STAT3,RAP1A,CRKL,ELK1,RAF1,PIK3CA,MAP2K1,GRB2,RAP1B,PTPN11 
Epidermal 
Growth Factor  
HRAS,SOS1,MAP2K4,EGFR,JAK1,MAPK3,SHC1,STAT5A,STAT3,ELK1,PRKCA,RAF1,PIK3CA,STAT1,CSNK2A1,MAP2K1,GRB2 
ERK pathway RPS6KA1,HRAS,SOS1,NGFR,DPM2,EGFR,GNAS,MAPK3,IGF1R,MYC,SHC1,STAT3,ELK1,RAF1,MAP2K1,PPP2CA,GRB2 
Mitogen-
activated 
protein kinase 
MAPK11,MAP3K6,MAP4K1,MAP2K3,MAP2K5,MAP3K4,RPS6KA1,RIPK1,MAPK12,MAPK10,MAP3K14,HRAS,MAP3K8,TGFB2, 
MAP2K4,NFKB1,DAXX,RELA,MAPK3,PAK1,MYC,MAX,SHC1,MAPKAPK3,MAP4K4,ELK1,RAF1,MAPK14,MAP3K7,STAT1,BRAF,MAPKAPK5, 
MAP2K1,MAPK9,GRB2,MAPK6 
Tumor Necrosis 
factor 1  
(TNFR1) 
DFFA,DFFB,TNFRSF8,TNFRSF5,TNF,RIPK1,MAP2K4,CRADD,PAK1,LMNA,TNFRSF10B,MAP3K7,TTRAP,PRKDC,FADD,LMNB2, 
CASP3 
Integrines HRAS,VCL,PTK2,SOS1,BCAR1,ZYX,CSK,MAPK3,RCK1,SHC1,ACTA1,PPP1R12B,RAP1A,CRKL,RAF1,MAP2K1,GRB2 
Mitochondrial DFFA,DFFB,PDCD8,BAX,BCL2L1,BCL2L2,BCL2,BIRC3,BAG5,BIRC4,CASP9,BAG1,CASP7,BAK1,BIRC2,CYCS,CASP3 
 
3.3.2 Microenvironment MDB 
MDB analysis 
 GSEA analysis of MDB revealed 13 pathways associated to unfavorable outcomes with 
T-cells, monocyte/macrophage and dendritic cells pathways as the most enriched gene sets. 
These pathways included genes reporting from specific T-cell populations, thus highlighting the 
important role of the microenvironment (Table 3.2). 
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3.4 Selection of genes with potential prognostic capacity and TLDA design format 64. 
As shown in chapter 3.3, GSEA analysis revealed specific gene patterns identified after 
comparison of gene expression data from two completely opposed biological situations 
(treatment responders (F) versus non-responders (U)). These results showed that supervised 
methods are useful when asking for specific biological questions between phenotypes and 
verified the initial hypothesis that treatment response in cHL was determined by a 
combination of factors related to both the neoplastic HRS cells and their tisular 
microenvironment. 
- Thus, Genes overexpressed by the neoplastic HRS cells (indeed confirmed by TMA analysis) 
comprised: 
a)  Genes related with signaling/ apoptosis 
b) Cell-cycle regulatory genes, mainly related with G2/M transition, and the regulation of 
spindle checkpoint. 
Table 3.2 GSEA pathways related to unfavorable outcome in Microenvironment Database (MDB) 
Pathway Genes 
T-Cells CR1,ADAM17,FURIN,CD4,TRA,CD1C,MAL,MLL,PRKCG,CD3G,PRKCH,FYN,CD3E,LEF1,DPP4,CD69,CD3D 
,SH2D1A,TXN,CD8B1,RAB27A 
Monocyte/ 
macrophage 
VDR,PTGS1,ITGAM,PECAM1,SIRPB1,ANPEP,CD4,SELL,MMP9,ITGB2,SELPLG,SDC2,CD44,CTSS,ITGA4,LCP1, 
ALDH1A1,STAT1,LYZ,TXN,ATP6AP2,RAB27A 
Dendritic cells TNFRSF11A,CR1,LILRB1,CD80,LILRB4,SIRPB1,S100A1,LAMP3,SOCS1,LTB,S100A10,CD83,CD86,S100A8,CYP27B1, 
TNFSF11,S100A11,S100B,CYP24A1,S100A3,RSN 
T cytotoxic cell THY1,CD2,TRA,ITGB2,CD8A,PRF1,GZMB,HLA-A,CD3G.CD3E,LEF1,CD3D,CD8B1 
T cell receptor JUN,NFKBIA,NFATC4,FOS,VAV1,PTPN7,TRA,PIK3R1,ZAP70,MAP2K4,NFKB1,NFATC3,LCK,RELA,CD3G,FYN, 
MAPK3K1,CD3E,PRKCB1,PPP3CB,CD3D,PIK3CA,GRB2 
Neutrophils ITGAM,PECAM1,ANPEP,NR3C1,FCGR2A,MMP9,FPR1,SELPLG,BST1,FCGR1A,PAK1,LYN,BIRC3,SERPINA1,LCP1 
,CD69,EMR3 
FAS ligand JUN,DFFB,CASP10,MAP2K4,CFLAR,PTPN13,DAXX,PAK1,MAP3K1,ARHGDIB,CASP7,MAP3K7,CASP3 
Fibroblast FGFR1,FGF3,TACR1,SHOX2,FRS2,THY1,ST5,DDR2,MICB,FGFR4,FGFR3,GTF2IRD1,OPTN,FGF7,FGF11,SDC2,ECHS1 
,ACVR1,FGF19,FGF13,BLNK,CTSL,SDCBP,GRB2,AGC1 
IL2RB JAK3,IL2RA,FOS,SYK,BCL2L1,SOCS3,PIK3R1,SOCS1,IL2RB,CFLAR,IL2RG,BCL2,PIK3CA,GRB2 
TH1 IL2RA,CXCL12,MMP2,IL18,MMP9,IL18R1,IFNGR2,CD86,IFNGR1,IFI30,IFI16 
B cell receptor  JUN,RAFTLIN,BTK,NFATC4,FOS,SYK,VAV1,CD79A,CD79B,NFATC3,LYN,MAP3K1,PRKCB1,MAPK14,PPP3CB,BLNK,GRB2 
Mastocytes GAB2,ADAM17,PLD2,FCGR2B,APC,PRKCD,FCER2,VEGF,PTK2,LCP2,PLSCR3,FCGR2A,MMP9,USF2,SELPLG,BST1, 
ATP2A3,ICAM3,AREG,LYN,PLSCR2,PRKCB1,PLSCR1,GRB2 
Natural Killer cells TGFB3,SYK,IL18,VAV1,CCR7,CD4,CCL3,PIK3R1,IL18R1,IFNGR2,PTK2B,PAK1,CXCR4,IFNGR1,HLA-A,CD69,PIK3CA 
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-  Additionally, genes that reflected specific cell populations of the immune response were 
identified, such as specific T-cells and monocyte/macrophage cells. 
These genes could reveal as useful prognostic markers; and prompted the design of a 
TLDA assay platform based on quantitative RT-PCR technology that was optimized to be 
applied to FFPE tissues (see material and methods for more details).  A general overview of the 
experimental approach followed is summarized in Figure 3.3 
GENE SELECTION
INITIAL DATASET
TDB
GSEA 
Gene Set Enrichment 
Analyis
1. TLDA design and methodological validation of targets_  64 -gene format
60 genes , 52 cases
MDB
T-test selection of genes FDR <0.15
cHL cell lines ( L428, L540, HDLM2, L1236)
29 cHLpatients
Genes 
overexpressed in 
cHL cell lines
Genes 
overexpressed in 
cHL tumor samples
Microenvironment
pathways enriched in  U 
2. TLDA design and analysis of an independent data set_  32- gene format
30 genes , 282 cases
Tumor Microenvironment
Tumor pathways
enriched in  U 
Favourable vs  Unfavourable
Figure 3.3 Experimental design. After characterization of the tumor (TDB) and microenvironment (MDB) 
databases, GSEA allowed the selection of genes to be included in TLDA assays. F, favorable; U, 
unfavorable. 
Initially, an assay that allowed the study of 64 genes was designed. From the most highly 
enriched pathways in the TDB and MDB, 56 representative genes (top score) were chosen 
(Table 3.3) for inclusion in TLDA assay. They were selected based on the strength of their 
ability to discriminate patients with a good or bad treatment response (enrichment score of 
the genes in each pathway) and the biological relevance of the pathway. In addition, 4 other 
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genes were also included in the platform: BCL2, IRF4, and FOXP3 based on their previously 
prognostic significance (Alvaro et al., 2005; Rassidakis et al., 2002a) and TNFSRF8 (CD30) due 
to its expression in HRS cells  
 In this first model, 4 endogenous genes (HMBS, GUSB, TBP and GAPDH) were included in 
order to select the two best ones for data normalization. GeNorm algorithm (Vandesompele et 
al., 2002)(available inside Integromics package ) detected  HMBS and GUSB as the most stable 
ones, thus being  selected for further analysis (see material and methods for details). 
Table 3.3 Top GSEA enriched pathways associated with unfavorable outcome  and  highest scoring 
genes  
GENE SETS ENRICHED IN 
TDB 
NES Nom p-val GENES TLDA assay 64 
G2M PATHWAY -1.67 0.016 AURKA CENPE MAD2L1 
    BUB1B CENPF MAPRE1 
    BUB3 CHEK1 NBS1 
    CCNH CSE1L NUMA1 
    CDC2 HMMR   
GS PATHWAY -1.50 0.052 RAMP. CCNH CDK7 
    CCNA2 CDC6   
     CCNE2  CDC2   
G1 PATHWAY -1.35 0.145 BCCIP CCNH CDKN2C 
HISTONE PATHWAY -1.26 0.151 H1F0 H2AFX HIST1H3D 
CHAPERON PATHWAY -1.24 0.269 DNAJA2 HSPA4 HSPA9B 
    HSP90AA1     
DRUGS -1.23 0.204 DCK RRM2 TYMS 
     MLH1 TOP2A   
MET PATHWAY -1.20 0.203 GRB2 PTPN11   
MAPK PATHWAY -0.83 0.736 GRB2 MAPK14 MAPK9 
    MAP3K7 MAPK6   
MITOCHONDRIAL PATHWAY -0.77 0.883 BCL2 BCL2L1 CASP3 
    CYCS     
GENE SETS ENRICHED IN MDB NES Nom p-val GENES TLDA assay 64 MODEL 
T-CELLS -1.50 0.063 CD3D CD8B1 DPP4 
    SH2D1A     
MONOCYTE/MACROPHAGE -1.39 0.161 ALDH1A1 ITGA4 LCP1 
    LYZ STAT1   
TCYTOTOXIC PATHWAY -1.13 0.367 CD3D CD8B1   
TH1 -0.80 0.656 IFI16 IRF4   
DENDRITIC PATHWAY -0.78 0.745 RSN     
NES_ Normalized Enrichment Score; Nom p val_ Nominal probability 
 
The final set of genes included a balanced representation of those associated with the 
tumor cells and microenvironment being intrinsically associated with the pathogenetic 
characteristics of cHL. As commented, G2-M pathway included several important genes 
associated with the regulation of the spindle checkpoint, such as AURKA, MAD2L1, BUB1B, 
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BUB3, CHEK1, and CDK1 (CDC2). Most of these genes are known to be involved in 
chemoresistance and some of them are considered as potential therapeutic targets. RSN, an 
intermediate filament-associated protein highly expressed in the HRS cells that may contribute 
to neoplastic transformation in Hodgkin´s disease (Hilliker et al., 1994),was also found in this 
study. 
Interestingly, there was also a representation of cell cycle regulators specifically 
related with drug metabolism including TOP2A (cellular target of Adriamycin), TYMS, and 
RRM2, which have been associated with drug resistance in different tumor models (Farrugia et 
al., 2003; Wang et al., 2004). In addition, the presence of the chaperones (frequently 
overexpressed in cancer cells) in the selected genes was taken into account with HSP90AA1, 
HSPA4 and HSP90A. 
On the other hand, microenvironment signature was overrepresented by genes 
involved in the Th2 immune response, such as cytotoxic and regulatory T cells (FOXP3), already 
described to independently predict patient survival (Kelley et al., 2007).  
3.5 TLDA analysis and relationship with treatment response.  The Integrated Risk Score. 
 This first TLDA assay model was applied to an initial set of patient samples obtaining 
adequate RT-PCR profiles (Ct value <35) for 43 out of the 52 FFPE cases analyzed (82.7%). 
Differences in the distribution of classic clinical variables (age, gender, stage) between the two 
groups were not statistically significant. Although the main aim was the development and 
technical optimization of an exploratory tool for cHL tumor model, normalized expression 
levels (∆Ct) (using HMBS and GUSB) of individual selected genes were on average 
overexpressed in the unfavorable group. Additionally, T-test comparison among outcome 
groups of all genes grouped into the Integrated Risk Score was significant (p=0.025) with 
higher expression levels in the Unfavorable outcome group (Figure 3.4). 
Due to the limited number of cases analyzed (43 cases); some overlap of the 
Integrated Risk Score values was observed. However, it confirmed the potential prognostic 
value of the genes included in this preliminary assay and prompted to study a larger series of 
patients for validation and development of a predictor model. In fact, ROC analyses showed a 
set of genes with significant p values (p<0.05): BCCIP; CASP3, CCNE2, CTSEL1, CTSL, CYCS, DCK, 
DNAJA2, HSP90AA1, HSPA4, ITGA4, LYZ, RSN and TYMS. A logistic regression model integrating 
these genes had an overall 100% predictive accuracy for the series (χ2 =51.049; p< 0.001). 
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When leave-one out cross validation (CV) was applied, classification accuracy decreased to 
69.5 % thus highlighting the need of further validation studies. 
 
Figure 3.4 Box-plots of the Integrated Risk Score. It was defined as the logarithmic mean of expression 
levels of all genes included in the TLDA assay format 64 (metagen), in each patient outcome group.  
Black line within the box represent the median of each. Box group values are within the first and third 
quartiles. Whiskers (error bars) extend from each end of the box to the adjacent values in the data and 
represent the most extreme values within 1.5 times the interquartile range from the ends of the box. 
Symbols, outliers. 
Despite the fact that RT_PCR is a sensitive and precise tool for determining gene 
expression in tissues, some cases yielded low quality Ct results (Ct>35) due to the inherent 
degradation and small amount of RNA extracted from FFPE tissues. The inclusion of a pre-
amplification step in the analysis was tested in 13 cases, including 2 previously considered to 
be low quality. Adding a pre-amplification step (PreAmp Master Mix , Applied Biosystems ) all 
cases yielded good results (100% Ct<35) showing  a mean reduction in Ct values of 4,49 cycles 
(mean Ct value= 25,62± 4,76 using PreAmp versus 30,1± 3,40 without preamp) without  
introducing any amplification bias. Thus, pre-amplification was included in all analyses did in 
the second part of this study to ensure results’ reliability. 
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3.6 Development of the predictor model:  Molecular Risk Score  
The genes included in the assay (TLDA format 32) used to develop the final predictive 
model (TLDA assay 32) were selected from the initial ones, chosen on the basis of their 
prognostic capability  (evaluated by logistic regression and  ROC analysis as previously 
commented) and their capacity to represent biological functions identified as relevant in cHL 
pathogenesis (Sanchez-Espiridion et al., 2009). Additionally, the strength and consistency of 
primer and probe performance was taken into account (Sanchez-Espiridion et al., 2009). This 
selection consisted of 30 genes that were tested in 282 samples and adequate RT-PCR profiles 
were obtained in 262 of 282 cases (93.9%). The samples were afterwards randomly split and 
assigned to either training (n= 183) or validation series (n=79) (See material and 
methods).Normalized expression levels (∆Ct) of individual genes varied considerably among 
samples. However, when univariate regression analysis was applied to the normalized 
expression data, a set of 20 genes were found to be significantly associated with treatment 
response (p < 0.05) (Table 3.4). 
These 20 genes identified by univariate logistic regression analysis were further 
studied by cross-validation to improve the initial selection. When cross validation methods 
were applied, the genes most frequently found in prognostic models consisted on a panel of 
11 genes included in the final model: BCL2, BCL2L1, CASP3, HMMR, CENPF, CCNA2, CCNE2, 
CDC2, LYZ, STAT1 and IRF4.  
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Ideally, a model based on relative contributions of genes clustered on their respective 
functional groups would be more consistent than one derived for individual genes. Then, these 
final 11 selected genes were classified into biological functional groups on the basis of their 
known biological relationship and their correlated expression estimated by the Pearson 
correlation coefficient (Table 3.5). Pearson correlation coefficient was significant between the 
genes included in each of the signatures (p<0.001) apart from IRF4 that was included as 
independent predictive gene since there were neither distinct functional relationship nor 
statistical correlation with other genes or pathways. 
Table 3.4 Univariate logistic regression analysis of significant genes and crossvalidation  analysis 
      Cross-validation algorithms 
     SVM DLDA KNN Total CV count (%) 
Gene name  p value  Hazard ratio (95% CI) CV % CV % CV %   
HMMR 0.000 1.160 (1.082- 1.243) 136 90.67 148 98.67 149 99.33 96.22 
LYZ 0.000 0.800 (0.738- 0.866) 131 87.33 149 99.33 147 98.00 94.89 
CENPF 0.005 1.148 ( 1.041- 1.265) 22 14.67 111 74.00 142 94.67 61.11 
CASP3 0.014 1.104 (1.020- 1.194) 26 17.33 115 76.67 134 89.33 61.11 
BCL2L1 0.001 0.836 (0.751- 0.931) 26 17.33 98 65.33 129 86.00 56.22 
STAT1 0.000 0.810 (0.748- 0.878) 21 14.00 103 68.67 125 83.33 55.33 
CCNE2 0.001 1.152 (1.057- 1.255) 21 14.00 98 65.33 127 84.67 54.67 
CCNA2 0.000 1.243 (1.137- 1.358) 18 12.00 102 68.00 120 80.00 53.33 
BCL2 0.000 1.191 (1.089- 1.303) 20 13.33 88 58.67 123 82.00 51.33 
IRF4 0.020 0.872 (0.777- 0.978) 13 8.67 63 42.00 108 72.00 40.89 
CDC2 0.000 1.123 (1.052- 1.199) 20 13.33 60 40.00 102 68.00 40.44 
MAD2L1 0.001 0.853 (0.779- 0.933) 15 10.00 49 32.67 98 65.33 36.00 
GRB2 0.000 0.868 (0.818- 0.921) 9 6.00 52 34.67 96 64.00 34.88 
TYMS 0.002 1.167 (1.058- 1.287) 12 8.00 46 30.67 92 61.33 33.33 
DNAJA2 0.004 0.849 ( 0.760- 0.947) 9 6.00 37 24.67 37 24.67 30.89 
H2AFX 0.000 0.884 (0.831- 0.941) 9 6.00 39 26.00 90 60.00 30.66 
IFI16 0.000 0.823 (0.740- 0.916) 9 6.00 37 24.67 90 60.00 30.22 
BUB3 0.001 0.838 (0.752- 0.934) 9 6.00 36 24.00 90 60.00 30.00 
ALDH1A1 0.007 0.878 (0.799- 0.965) 9 6.00 37 24.67 37 24.67 30.00 
HISTH3D 0.000 0.876 (0.827- 0.928) 9 6.00 35 23.33 89 59.33 29.56 
Note. Genes with total crossvalidation (CV) count >40 % were selected. SVM_supprt vector machine; DLDA_diagonal 
linear discriminant analysis. NN_ K-nearest neighbor 
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Individual genes were weighted using diagonal linear discriminant analysis (DLDA) into 
their corresponding functional pathways, and then subsequently correlated with the clinical 
patient outcome using multivariate logistic regression. The multivariate logistic regression 
analysis correlating the mentioned functional pathways with the clinical patient outcome 
showed that Cell Cycle and Apoptosis terms were associated with an unfavorable outcome 
whereas IRF4 and Macrophage activation seemed to have protective effects. The optimized 
final model was based on relative contributions of each of the four gene functional terms, as 
described by the following equation: 
 
Molecular Risk Score = exp (fx)/ [1+exp (fx)], where f(x) = 
Constant (-0-913) + (0.401 x Apoptosis) + (0.284 x Cell Cycle) + (-0.301x Macrophage Activation) + (-0.143 x IRF4). 
 
This equation generated a continuous probability function defined as Molecular Risk 
Score (MRS) to treatment failure that was calculated for each case and ranged from 0.06 to 
0.813 values. In order to stratify patients according to their MRS value we used ROC analysis to 
define a threshold dividing the series into high-risk group (MRS≥0.3) and low-risk group 
(MRS≤0.3) (Figure 3.5). 
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Table3.5  Gene expression correlation analysis of genes grouped in pathways 
Macrophage activation LYZ STAT1       
LYZ Pearson correlation 1        
p  value          
N 263        
STAT1 Pearson correlation .559(**)        
p value 0.000         
N 263 263       
Apoptosis  BCL2 BCL2L1 CASP3     
BCL2 Pearson correlation 1       
p  value         
N 263       
BCL2L1 Pearson correlation .293(**) 1      
p  value 0.000        
N 263 263 1     
CASP3 Pearson correlation .387(**) .132(*)      
p value 0.000 0.032       
N 263 263 263     
Cell Cycle CENPF CCNA2 CCNE2 CDC2 HMMR 
CENPF Pearson correlation 1     
p  value       
N 263     
CCNA2 Pearson correlation .474(**) 1    
p  value 0.000      
N 263 263    
CCNE2 Pearson correlation .688(**) .433(**) 1   
p  value 0.000 0.000     
N 263 263 263   
CDC2 
 
Pearson correlation .595(**) .525(**) .535(**) 1  
p  value 0.000 0.000 0.000    
N 263 263 263 263  
HMMR Pearson correlation .615(**) .497(**) .609(**) .596(**) 1 
p value 0.000 0.000 0.000 0.000   
N 263 263 263 263 263 
IRF4  -           
*** significant correlation 
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Figure 3.5.Panel of 11 genes and the molecular risk algorithm.  A) The molecular risk algorithm was 
based on the relative contributions of each of the four gene functional groups from the tumoral HRS and 
their reactive microenvironment as follows:      Molecular Risk Score = exp (fx)/ [1+exp (fx)],  where fx = 
(-0.319) + (0.401 x Apoptosis) + (0.284 x Cell Cycle) + (-0.301 x Macrophage activation) + (-0.143 x IRF4). 
Coefficients were derived from a multivariate analysis, in which positive values indicate that a higher 
level of expression is correlated with a worse outcome, and negative coefficients indicate that a higher 
level of expression of the pathways is associated with better outcomes.  B) Molecular Risk Score as a 
continuous function was used to set a threshold for patient´s stratification by ROC analysis. Patients 
were stratified according to the levels of the molecular risk score into low-risk (< 0.3) and high-risk (≥0.3) 
groups. 
3.7 Validation of the Molecular Risk Score. 
3.7.1 T test comparison: Favorable versus Unfavorable patients. 
 The MRS showed significant differences between outcome groups either in training or 
validation datasets and predicted treatment response with an accuracy of 68.9 percent in the 
estimation dataset and 70 percent in the validation dataset. As expected, patients with 
unfavorable responses showed, on average, higher expression levels than those with favorable 
responses (Figure 3.6). Pathways of MRS score were indeed differentially expressed among the 
Outcome groups at significant values (with exception of IRF4 p=0.074). In agreement with 
estimated coefficients Monocyte/ Macrophage activation  and IRF4 were overexpressed in the 
favorable outcome groups ( thus, with  a potential protective effect ) whereas Apoptosis and 
Cell Cycle pathways showed higher expression in the unfavorable group of patients( Figure 
3.7). 
  
Figure 3.6 MRS differences in validation and estimation sets of samples between favorable (F) and 
unfavorable (U) outcomes. Significant p values were obtained from comparisons using t
Figure 3.7 T-test comparisons of biological functional groups included in the MRS between patients 
with favorable (F) and unfavorable outcome (U).
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3.7.2 Survival Analysis.  Is our model valid? 
The survival estimates of failure-free survival (FFS) in patients from estimation (N = 
183) and validation (N = 79) sets after classification into risk groups according to their MRS 
values (high risk versus low risk) gave significant results in both datasets: 5-year FFS 
probabilities 75.6% versus 45.9 %,( log rank statistic p≈0.000) in estimation and 5-year FFS 
probabilities 71.4% versus. 43.5%, (log rank statistic p<0.004) in validation set respectively. 
However, when overall survival (OS) was used as clinical endpoint not significant results were 
obtained for the validation dataset (log rank test p= 0.38). This was probably due to the low 
number of events (deaths) presented in the validation dataset, thus indicating MRS score was 
not valid for this clinical endpoint. In addition, when all the entire series was analyzed 
significant results were obtained either for FFS or OS (Figure 3.8). 
It should be mentioned that main´s clinical endpoint for this study was first treatment 
outcome (Favorable versus Unfavorable) used for GSEA analysis and MRS development; and 
secondly, FFS was considered for survival analyses. As commented above, the risk score had a 
prognostic effect on FFS in the small independent validation dataset, but not significant effect 
on OS in the validation set was observed. Results obtained for all entire series were not taken 
into account because of a biased statistical analysis and over fitting, thus being just used for 
graphical representation and description of the series.  
These clinical endpoints ( outcome and FFS)  were selected because overall survival (OS) 
involves three other factors that have to be considered separately and were not considered in 
this work (Hasenclever and Diehl, 1998) :  
1. The ability of the initial treatment to control the disease. 
2. An appreciable second chance of a cure with salvage treatment. 
3. Deaths due to the late toxicity or disorders unrelated to Hodgkin´s disease in patients 
with continuous complete remissions, 
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Figure 3.8 Overall and failure-free survival (OS and FFS) analyses using Kaplan-Meier and log-rank test 
in the estimation and validation sets, and in the whole series of patients. Patients are stratified by the 
MRS values (high risk ≥0.3 versus low risk w<0.3). 
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3.8 Integrative Model. Molecular Risk Score and the traditional clinical variables. 
Next step was to evaluate whether the MRS was adding any prognostic value to the 
already established and commonly used IPS. No relation was observed between the individual 
IPS factors and the molecular risk score (low- and high-risk groups), with neither interaction 
nor confusion factors between variables observed (χ2 test non significant).  
In a multivariate Cox proportional hazards model using FFS as dependent variable; just 
MRS was significant (Table 3.6 A). This result was striking, and probably reflecting the 
limitations of this traditional clinical score (Hasenclever and Diehl, 1998).Thus, we analyzed 
each one of the different variables comprising IPS (Hemoglobin, Albumin, Leucocytosis, 
Lymphopenia, Age, Stage IV and Gender) finding  Stage IV also significantly associated with FFS 
in the entire series when a backward stepwise selection Cox regression model was applied 
(Table 3.6.B). 
Table 3.6  The Molecular Risk Score (MRS) and the IPS variables  
A. International Prognostic Score (IPS) and Molecular Risk Score (N = 262) 
 p value Hazard ratio (95% CI) 
Molecular Risk Score 0.000 24.362 (6.268-94.691) 
IPS 0.205 1.111 (0.944-1.309) 
B. IPS variables and Molecular Risk Algorithm (N = 262) 
 p value Hazard ratio (95% CI) 
Molecular Risk Score  0.000 24.715 (6.804-89.768) 
Hemoglobin (< 10.5 g/dl) 0.352 1.243 (0.787-1.963) 
Albumin (< 4 g/dl) 0.504 1.157 ( 0.755 - 1.772) 
Leucocytosis (≥ 15,000/mm
3
) 0.256 1.312 ( 0.821 - 2.095) 
Lymphopenia (< 600/mm
3
) 0.555 0.820 (0.425 - 1.583) 
Age (≥ 45 yr) 0.369 1.227 (0.785 - 1.916) 
Stage IV 0.041 1.552 (1.018 - 2.360) 
Male gender 0.753 0.936 (0.618 - 1.416) 
Finally, and integrative model (Stage IV and MRS) was developed in a Cox regression 
model able to identify a subgroup of patients with a very bad outcome when patients series 
was divided into quartiles. (Fourth quartile: 5-year FFS of 24.3% p<0.0001) (Table 3.7 and 
Figure 3.9). 
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Table 3.7 Cox regression analysis of variables from Integrative model  
 Integrative Cox model (N = 262)  
 p value Hazard ratio 
Molecular Risk Score 0.000 23.782 (6.041 - 94.340) 
Stage IV 0.025 1.409 (1.044 – 1.900) 
 
Figure 3.9 Integrative Model Risk of cHL. The final Cox model integrated the molecular risk score (MRS) 
and Stage IV. Patients in the quartiles 1, 2 and 3 had comparable FFS rates at 5 years (5-year FFS: 76.4 %, 
79,3% and 69,7% respectively) while patients in the quartile 4 showed a 5-year FFS of 24,3 percent  
(p<0,001) 
Moreover, these results showed that MRS biological model was independent of and 
complementary to the conventional International Prognostic Score using multivariate Cox 
proportional hazards analysis. 
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3.9 Conclusion and final remarks. 
As a summary, in this first part of the work: 
- Using two series of training and validation sets of advanced classical Hodgkin lymphoma 
patients an IPS-independent Molecular Risk Score (MRS) has been developed. 
- The MRS described consists on a quantitative RT-PCR assay for patients with advanced cHL, 
incorporating a limited number of genes and pathways from tumor and microenvironment cell 
components, designed for its application to formalin-fixed paraffin-embedded routine 
samples. 
- The MRS integration with clinical stage IV makes possible to derive an Integrative model able 
to identify a subgroup of patients with very bad outcome (a quartile with 24, 3 % FFS at 5 
years). 
- The roles that both tumor components, HRS cells and their reactive microenvironment, are 
playing in patient outcome need to be validated in further studies, since other recent studies 
are showing a relationship between the presence of tumor associated macrophages and a 
poorer patient outcome.  
Some comments and their respective answers than can be concerned are listed below. 
1. It could be thought that MRS results were biased_ However; different datasets were 
used to develop and test the model and its genes.  
2. It could be thought that results are overoptimistic_ To avoid this, crossvalidation 
algorithms were applied 
3. What are they adding to the classical variables? _The model is adding biological 
information (reporting from specific genes and pathways) underlying treatment 
resistance. 
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RESULTS II _MicroRNA signatures with Prognostic Significance in Advanced Classical 
Hodgkin Lymphoma. 
 
MicroRNAs (miRNAs) are small noncoding RNA molecules that regulate gene 
expression at the post-transcriptional level through mRNA interference. They are 
currently emerging as important regulators of biological processes such as proliferation 
and differentiation, and their role in cancer pathogenesis has been demonstrated in 
several malignancies. 
Some attempts have been made to elucidate specific miRNA signatures for the 
characteristic HRS tumor cells and their microenvironment. However, despite these 
studies, the potential prognostic role of miRNA signatures in cHL remains unclear and it 
has not been yet well investigated the relevance of microRNA expression in cHL and 
their putative value for patient outcome prediction. 
In the study reported here, the aim was to investigate the relevance of 
microRNA expression in cHL within a prognostic context. Thus, miRNA expression data 
from the analyses of advanced cHL samples and cHL derived cell lines were used to 
identify specific miRNA profiles from tumoral cells and their non-tumoral 
microenvironment associated with lack of maintained response (in a similar approach 
followed in the first part of this thesis work) including also reactive lymph nodes and 
tonsils as controls to elucidate specific miRNAs for the malignancy. .Additionally, the 
influence of EBV infection on the expression pattern of miRNAs in the patient’s samples 
was examined.  
Finally, a panel of miRNAs was selected to be further studied in a large set of 
patients to derive a miRNA signature able to classify patients and bioinformatic 
analyses were used for identification of molecular pathways and target genes 
potentially altered by the expression of these miRNAs. 
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A general overview of the work is summarized in Figure 4.1  
 
Figure 4.1: Experimental design. The whole series of patients was divided in two major groups, a 
discovery group (29 patients with available frozen tissue for profiling using array technologies) and a test 
group (220 patients with available FFPE tissue from the diagnostic pathological sample). In contrast to 
the experimental approach followed in the first part of this thesis work, all patient samples from test 
group (N=220) were used in the subsequent statistical analyses.  This was used initially looking for 
miRNAs with the most prognostic ability (logistic regression analyses), to afterwards derive a final Cox 
model. 
 
 
 
 
 
  
4.1 Identification of miRNA signatures
4.1.1 Correlation between EBV
To date, hundreds of miRNAs have been identified in humans and other species, 
including viruses. Furthermore,
and that there is an interaction between the host miRNAs and virus mi
2004; Kewalramani et al., 2004
patients. However, the precise role of the EBV in the
interaction between the virus and the malignant cells in cHL might be mediated in part by 
miRNAs. Thus, the presence of EBV in tumors was assessed by conventional 
immunohistochemistry for LMP1 protein and in situ hybridization for EBERs
further explore whether a specific signature of miRNAs was associated with EBV status. For the 
30 cases analyzed, 6 out of the 30 cases were EBV+ whereas the 24 remain
shown neither LMP1 nor EBER1 and EBER2 protein expression.
Figure 4.1  EBV immunohistochemistry pattern
showing positive expression for LMP1 and  positive EBERs in situ hybridization.
First, non supervised analyses 
of EBV+ and EBV- samples, with only some EBV+ tumors clustering together associated wit
overexpression of some EBV miRNAs. 
overexpression of these miRNAs whereas some EBV
encoded miRNAs.  
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- encoded miRNA profiles and EBV status 
 it has been reported that viruses have their own miRNA set 
RNAs 
). EBV is present in the malignant cells of 40% to 60% of cH
 pathogenesis of cHL is unknown. The 
 
.  Immunohistochemical staining of a EBV positive case 
 
of EBV encoded miRNAs showed a random distribution 
Interestingly, many EBV+ cases showed no 
- cases did show high levels of some EBV
Results II 
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Prior studies have shown miRNAs whose expression is influenced by the presence of 
EBV (Wong and Altekruse, 2009). In EBV+ cHL cases compared to EBV- cHL cases, miR-96 , miR-
128a, miR-128b, miR-129 and miR-205 have been shown to be underexpressed whereas miR-
28, miR-132, miR-140 and miR-330 are overexpressed. However, in this set of cHL cases, when 
supervised analysis ( Pomelo T-test ) was applied, the obtained results showed no statistically 
significant differences between EBV+ and EBV- cases in the expression of neither EBV-encoded 
miRNAs (Figure 4.2) nor human miRNAs. This could be due to the low number of EBV positive 
cases among the analyzed ones (just 4 out of the 30 cases analyzed). 
However, although no miRNA signature associated with EBV infection was found,; 
when EVB status was not taken into account, high expression levels of some EBV encoded 
were  observed in cHL tumor samples. Indeed, the signature identified in cHL (when compared 
tumor samples to lymph nodes and tonsil controls) included some EBV-encoded miRNAs such 
as ebv-miR-BART2-5p, ebv-miR-BART5, ebv-miR-BART12, ebv-BART13, ebv-BART16 and ebv-
miR-BART-19-3p. These miRNAs are potentially associated with the viral latency status and 
may serve as an immunomodulatory mechanism in the tumors. 
Thus, although EBV infection seems to be a common finding in cHL, this study was not 
able to identify any specific miRNA signature associated with EBV status. In contrast, some EBV 
negative cases were observed as able to overexpress specific EBV miRNAs thus pointing at the 
limitations that current inmunohistochemical methods based on viral proteins ( LMP1, and 
EBERs) that might not be enough robust to accurate identify all EBV positive cases. 
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(-2,4 ; +2,4) 
Figure 4.2 Supervised t-test (Pomelo tool) of samples EBV-positive and EBV-negative cases. As 
commented, no significant ebv-associated miRNAS were differentially expressed between EBV- and 
EBV+ cases. NA _ ebv- status not determined.  The arrow is highlighting Ebv-miR-Bart-5p remarkable 
expression observed in ebv+ cases. 
The presence of ebv-miR-BART5 in the cHL signature must be remarked and 
mentioned due to the previous demonstration of its antiapoptotic function of this viral miRNA 
that provided the first example for viral modulation of apoptosis through a miRNA. Plausibly, 
different viral miRNAs might target different cellular proapoptotic proteins to promote host 
cell survival. (Choy et al., 2008). Moreover, PUMA has been identified as a cellular target of this 
EBV encoded miR-BART5. This might reveal a new molecular mechanism through which EBV 
confers resistance to apoptosis in HRS cells by counteracting the proapoptotic function of p53. 
Interestingly and also in agreement with prior studies  (Navarro et al., 2007) the small number 
of either cellular miRNAs or EBV- encoded mirRNAS among EBV+ cases and EBV – cases , could 
lead to hypothesize that EBV is not a primary transforming event in cHL. 
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4.1.2 Identification of tumor and microenvironment signatures 
Initial studies are showing that miRNA losses and gains may explain some of the 
biological and clinical features of different lymphoma types, and recent analyses of miRNA 
expression in cHL cells and tumors have also demonstrated deregulated expression of some 
miRNAs in this malignancy.  
To investigate whether specific miRNAs signatures are associated with cHL 
pathogenesis, we assessed the expression levels of 723 human and 76 viral miRNAs using a 
commercially available microarray platform (Agilent technologies). We identified the miRNA 
profile of cHL tumor samples after comparison with normal tissue controls, and characterize 
the signatures attributable to both the neoplastic cells and the microenvironment using miRNA 
expression profiles of derived cHL cell lines.  
“In silico” microdissection approach considering cHL derived cell lines as a model 
system of HRS cells was used in the elucidation of miRNA signatures attributed either for 
tumoral cHL cells or microenvironment.  Thus, supervised T-test (Pomelo II tool, 
http://pomelo2.bioinfo.cnio.es ) of miRNA expression data from 29 frozen tumor samples 
(without overlap with the ones used in gene expression project (Results I) and 5 cHL derived 
cell lines (L428, L1236, L540, HDLM2, KHM2) allowed the identification of 234 miRNAs 
differentially expressed (FDR<0.15) between them. 
Those miRNAs overexpressed in cHL cell lines (134 out of 234) represented HRS miRNA 
signature whereas those overexpressed in tumor samples (the remaining 100 out of 234) 
represented microenvironment signature and were evaluated afterwards for outcome 
association (F vs U).This initial analysis described a miRNA signature in cHL tumors, that 
contained miRNAs putatively expressed by the neoplastic HRS cells or the microenvironment. 
Some of the miRNA identified as part of the cHL signature have been previously described in 
this disease such as miR21, miR31 and miR-17-92 cluster members (miR-17, miR-19a) (Navarro 
et al., 2008; Wong and Altekruse, 2009). As expected, miR-155 known to be overexpressed in 
cHL cell lines showed a strong expression pattern in the cHL derived profiled in this study 
(Figure 4.3). Other members included in the signatures like miR-590-5p, miR-143, miR-145, 
miR-126 have been also described in different tumor types and could have a role in cHL.  
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Figure 4.3 Supervised T-Test between tumoral samples (1) and cHL derived cell lines (2). Heatmap 
represents the 100 top-score differentially expressed genes FDR (<0.15) (either overexpressed (RED) or 
underexpressed (GREEN). As commented, miR-155 showed strong expression levels in cHL cell lines in 
comparison to tumoral samples (arrow). 
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When these identified miRNAs were compared with the previously published miRNA 
signature of cHL (Navarro et al., 2007),  7 out of the 25 miRNAs published by Navarro, showed 
higher expression levels in tumor samples compared to the controls. These consisted on miR-
21, miR-23b, miR-26b, miR-30b, miR-31, miR-126 and miR-135a. However, other known 
miRNAs to be specific for cHL such as miR-16 and miR-24 (Wong and Altekruse, 2009) were not 
observed in the cHL´s signature identified by  this work.  
 
4.1.3 Clinical correlations. Identification of miRNAs outcome-associated in cHL 
 Clinical data of 29 patients were available, thus allowing the study of the relationship 
between miRNA signature and clinical outcome. Using univariate logistic regression analysis, 
response to ABVD therapy of cases was compared: favorable outcome (F), (sustained complete 
response) versus unfavorable outcome (U) (refractary disease). 
When patient outcome was taken into account and based on univariate logistic 
regression analysis, a set of 34 miRNAs were differentially expressed (p<0.05) among 
outcomes and thus being considered for further evaluation by qRT-PCR using FFPE samples 
(Table 4.1). From this set, some miRNAS showed remarkable expression in the cHL cell lines in 
agreement with the previously elucidated tumoral and microenvironmental signatures, thus 
probably reflecting functional properties of the HRS cells whereas the others informed from 
properties of the reactive infiltrate without expression in cHL cell lines in agreement with the 
signatures previously identified (Figure 4.4). Interestingly, these initial selection included 
members of the miR-17-92 cluster such as miR-17, miR-92a, miR-92b and other miRNAs known 
to be involved in cancerogenesis ( like miR-21, miR-21* and mirR-30d). 
The observed differential expression pattern between HRS cell lines (representative of 
HRS cells) and  tumor samples (representative of microenvironment) of miRNAS was clearly 
seen with exception of miR-92b*. As seen in Figure 4.4, expression of miR-92b* was observed 
for either from both HRS cells and the microenvironment. Thus, it should be remarked that 
miRNA adscription to microenvironmental or HRS cells signatures was done taking into 
account statistical T-test results and median general expression of miRNAS between the two 
compared groups. 
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Table 4.1. MirRNA prognostic signatures identified by "in silico" microdisecction. ( N=29) 
Composition of the HRS cells miRNA signature  Composition of the microenvironment miRNA signature 
miRNA Univariate Regression 
Analyses  
cHL cell lines 
expression 
miRNA Univariate Regression 
Analyses 
cHL cell lines 
expression 
hsa-miR-17* 0.0055339 low  hsa-miR-92b* 0.004834 low  
hsa-miR-25 0.0243501 low  hsa-miR-26a 0.0260448 low  
hsa-miR-30d 0.0289642 low  hsa-miR-27b* 0.0446511 low  
hsa-miR-320 0.0359278 low  hsa-miR-148b* 0.0006499 no 
hsa-miR-15b* 0.0359478 low  hsa-miR-204 0.0011748 no 
hsa-miR-30e 0.0367626 low  hsa-miR-539 0.0037592 no 
hsa-miR-23a 0.0476105 low  hsa-miR-609 0.0045141 no 
hsa-miR-216a 0.0486403 low  hsa-miR-132 0.0060738 no 
hsa-miR-93 0.0489202 low  hsa-miR-31* 0.0118676 no 
hsa-miR-378 0.0087782 yes hsa-miR-628-3p 0.0157169 no 
hsa-miR-21* 0.0131724 yes hsa-miR-503 0.0162567 no 
hsa-miR-708* 0.0174565 yes hsa-miR-621 0.0197161 no 
hsa-miR-551a 0.0253349 yes hsa-miR-637 0.0272346 no 
hsa-miR-92a 0.0302539 yes hsa-miR-300 0.029759 no 
hsa-miR-130b 0.0330384 yes hsa-miR-423-5p 0.0324985 no 
hsa-miR-21 0.0371476 yes hsa-miR-937 0.0346731 no 
      hsa-miR-559 0.0371576 no 
      hsa-miR-888 0.0489402 no 
Note. Univariate regression analyses between patient outcomes ( p<0.05 as cut-off value) 
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 (-2.4 ; +2.4) 
Figure 4.4 Heatmap miRNAs prognostic signatures identified by “in silico” microdisecction and 
Univariate Regression Analyses using outcome (Favorable versus Unfavorable) as dependent variable. 
4.2 Laser capture microdissection of HRS cells and microenvironment 
To further investigate whether miRNA composition of both signatures identified by “in 
silico” microdissection was a consistent approach, two of the most expressed miRNAS in cHL 
cell lines (miR-21 and miR-30d) were additionally validated by laser capture microdissection 
(LCM). First, CD30 marker was analyzed as a positive control for HRS cells, thus selecting 800-
1000 HRS cells to be microdiseccted including also fragments of their surrounding 
microenvironment in separate tubes and measuring miRNA expression by RT-qPCR. 
Comparison of both normalized miRNA expression levels (∆Ct) from HRS cells and the reactive 
infiltrate showed higher expression of miR-21 and miR-30d in tumoral HRS cells, thus 
supporting the previously identified miRNA signatures (Figure 4.5). Higher expression in HRS 
cells was more remarkably for miR-30 whereas subtle differences were seen for miR-21.In 
agreement with this results,  preferential expression of miR-21 in the cytoplasm of HRS cells 
has been already demonstrated by other studies by chromogenic in situ hybridization(Navarro 
et al., 2007). 
  
Figure 4.5 Laser capture microdissection of HRS cells (
and miR-30d, normalized levels using RNU44 and RNU48. 
identification before and after microdissection process. B) Normalized (
used as endogenous miRNAs, from both HRS cells and microenvironment fragments.
4.3 MicroRNA signatures related to treatment response and patient outcome
The first endpoint of this study used for initial miRNA selection was the response to
standard first-line treatment considering favorable response (F) and unfavorable response (U), 
as mentioned above without considering data from second
bone-marrow transplantation. 
miRNAs were differentially expressed among patients with favorable and unfavorable 
outcomes, thus being selected and further studied in an independent set of 220 FFPE samples
recruited from different inst
Anderson Cancer Centre (Houston, TX). 
parameters (age, gender, stage, IPS, the individual variables contained in IPS and outcome
favorable versus unfavorable-
(N=220) were not statistically significant (Pearson chi
characteristics of the whole set
and Methods Section. 
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4.3.1 Logistic regression analyses 
Initially, miRNA final selection was done by backward stepwise logistic regression 
analysis process and revealed a 4-miRNA signature (miR-21, miR-30d, miR-30e and miR-92b*) 
related to outcome (Table 4.2) that was able to predict treatment response with an overall 
accuracy of 69.5 percent. 
Table 4.2.  Logistic regression model Test dataset ( N= 220 ) 
 B Sig. Exp(B) I.C. 95.0% para EXP(B) 
mir21 .193 .030 1.212 1.019 1.442 
mir92b* .280 .003 1.323 1.099 1.594 
miR30d -.209 .018 .811 .683 .964 
mir30e -.279 .000 .756 .665 .860 
Constant -1.722 .000 .179   
Table 4.2 Logistic regression analysis and classification table of the miRNA model. 220 FFPE tumor 
samples were analyzed and adequate miRNA RT-PCR profiles were obtained in all cases. Normalized 
expression levels (ΔCt), using RNU44 and RNU48 as endogenous of the individual miRNAs varied 
considerably among samples. However, a multivariate logistic regression analysis identified a 4-miRNA 
signature able to predict treatment response with an overall accuracy of 69, 5 percent. 
In addition, a miRNA expression-based model using the expression of these 4 
microRNAs as a continuous variable was able to predict two risk groups with differences in 
survival probability with FFS at 5 years of 70,7% versus 42,3%  (p=0.03). Its predictive 
performance in the test group of patients was confirmed using the integrated area under the 
ROC curve (ROC value = 0.694). 
4.3.2 Survival analyses. The miRNA score 
In a similar approach as followed in the first part of this thesis work, a Cox proportional 
hazards model analysis was performed to determine the association of the miRNAs initially 
found to have potential association with outcome in the logistic regression analyses. Finally, 
Cox proportional hazard and survival models based on the miRNA expression were derived for 
the entire series (N=220). 
Using a backward stepwise selection algorithm, a Cox model for the entire series 
(N=220) was constructed containing miRNAs found to be associated with FFS.  This analysis 
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highlighted the same 4-mIRNA signature previously found by regression analysis with miR-21, 
miR-92b*, miR-30d and miR-30e significantly associated to FFS (Table 4.8). 
In this multivariate Cox analysis, miR-21 and miR-30d were shown to be positively 
associated with poorer outcomes and FFS (Exp (B) = 1.239 and 1.275) whereas overexpression 
of miR-92b* and miR-30e seemed to have a protective effect.   The 4-miRNA signature ranged 
from 0.291 to 0.895 and was associated to FFS.  Its classification accuracy performance was 
confirmed using the integrated area under the ROC curve (ROC value = 0.727) and after leave-
one-out cross-validation, a 70 % correct classification rate was observed. Additionally, this 
signature was able to stratify patients according to the median expression of the miRNA 
signature into high and low risk groups respectively (cut off point =0.669). Thus, Kaplan-Meier 
estimates showed significant differences in FFS probability between the low risk and the high 
risk groups with 5-year FFS of 77.8 % versus 40.2% (Figure 4.7). 
Table 4.8  Backward stepwise Cox regression analyses in the whole entire series N=220 
  B Sig. Exp(B) IC 95.O% para EXP(B) 
mir21 0.214 0.040 1.239 1.009 1.520   
mir92b* -0.294 0.000 0.745 0.640 0.868   
miR30d 0.243 0.018 1.275 1.043 1.559   
mir30e -0.225 0.023 0.799 0.658 0.970   
 
Figure 4.7 Kaplan Meier analysis failure free survival model miRNA signature.  The final Cox model 
integrated the 4 miRNAs was able to identify two risk groups according to the median miRNA signature 
expression: FFS- 5 years survival rates 77.8 % versus 40.2 % into low and high risk groups respectively. 
 
P=0.0000 
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4.4 MicroRNA target analysis. The miRNA regulatory network 
4.4.1 Bioinformatics target prediction. Diana-MirPath 
In order to gain a deeper insight into the network of genes that might be regulated by 
the set of outcome- related  miRNAs we interrogated the current miRNA target prediction 
databases available,  MiRBase, TargetScan and Tarbase (this last one containing target genes 
experimentally validated). A high amount of targets for each miRNA were identified: as an 
example 198 genes for miR-21, 994 genes either for miR-30d or miR-30e and 640 genes for 
miR-92b* using TargetScanv5. Thus, to summarize results or extract the most relevant ones we 
focused on those target genes commonly found in the different databases. 
Interestingly, the predicted miRNA- gene pairs found for both miR-21 , miR-30d and 
miR-30e included BCL2, BCL2L1, BCL11, BAX, PDC4, RAS, TRAIL3 and p53 (PTEN) among others, 
thus suggesting the potential crucial role of the miRNA regulatory network in the deregulated 
apoptosis mechanism observed in cHL malignancy.  Again, genes implicated in apoptosis 
regulation (BCL2, BCL2L1, BCL11 and BAX) were highlighted, in agreement with the already 
identified signatures as outcome related by microarray gene expression and RT-PCR assays 
(Results I). 
Table 4.9 Target genes mirRNAs include in the signature 
miRNA ID Chr. Pos. Putative Targets  
hsa-miR-21 17q23.1 PTEN*,PDCD4*,TMP1*,SERPINB5*, BCL2, FASLG, IL12A, CDK6, CDCD25A, CCL1, CCL20, 
CCL22, CCR7, PIK3R1, PPP3CA, ACV1R1C,ACVR2A,BMPR2,PITX2,SAMAD7,TGFBR2, BTK, 
NFAT5, MAP2K3, NTF3, MAP3K1, FASLG, FGF1, DUSP8, PPP3CA,TGFBR2, RPS6KA3,CNTFR, 
LIFR,SPRY1, SPRY2, LRP6, 
hsa-miR-30d 8q24.22 BCL2, CASP3, CCNE2, CDC7, IL1A, IL2RA, IL28RA, MAP3K12, MAP3K5,MAP4K4, 
ACVR1,SMAD1,SMAD2,TFDP1, THBS2, KRAS, LYN, VAV3, VAV2, PPP3CA, PPP3CB, PIK3R2, 
NFAT5, PIK3CD,RPS6KA2, CACNB2, BDNF, CRKL, TAOK, SOS1, RAP1B, NLK, NF1, RASA1, 
PDGFRB, NCK2, CBLB, PLCG1, PRKAR1A, SOCS1, LIFR, LEPR, IFNAR, SOCS3, CBLB, JAK1, 
CLCF1, DBF4, E2F3, YWHAZ, ORC2L, TFDP1, ABL1, NFYB, PSME3,HSPA5, 
ITGA6,ITGA5,ITGB3,CAMK2D,LRP6,TBL1X,VANGL1,PRICKLE1,NLK,IFNAR2,SERPINE1,IGF1 
hsa-miR-30e 1p34.2 BCL2, CASP3, IL1A, IL2RA, IL28RA, CCNE2, CDC7,ACVR1, SMAD1, SMAD2, TFDP1, THBS2, 
KRAS, LYN, VAV3, VAV2, PPP3CA, PIK3R2, NFAT5, PIK3CD, PPP3CB, MAP4K4, RPS6KA2, 
CACNB2, BDNF, CRKL, TAOK1, SOS1, RAP1B,NLK, NF1, RASA1, MAP3K12, MAP3K5, 
PDGFRB, NCK2, PIK3R2, CBLB, PLCG1, PRKAR1A, SOCS1, LIFR, LEPR, IFNAR2, SOCS3, CBLB, 
JAK1, CLCF1, DBF4, E2F3, YWHAZ, ORC2L, TFDP1, ABL1, NFYB, PSME3, HSPA5, ITGA6, 
ITGA5, ITGB3, CAMK2D, LRP6, TBL1X, VANGL1, PRICKLE1, SERPINE1, IGF1 
hsa-miR-92b* 1q22 CDK6, CDKN1C , CDC27, CDC42,MAP2K4, MAP3K13, BMPR2, PPP2R2A, RBL2, SMAD6, 
SMAD7, SMURF1, SP1, NFAT5, PIK3R3, , DUSP5, RPS6KA4, RAP1B, NLK, DUSP10, NF1, 
SPHK2, , PRKAR2B, E2F3, , NFYC, NFYB, ITGA6, ITGA5, CXCL5, CTNNBIP1, 
DOCK5,FZD10,TRAF3,SESN3 
The  putative target genes shown were selected based on functional aspects ( Diana-mirPath) and statistical significance ( 
p<0.005).  Chr. Pos. _ Chromosomal position. 
Putative targets identified using mirBase and Target Scan 
* Target genes experimentally validated were identified from TarBase (experimentally validated). 
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A summary of all putative target genes found by the different bioinformatic target 
prediction softwares used (TargetScan, mirBase and TarBase) is shown in Table 4.9.  
The different target prediction algorithms used to look for potential miRNA targets , 
followed similar rules such us the near- perfect sequence match between the first 8 
nucleotides of the 5´end of the miRNA  ( the so called “seed-region” ), conservation of the 
binding site between related species and  thermodynamic parameters. The consequences of 
varying so many parameters are that many times there is little overlap between different 
predictions making it difficult to distinguish true targets from false positives. Nonetheless, it´s 
widely accepted that targets predicted by more than one algorithm have more chances to be 
true targets, thus being the experimental procedure followed in this work (choosing those 
common targets among the different algorithms used) a way to minimize the putative false 
positive results. 
Additionally, to further understand the biological significance of the different identified 
targets, we included Diana-mirPath software (Papadopoulos et al., 2009), a web-based 
computational tool developed to identify molecular pathways potentially altered by the 
expression of single or multiple microRNAs ( http://diana.cslab.ece.ntua.gr/pathways). This 
approach looked for pathways associated to these target genes, paying special attention to 
those ones related to lymphoma pathogenesis. These combined analysis of miRNAs, with 
bioinformatic target prediction from Diana- mirPath revealed a series of genes and pathways 
potentially targeted by the 4 miRNAs of the signature (Table 4.10).  
Table 4.10 Diana-mirPath. Pathway analyses miRNAs included in the signature  
   miRNA ID 
KEGG Pathway  (all miRNAS ) hsa -mir21 hsa-mir30d  hsa-mir-30e hsa-mir-92b 
   - ln(pvalue)   - ln(pvalue)  - ln(pvalue)  - ln(pvalue)  - ln(pvalue) 
TGF-beta signaling pathway  5,39 9,50 0,17 0,17 3,37 
B cell receptor signaling 
pathway  
5,03 5,98 5,52 5,52 0,32 
MAPK signaling pathway  4,52 7,73 1,69 1,69 0,24 
T cell receptor signaling 
pathway  
3,98 1,44 5,86 5,86 0,12 
Apoptosis  2,09 3,82 1,77 1,77 0,11 
Jak-STAT signaling pathway  1,83 4,39 1,94 1,94 2,22 
Cell cycle  1,29 0,01 1,0 1,0 0,40 
P53 signaling pathway 0,09 0,42 0,15 0,15 0,14 
Note _ -ln (p-value): negative natural logarithm of the enrichment p-value calculated for the specific pathway.  The 
program considers as biologically relevant all those pathways with -ln ( p value ) >0  
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A total number of 156 Pathways were highlighted including essential pathways for 
lymphoma survival like TGF-signaling pathways, MAPK signaling pathway, Cell cycle, Apoptosis, 
Jak-STAT signaling pathway, T-cell and B cell receptor signaling pathways. This Diana-mirPath 
bioinformatic analysis also highlighted genes from p53 signaling pathways as putatively 
targeted by the 4 miRNA signature mainly associated to mir30d in agreement with other works 
((Kumar et al.). 
4.4.2 Correlation analyses. 
Finally, correlation analysis was performed using gene expression and miRNA 
expression data from samples that overlapped among both projects, gene expresion project 
(RT-PCR from TLDAS) and miRNA project (RT-PCR data for miRNA Taqman Assays) including the 
11 genes for the MRS model and the 4 miRNAs in the signature. 
 
A set of 96 patient samples had both data (GEP from the 11 genes included in the 
model and miRNA expression obtained by RT-PCR), corresponding all samples to MD Anderson 
Houston cancer centre series.  Interestingly, significant correlation pairs were identified, 
including miR21-BCL2L1 (Spearman's rho correlation coefficient=0.222; p=0.033) and miR21-
CASP3 (Spearman's rho correlation coefficient =-0.207; p=0.043).  The pair miR21-BCL2 
showed a negative correlation coefficient (Spearman's rho correlation coefficient=-0.136) 
although this comparison was not significant.  
 
When apoptosis pathway (BCL2, BCL2L1 and CASP3) was correlated with mir21 
expression a significant correlation was found (Spearman's rho correlation coefficient=0.158); 
p=0.041). These results were again suggesting a crucial role of the identified miRNAS in the 
signature (especially for miR21) into the observed deregulated apoptosis in cHL. Additionally, 
significant correlations were found between both mir21 and mir30d and genes from Cell cycle 
pathway (CCNA2, CCNE2, CENPF and CDC2). However, no other significant correlations were 
found between the other miRNAs included in the signature and the genes included in the MRS 
model neither for mir30e nor mir92b*. 
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5.1 RT-PCR based models. Technological development 
5.1.1 RNA from FFPE samples and qPCR. TLDAs 
As demonstrated by all the studies done until now, transcriptional analysis of cancer is 
proving to be a powerful and increasily useful tool in biomedical research. A goal of these 
studies is the use of gene expression patterns revealed by transcriptional profiling to 
understand the pathogenesis of the disease and then predict prognosis and responsiveness to 
therapy.  However, the practical applications of these advances in the routine clinical care of 
patients are rare, mainly due to the limitations arising from the relatively few cases that can be 
studied when using frozen specimens.  
In this study it has been shown that robust methodologies, based on quantitative RT-
PCR, are suitable for expression profiling of tumors and can be applied to routine FFPE tissue 
samples and that new platforms such as the TLDAs allow an accurate analysis of a limited 
number of genes. Hundreds of reactions can be done simultaneously, enabling large numbers 
of cases to be rapidly assessed. These technologies would be especially useful for identifying 
gene signatures of prognostic significance as it has been already done in other tumor types 
(Glenn et al., 2007). 
From a methodological point of view, quantitative RT-PCR is a robust method to 
quantify RNA abundance being the procedure highly sensitive and reproducible as long as the 
initial RNA is intact. However, breaks in the RNA due to chemical or enzymatic cleavage reduce 
the number of molecules that contain intact amplicons and the number of molecules available 
for amplification decreases. When the described TLDA platforms were initially tested to 
evaluate the feasibility of this tool and the suitability of FFPE samples some limitations were 
detected.  Those limitations were overcome with the optimization of extraction protocols and 
the correct design of the TLDAS. 
 As a summary , in Table 5.1 are listed the problems found during initial setting up of 
the technique, their main cause of origin , the solutions and additional factors that can be 
taken into account to improve  RNA extraction. These included the efficiency of RNA recovery 
from archival samples, fragmentation of the RNA during fixation, quality of PCR primers and 
the size of the amplified amplicon.  Some of these factors were quite difficult to control. While 
many problems related to the isolation of RNA from FFPE can be solved with high 
concentration of proteinase K and long incubation times (overnight) at elevated temperature 
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followed by phenol-chloroform extraction, the fragmentation of the RNA remained the most 
critical factor inherent to the sample and there was not solution. However, in our hands 93, 90 
% of FFPE analyzed samples yielded significant results using phenol /chloroform extraction 
protocol as described in Material and Methods and in agreement with previous works ((Koch 
et al., 2006). 
Table 5.1.  Limitations concerning RNA from FFPE tissues. 
Problem Origin Solution  Additional factors 
1.Low quality RNA It depends on 
the sample  
There is not solution 
93.90% of the samples 
yielded analyzable data 
based on our results  
Sample processing 
Storage time ( less than 10 years) 
2.Low amount RNA It depends on 
the sample 
Number and thickness of 
paraffin sections /  
 (3 sections of 30um) 
Extraction protocol  
Preamplification  
Phenol / chloroform extraction 
Commercial kits 
(column based) 
3.Genes selected   Study´s 
design  
Amplicon length(<100bp) 
 
Choose correct assays  
Load enough RNA 
Additional recommendations included also the preferential use of samples no older 
than 10 years in storage time and to avoid column based extraction protocols (von Ahlfen et 
al., 2007). Interestingly, more recent works suggest that it is also possible to extract mRNA of 
sufficient standard good quality for further transcriptomic analysis from minute FFPE samples 
up to 15 years old (Stewart et al., 2011). Thus, exploitation of retrospective tissue collections 
with robust associated clinical data is possible, although in our hands cases very old didn’t 
work as well as the others, thus suggesting the convenience of quite new samples as 
published. 
We analyzed in more detail the consequences of RNA fragmentation and amplicon size 
on RT-PCR and Ct values. From a theoretical point of view, qRT-PCR is affected by RNA 
fragmentation, as every break in the RNA that occurs between two primers inevitably 
separates the two ends of the amplicon into two different cDNA molecules and is therefore 
lost as template for subsequent PCR reactions. In agreement with this hypothesis, small 
amplicons resulted in more stable delta Ct values (< 32 cycles) than relatively large amplicons 
(median Ct values 32-36 cycles). This phenomenon was previously shown for large amplicons 
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which failed to generate measurable expression values (Godfrey et al., 2000; Lehmann and 
Kreipe, 2001; Specht et al., 2001). As a conclusion, short amplicons should be used for 
quantitation. Therefore, to ensure high quality and fidelity of the TLDA assays amplicon length 
was also considered as selection criterion for genes included in the study, discarding genes 
with longer amplicon length and choosing those ones with length that were preferentially 
lower than 100 base pairs (bp).  
Additionally, we investigated the optimal system of normalization to ensure reliability 
of the qPCR data and 4 putative control genes (HMBS, GUSB, TBP and GADPH) were included 
in the Low Density Arrays (TLDAS) , afterwards selecting two of them (HMBS and GUSB) as 
controls according to GeNorm procedure developed by Vandesompele et al.(Vandesompele et 
al., 2002). As published, degradation related shifts of Ct values can be compensated by 
calculating DeltaCt values between test genes and the mean values of several control genes.  
Thus, these two endogenous selected genes were used to compensate for the changes in 
expression levels resulting from the increased fragmentation of RNA. GeNorm normalization´s  
procedure based on several genes has been already demonstrated by previous studies 
(Antonov et al., 2005) and allowed us to obtained reliable and robust data.  
This study shows how the capabilities of RT-qPCR have been expanded with the 
development of the TLDA platform. Low amount of RNA is required, small amplicons can be 
included and the results obtained from RNA isolated from FFPE tissues  correlates well with 
those ones obtained from fresh tissue (Steg et al., 2006). The application of this RT-PCR based 
platform on two subsequent series of paraffin embedded samples (52 and 282 samples) 
demonstrated the feasibility of applying the platform to paraffin embedded specimens, 
although only short amplicons gave rise to estimable results in the initial TLDA 64 format 
platform as previously commented. However, when the genes included in the TLDA platform 
were subsequently selected taking into account their biological interest, short amplicon 
lengths and several endogenous control genes were used for data normalization, good quality 
data were obtained.  
The approach proposed in this work has been done in breast cancer and other tumor 
types. Based on the preliminary results, we moved a step forward and examined whether RNA 
preamplification could be used in combination with TLDA in order to recover those samples 
that didn´t amplify. Preamplification is a method whereby nanogram amounts of total cDNA 
undergo a multistep process for linear amplification of the initial RNA fraction once it has been 
retrotranscribed to cDNA.  Reproducibility and reliability of Preamplification have been proved 
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and applied also in other works (Ciotti et al., 2009).  In this thesis work was an optimal way to 
ensure precision of Taqman assays, yielding Ct values inferior to 30 cycles, something that is 
especially Important to note taking into account that precision of Taqman arrays started 
dropping of at Ct 30-32 as the number of copies approached to less than 10 copies /µl.  (As 
noted by the manufacter´s recommendations, Applied Biosystems). 
As a final conclusion, TLDA methodology presented in this study represents a robust 
and reproducible technique for quantifying gene expression in tens to hundreds of 
independent genes concurrently in RNA samples isolated from FFPE tissues. It constitutes a 
significant advance in multivariate gene analysis that is less time and labor intensive than 
individually analyzing single genes. 
5.1.2 MiRNA from FFPE samples and qPCR 
Despite the successful results obtained by TLDA (qRT-PCR) from total RNA extracted 
from FFPE whole tissue sections, we additionally evaluated microRNA as an alternative analyte 
for gene expression studies of FFPE samples. Since recovery of quality intact mRNA compatible 
with molecular techniques is often difficult due to the high degradation as previously 
commented, we analyzed the performance of the total miRNA and RNA yield, miRNA recovery 
and robustness of real-time PCR in cHL FFPE samples.  Hypothetically the small size of these 
miRNAs (21 nucleotides medium length) would make them ideal for this kind of molecular 
analyses. In agreement, miRNAs generated quantitative reverse transcription-polymerase 
reaction signals that were more robust and reliable (in terms of lower Ct values, median Ct 
values 25-30 cycles) in comparison with longer mRNAs independently of FFPE block´s age and 
RNA quality. Based in these results, we concluded that miRNA recovery and expression analysis 
when using FFPE samples are more robust and accurate than total mRNAs. This observation 
has been also previously commented by other studies (Doleshal et al., 2008) highlighting the 
suitability and emerging interest of miRNA analyses as a potential diagnostic and prognostic 
tool (Chen et al., 2008).  
In general, mRNA – based assays using total RNA seem to be less reliable, primarily due 
to the suboptimal RNA qualities in these total RNA specimens (92.90 % of adequate RT-PCR 
profiles in total RNA vs. 100 % accurate profiles in miRNA). In contrast to the high degradation 
observed in total RNA samples, miRNAs were uniformly well preserved in the formalin paraffin 
embedded tissues, presumably due to their small size.  This advantage indicates that miRNA 
based assay is most well suited for the molecular analysis of routinely processed formalin-fixed 
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tissues.  Despite differences in the efficiency of the amplifications, this work has proven that 
archival tissue samples can be used for expression profiling either for both genes and miRNAs. 
RNA derived from FFPE samples will be always substantially degraded and this inevitably will 
affect accuracy and sensitivity of expression measurements based on real-time PCR. 
Nevertheless, reliable measurement can still be made for many genes and miRNAs. A 
combination of both miRNA and genes would be and ideal approach to help in the 
identification of prognostic markers and biological processes underlying the different 
malignancies. 
5.2 Gene expression profiling and classical Hodgkin lymphoma 
5.2.1 Microarray-based gene expression and microdisecction 
Gene expression signatures have been identified for the most common types of non-
Hodgkin lymphoma. These studies have proved the ability and feasibility of these technologies 
to identify pathogenic mechanisms, new molecular targets and biological processes involved in 
lymphomagenesis. In addition, the relationship between clinical outcomes and expression 
profiles of different lymphoma types has been proved(Alizadeh et al., 2001). Regarding 
Hodgkin lymphoma, gene expression analysis could provide vital clues and new insights to the 
pathogenesis of the disease and potentially identify specific patterns related with tumor 
aggressivity and/or sensitivity to therapy. However, as mentioned in the introduction of this 
thesis work, the clinical and histological heterogeneity of classical Hodgkin lymphoma and the 
characteristic scarcity of HRS cells have prevented molecular studies.  
Fortunately, during the past ten years, a number of approaches including 
microdissection have tried to resolve the variability in measurements derived from tumor 
heterogeneity. Another approach used in this  work and designated as virtual or  in silico 
microdissection (Alizadeh et al., 2001), avoids the laborious and time-consuming step of 
anatomic microdisecction and consists of confronting the gene expression profiles of whole 
tissue samples to those of cell lines representative of different cell lineages, differentiation 
stages, or different signaling pathways.  This strategy has been used in recent studies (Navarro 
et al), aiming the analysis of whole tissue sections as a good alternative. 
Despite the lack of a perfect model of HRS cells, we hypothesized that gene expression 
analysis on cHL derived cell lines would help to know more about the biology and putative 
pathogenic mechanisms underlying cHL as previously done by other groups (Kuppers et al., 
  
2003; Schwering et al., 2003a
expressed by HRS cells.   
The first part of this thesis work wanted to perform gene expression analysis of whole 
cHL tissues focusing on advanced cHL cases with a double aim: first
either with the neoplastic HRS cells and the microenvironment (By supervised analysis 
comparing gene expression patterns from HL
expression signatures that could be implicat
comparing gene expression patterns from patients with good and bad outcome) .Due to the 
complex composition of the elucidated gene signatures and thinking of a potentially clinical 
application, the attention was finally focused on the development of a model able to classify 
patients according to therapy response that could be applied to a routine diagnostic setting. In 
a multistep approach we first reduced the number of potential predictive genes by using the
GSEA bioinformatic approach and second we move forward from Microarray techniques 
(frozen samples required, economically expensive) to RT
samples easily available, economically affordable) in order to develop a predictive m
potential clinical application. Analyzing a larger and independent patient series, finally a 4
cluster/ 11-gene model was derived from an initial selection of 30 potentially predictive 
markers.  
Figure 5.1 General overview of the different and su
TLDA- Taqman low density arrays. 
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5.2.2 GSEA 
To develop a predictive model clinically useful and simplify the identified signatures, 
the reduction in the number of genes was needed, always preserving the biological 
significance. Thus, Gene set Enrichment Analysis (GSEA) was a very useful tool in this issue and 
allowed the identification of pathways and genes implicated in treatment failure.  
Using GSEA, we found a number of gene sets relevant to biological treatment 
resistance processes with high complexity; these comprised members of different signaling 
pathways ( such us JAK-Stat and apoptosis)  ,the interleukin- and chemokine-family, Cell-cycle 
regulatory genes, including cyclin-dependent kinases, and genes mainly related with G2/M 
transition, G1/S phase and the regulation of spindle checkpoint. Additionally, genes that 
reflected specific cell populations of the immune response were identified, such as specific T-
cells and monocyte/macrophage cells in agreement with previous results. This suggests that, in 
cHL, there may be a limited number of gene sets responsible for the treatment failure 
observed in some advanced stages. Moreover, our identified signatures highlight the same 
biological processes found to be associated with outcome by other studies.  
The comparison performed at a gene set level enabled the identification of common 
biological processes associated to a specific biological question (In this particular case 
treatment failure, favorable versus unfavorable outcomes), and demonstrated that GSEA 
embedded in the statistical workflow procedure is a suitable approach to study gene 
expression data, improving the analysis avoiding the loss of biological information derived 
from single gene studies. A systematic approach such as GSEA is needed to analyze raw data 
from microarray analyses. However, it must be said that when the mass of raw data is derived 
from a relatively small number of tissue samples (like in this case, 29 samples) results are 
descriptive and validation studies are afterwards needed.   
5.2.3 The Molecular Risk Score model 
Important functional pathways were highlighted by GSEA analysis to be related to 
treatment response but the final model presented in this work included just the expression of 
11 genes grouped into 4 pathways.  
In the MRS model, expression of BCL2, BCL2L1, CASP3, HMMR, CENPF, CCNA2, CCNE2 
and CDC2 included in Apoptosis and Cell Cycle pathways respectively correlated with short FFS, 
in agreement with the repeated observed abnormal expression of antiapoptotic BCL2 family 
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proteins in HRS cells (Bai et al., 2007; Garcia et al., 2003), thereby contributing to their survival.  
Both, BCL2 and BCL2L1 are frequently expressed by HRS cells and their levels have been 
associated with short FFS patients treated with ABD or equivalent regimens (Rassidakis et al., 
2002a). This confirms the importance of Apoptotic regulators for cHL outcome prediction and 
the complex regulatory network of this process.  
The second signature, Cell Cycle (HMMR, CENPF, CCNA2, and CCNE2) was mainly 
composed by genes encoding for regulatory proteins of the S and G2/M phases of the cell 
cycle (as identified by GSEA analyses), pointing out directly to the implication of cell 
proliferation in treatment resistance, which is again in agreement with already identified 
markers.  Interestingly, a significant prognostic value for CDC2 (CDK1) and CCNA2 (Cyclin A2) at 
protein level has been described for both cHL (Bai et al., 2004) and non- Hodgkin lymphomas 
(Wolowiec et al., 1999) (related to both  FFS and OS).  These results provide more evidences 
that the cell cycle and apoptosis regulation are profoundly disturbed and closely related in cHL 
disease. 
In addition, IRF4 (MUM1) expression was associated with longer FFS. This gene is an 
interferon regulatory factor, lymphocyte specific , induced after nuclear factor- B (NF-ĸB) 
activation , which controls B-cell proliferation and differentiation and has recently been shown 
to be up-modulated by CD40 engagement in HL cells (Aldinucci et al.). The lack of IRF4 protein 
has been previously associated with outcome in cHL, representing a potential adverse 
prognostic factor.  
Interestingly, both IRF4 and BCL2L1 represent well-known NF-ĸB target genes whose 
expression is induced after NF-ĸB pathway activation. Thus, the MRS included important 
subrogates from the NF-ĸB activation, thought to be an essential pathogenetic mechanism in 
this disease.  In fact, it has been recently described how the inhibition of the canonical NF-ĸB 
pathway enhances the proapoptotic effects of Adriamycin, thus also identifying NF-ĸB 
inhibition as an interesting therapeutic approach. (Bednarski et al., 2009). 
 
 Finally, LYZ and STAT1 genes, observed to be expressed at high levels in a subset of 
tissue monocytes and activated macrophages, were also included in this model, and correlated 
with prolonged FFS and better outcome.  These results are in contrast with other published 
data (Sanchez-Aguilera et al., 2006; Steidl et al.) in which a signature overexpressed in patients 
with unfavorable outcomes was found, mainly including genes expressed by specific 
subpopulations of macrophages. The discrepancy in the results concerning the role of 
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macrophages may have arisen from technical differences (RT-PCR vs. microarray gene-
expression and immunohistochemistry) or the selection of markers such as LYZ and STAT1 in 
this study, reflecting a specific functional status of the monocyte-macrophages.  Different 
series of patients have been investigated in the different studies using three main techniques: 
GEP, IHC and QT-PCR.  Distinct macrophages markers (LYZ, STAT1, CD68 and CD163) illustrating 
different functional subpopulations have been found associated with favorable or unfavorable 
outcomes in these series. The differences in the different studies are too important as for 
reaching a simple conclusion; this is why in the MRS model LYZ and STAT1 were denominated 
as markers of activated macrophages, avoiding the use of the term macrophage-markers. It is 
not clear whether the expression of these markers (STAT1 and LYZ)) is related or not with the 
number of macrophages, but both are markers either of specific macrophage subpopulation or 
specific stages of macrophage activation. 
 
Importantly, RT-PCR studies do not intend to restrict the analysis to specific cell types, 
and are measuring RNA extracted from the whole tissue. Thus, we can´t conclude whether 
there is any inconsistency between the results, or if there is a contradiction between results 
obtained by others and our data. Different things are compared using diverse techniques in 
series of patients that have been collected using different criteria (advanced HL or just all 
classic HL stages).  This fact indicates that prognostic parameters are strictly dependent of the 
technique used and the sample selection.  Nevertheless, with the adequate case selection and 
using multicenter studies, general conclusions can be obtained when prospective validation 
studies are performed. 
 
5.3   Gene expression profiling studies in cHL and survival.  
 
5.3.1 Identifying genes associated with disease outcome in CHL 
To date (year 2011), only four studies based on gene expression profiling have been 
published and reported by different teams, including the one from this thesis work. All of them 
using nonmicrodiseccted frozen samples (whole tissue samples) obtained from patients with 
cHL during diagnostic lymp-node biopsies and leading to the discovery of new prognostic 
factors. In general, the number of frozen profiles samples studied was relatively small with 
exception of the study reported from Steidl et al. (Table 5.2). 
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Table 5.2  Gene expression profiling of in silico microdissection 
Reference cHL tumor samples Microarray 
platform Nº of 
genes 
Control 
samples 
Gene signature 
associated 
with 
Validation 
set 
Multivariate 
analysis 
(Devilard et 
al., 2002) 
21 samples limited 
and advanced stages 
 ~1000 genes   Cell lines  
Tissues 
(adenitis, 
lymphomas) 
Sustained CR No No 
(Sanchez-
Aguilera et al., 
2006) 
29 samples advanced 
stages 
~9.348 genes Cell lines  Sustained CR 250 samples IHC 
TMA 
No 
(Chetaille et 
al., 2009) 
63 samples limited 
and advanced stages 
~16.000 genes Cell lines  
 Tissues 
(adenitis, 
lymphomas) 
Sustained CR 146 samples IHC 
TMA 
EFS OS 
(Steidl et al.) 130 samples limited 
and advanced stages 
~25.000 genes No Absence of P 166 samples IHC 
TMA 
PFS 
OS 
cHL_ classical Hodgkin lymphoma; RS: Reed Sternberg, IHC: immunohistochemistry; TMA: Tissue microarray; EFS; event-free 
survival;CR: complete remission;  P: progression; OS: Overall survival; PFS: progression-free survival, DSS: disease-specific survival 
 
Despite some limitations inherent to all the studies, such as the use of different control 
samples, there are some common conclusions to most of them, such as the relevance of B cells 
and macrophages on patient outcome, thus pointing out to the important role of both the 
tumoral component and the microenvironment, as initially hypothesized in this work. 
Additionally, signatures found in this work by the GSEA analysis and the TLDA RT-PCR arrays 
highlighted the same functions identified by other studies (Table 5.3), confirming their results. 
In addition to the already performed studies, the work done in this thesis adds 
something new, being an interesting (although preliminary attempt) to translate gene profiling 
results (always dependent from frozen sample availability) to the routine diagnostic clinical 
setting. Here, the design of a real time PCR –based low density array including relevant genes 
identified  by reanalyzing gene expression data and finally leading to the development of an 
score ( Molecular Risk Score _ MRS) able to identify patients with different risks to treatment 
failure, is presented .  
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Table 5.3. Gene expression signatures outcome related in cHL.   
Technique  N HRS cells signatures  Microenvironmental signatures Ref 
GEP 29 Cell cycle, apoptosis, signals 
transduction. 
Immune response, extracellular 
matrix, adhesion and cell- cell 
signaling 
(Sanchez-Aguilera 
et al., 2006) 
RT-PCR array 52 Cell cycle ( G2-M  and G1 
pathway s) , histones , 
chaperones   and  MAP 
kinase pathway,  
T cell pathway , Monocyte 
Macrophage  
(Sanchez-
Espiridion et al., 
2009) 
RT-PCR array 282 Cell cycle, apoptosis  Macrophage activation, IRF4 (Sanchez-
Espiridion et al., 
2010) 
GEP 63 BCR signaling,  apoptosis, cell 
metabolism  
Stroma remodeling genes (Chetaille et al., 
2009) 
GEP  130 HRS cell related genes  Macrophages, Monocytes 
Metaloproteinases, angiogenic 
cells 
(Steidl et al.) 
N_number of samples; ref_ reference;GEP_ Gene expression profiling;RT-PCR_ reverse-transcription polymerase  
chain reaction.   Adapted from (Derenzini and Younes, 2011) 
 
5.3.2 Macrophages and outcome in Hodgkin lymphoma 
The main conclusion that arises from the different works done till now is that the 
presence and features tumor associated macrophages is related with the outcome of classical 
Hodgkin lymphoma. Multiple reports now support the value of tumor associated macrophages 
in pretreatment biopsies for outcome prediction in classical cHL, although there is still some 
debate about the precise markers to be analyzed. Most important evidences have been 
suggested from gene expression profiling studies (Table 5.2) of large patient´s series, as also 
done in this work. Interestingly, from these studies two markers (CD68, CD163) in particular 
have emerged as putatively useful immunohistochemical markers. The different studies used 
gene expression profiling to identify a gene signature of tumor-associated macrophages 
associated with treatment failure, in an approach methodologically similar to the one here 
followed.  
 
 The exact role that macrophages play is still under discussion, their activation stage 
and immune polarization pattern (thus, balance between Macrophage type 2 (M2) or type1 
(M1) populations, each one having different biological effects, seems to be critical in the final 
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outcome of patients. Conclusions are out of the scope this thesis work, but our GSEA analyses 
also identified a set of genes (ALDH1A1, LYZ, and STAT1) related to monocyte /macrophage as 
overexpresed in patient with unfavorable outcomes. Moreover, Molecular Risk Score Model 
included also genes related to macrophages as associated to treatment outcome, thus again 
highlighting their role in cHL outcome prediction. 
 
5.3.3 Influence of other populations (GSEA pathways). 
Data obtained either by GSEA analyses and the subsequent development of MRS 
reinforced previous observations done by previous works concerning the influence of B cells, 
different T-cell subsets (T regulatory cells, T helper, cytotoxic T cells), Natural killer (NK) cells, 
and stromal components in the cHL outcome. Besides further detailed molecular 
characterization of HRS cells, it appears that cellular enrichment, and a better characterization 
of macrophages, B cells and T cells from primary clinical material will be critical to gain further 
insight into the unique phenotype and profile of cHL. Therefore, as observed by the signatures 
here identified, in classical Hodgkin lymphoma many processes (related to either both HRS 
cells or microenvironment) are implicated in patient´s outcome. A better understanding of this 
complex scenario will help in the identification of patients at high risk of relapse. 
5.4. MicroRNAs and classical Hodgkin lymphoma. New insights into outcome prediction and 
pathogenesis. 
In the second part of this thesis work, we decided to investigate the relevance of 
microRNA expression in cHL and used miRNA expression data from the analysis of advanced 
cHL samples and cHL-derived cell lines to identify identify specific miRNA profiles from the 
tumoral cells and their non-tumoral microenvironment, that were associated with lack of 
maintained response, following the same schema as for the one followed for MRS 
development. Functional and practical relevance of microRNA expression signatures in 
advanced cHL was investigated. Thus, using microarray analyses of freshly frozen tissue we 
identified a specific 34 miRNA signature that included miRNA deregulated in the 
microenvironment and in the tumor cells. Further analyses using RT-qPCR in an independent 
series of 220 advanced cHL patients derived a four miRNA signature able to classify cHL 
patients according to treatment response.  
This signature included already described oncomirs such as miR-21 and miR-30d 
(Kumar et al.; Medina et al.). In agreement with these results, overexpression of miR-21 has 
  Discussion 
 
 
115 
been reported in cHL and other lymphoma types (Gibcus et al., 2009; Navarro et al., 2008; 
Rossi et al., 2010). Additionally, its overexpression has been associated with poorer prognosis 
in many tumor types: squamous cell carcinoma (Gao et al., 2011), non-small cell carcinoma of 
the lung(Gao et al., 2011), esophageal cancer (Hummel et al., 2011), colorectal 
adenocarcinoma (Kulda et al., 2010), pancreatic cancer (Hwang et al., 2010), and astrocytoma 
(Zhi et al., 2010). Also, anti-miR-21 treatment inhibits cell growth in vitro and tumor growth in 
a breast cancer mouse model (Si et al., 2007).  Moreover, a mouse model conditionally 
expressing miR-21 lead to a pre-B-cell lymphoma (Medina et al.), and when miR-21 was 
inactivated, the tumors regressed completely. 
The other interesting member of the identified signature related to poorer outcome is 
miR-30d that has been reported to promote tumor invasion and metastasis, in hepatocellular 
carcinoma, and a prognostic signature for this tumor also included this miRNA (Yao et al., 
2010). MiR-30d is co amplified with miR-30b (8q24.22-23) in medulloblastoma, independent of 
MYC amplification (Lu et al., 2009).  Also, inhibition of miR-30d expression increases 
endogenous p53 expression and induces cellular apoptosis in several cell lines, including one 
from multiple myeloma without TP53 mutations (Kumar et al.). 
Finally, the other two members of the identified signature (miR-30e and miR-92b*) 
have been also related to several cancer types. Thus, miR-30e has been related to metastasis-
related hepatocellular carcinoma (Budhu et al., 2008) whereas miR-92b* has been found to be 
overexpressed in brain primary tumors. 
Due to the oncogenic features of these miRNAs found in other types of cancer, in 
Hodgkin lymphoma the overexpression of miR-21,miR-30d, miR-30 and miR-92b* could have a 
functional relevance in the prognostication of the disease course and could represent 
interesting therapeutic targets. Moreover, miR-21 and miR-30d, are thought to target 
apoptosis regulation (BCL2, BCL-XL, BCL11, BAX, PCD4, RAS) known to be altered in cHL, thus 
suggesting an interesting link among miRNA abnormal expression and the characteristic 
deregulated apoptosis of HRS cells. In agreement with this hypothesis, correlation analyses 
between our gene and miRNA expression data supported this relationship.  Nevertheless, 
despite our promising results, this has to be further validated by functional analyses in cHL cell 
lines looking for targets and putative mechanisms underlying the observed effects (see 5.6 
Perspectives). 
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5.5 A combined approach_ miRNAS and genes.  
As commented, transcriptional analysis has identified gene, miRNAs and pathways 
associated with clinical failure in HL, but both the biological relevance and clinical applicability 
of these data are still pending of further development.  Thus, a combined analysis of samples 
including both expression levels (genes and miRNAs) could help in a better understanding in 
the cHL malignancy. 
The main goal of this work was to search for a gene and miRNA signature associated 
with clinical outcome and treatment response in cHL patients treated with ABVD or variants 
using FFPE tissue samples. Interestingly, when combined both signatures significant 
interactions where found between genes related to apoptosis (BCL2, BCL2L1 and CASP3) and 
Cell cycle (CCNA2, CCNE2, CENPF and CDC2) with miR-21 and miR-30d expression, thus 
probably indicating direct modulation of the intrinsic apoptosis pathway and the cell cycle, 
respectively.  
Taken together, these results suggest that overexpression of these miRNAs could 
inhibit drug-induced apoptosis, and could be linked with the clinical resistance to 
chemotherapeutic therapy of cHL.  
5.6 Perspectives.  miRNAs, translating Basic Science into Therapy. 
The emergence of miRNAs as important cancer prevention genes is likely to have a 
large effect on gene therapies that are designed to block tumor progression. Large-scale 
expression screens, similar to those described in this thesis work, that compare miRNA levels 
in tumors with different molecular phenotypes; will be useful for identifying novel miRNAs that 
are involved in chemoresistance and biological processes underlying cHL pathogenesis. 
Functional screens designed to select miRNA genes that specially control processes known to 
be altered in cHL, such as apoptosis will also help in this search. Interestingly, this study 
highlighted the abnormal expression of a small set of miRNAS, including miR-21 (expressed in 
different tumor types as mentioned). In the future, the administration of synthetic anti-sense 
oligonucleotides that encode sequences complementary to mature oncogenic miRNAs might 
effectively inactivate miRNAs in tumors and slow their growth. Preliminary data using cHL cell 
lines (L428 and L1236) suggest that inhibition of two of miRNAs from the identified signature 
(miR-21 and miR-30d) sensitizes cHL cells to doxorubicin treatment and thus might constitutive 
an alternative therapeutic approach in cHL.  
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CONCLUSIONS/CONCLUSIONES 
1. Specific gene and miRNA signatures for the HRS cells and their microenvironment can 
be identified in cHL tissue samples, and improve the understanding of cHL 
pathogenesis. 
2. Specific gene and miRNA patterns can be identified by comparing expression data from 
two completely opposed biological situations (treatment responders (Favorable 
outcome) versus non-responders (Unfavorable outcome) being GSEA analysis a 
convenient tool for elucidation of gene pathways and biological processes associated.  
3. Treatment response in advanced cHL patients is partially determined by a combination 
of factors related to both either the HRS cells and their reactive microenvironment. 
Classical HL microenvironment plays a role in the disease pathogenesis, promoting 
tumor growth, survival and immune escape. Thus, treatment response in cHL was 
observed  to be related with: 
a. Gene sets / functional pathways enriched in the HRS cells: G2/M checkpoint of 
the cell cycle, Regulation of the S phase and G1/S transition, Histone 
modification, Drug metabolism, Chaperons and the MAP kinase signaling 
pathways. 
b. Gene sets / functional pathways enriched in the microenvironment: T-cell 
populations: T-cytotoxic cells, Natural Killer cells and Macrophage activation. 
4. Real time quantitative PCR (RT-qPCR) provides an effective technique for analyzing 
gene and miRNA expression in RNA and miRNA isolated from FFPE tissues. 
Additionally, it can be used for clinical prediction in HL paraffin-embedded diagnostic 
samples, using a selection of genes and miRNAs identified after analysis of the initial 
molecular signatures.  
5.  An 11-gene model including 4 functional pathways (cell cycle, apoptosis, macrophage 
activation and interferon regulatory factor 4) can identify groups of patients with 
different risks of treatment response and failure. This model defined as Molecular Risk 
Score (MRS) can be combined with Stage IV to improve patient´s stratification and 
derive an Integrative model able to identify a subgroup of patients with very bad 
outcome. 
6. A 4-miRNA signature is related to outcome in advanced cHL patients and can stratify 
patients (high- versus low-risk patients) according to their median expression levels. 
This signature includes previously described oncomirs such as miR-21, miR-92b* and 
other relevant regulators of cell functions such as miR-30d and miR-30e. 
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CONCLUSIONES 
1. En linfoma de Hodgkin, es posible la identificación de firmas moleculares de genes y 
microRNAS características de ambos componentes tumorales, células de Hodgkin y Reed 
Sternberg y su microambiente tumoral, mediante el análisis de muestras tumorales.  
2. Perfiles específicos de expresión de genes y microRNAs pueden ser identificados por 
comparación de datos de expresión de fenómenos biológicos opuestos, tales como respuesta a 
tratamiento (pacientes respondedores vs pacientes no respondedores), constituyendo la 
herramienta bioinformática GSEA de gran utilidad cara la caracterización de las rutas y 
fenómenos biológicos implicados. 
3.  La respuesta a terapia en pacientes con linfoma de Hodgkin está determinada por una 
combinación de factores relacionados con las propias células neoplásicas y su complejo 
microambiente. Dicho microentorno constituye una parte funcional de la enfermedad con un 
papel relevante en la promoción del crecimiento tumoral y la supervivencia del tumor. Así, la 
respuesta a terapia en linfoma de Hodgkin clásico se asocia con alteraciones en: 
a. Rutas biológicas y genes atribuibles al componente tumoral (células HRS) l: puntos 
de control mitótico G2/M, G1/S y fase S),  modificación de histonas, metabolismo de 
drogas, chaperonas y la ruta de señalización de las MAP quinasas.  
b. Poblaciones celulares específicas del microambiente tumoral: poblaciones de células 
T, células T citotóxicas, células Natural Killer (NK) y distintos estados de activación de 
macrófagos.  
4. Los ensayos basados en PCR cuantitativa  constituyen una aproximación robusta y fiable 
para el análisis de expresión de genes y microRNAs  en muestras parafinadas con potencial 
aplicabilidad clínica.  
5. Se ha desarrollado un modelo predictivo de fallo terapéutico  basado en la expresión de 11 
genes  agrupados en sus correspondientes grupos funcionales (Ciclo celular, apoptosis, 
activación de macrófagos y factor regulador de interferon  (IRF4)). El algoritmo desarrollado 
(Riesgo Molecular) es capaz de identificar subgrupos de pacientes con diferentes 
probabilidades de fallo.  Su combinación con la variable clínica  estadio IV permite la 
identificación de un subgrupo de pacientes de muy mal pronóstico. 
6. Se ha identificado una firma molecular de 4 microRNAs asociada a pronóstico en linfoma de 
Hodgkin avanzado.  La expresión miR-21, miR-30d, miR-30e y miR-92b* permite la 
estratificación de pacientes en dos grupos de riesgo (alto versus bajo riesgo) acorde con su 
mediana de expresión. 
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JoaquI¤n Gonza¤ lez-Carrero,12 Concepcio¤ n Poderos,13 CarmenBellas,5Manuel F. Fresno,14 CesarMorante,15
MariaJ. Mestre,8 Miguel Mendez,9 FranciscoMazorra,16 Eulogio Conde,17 Angel Castan‹ o,10
Pedro Sa¤ nchez-Godoy,11Jose¤ F.Tomas,4 ManoloM.Morente,2 Miguel A. Piris,1andJuan F. GarcI¤a1,3
for the Spanish Hodgkin’s Lymphoma Study Group
Abstract Purpose:Despitemajoradvances inthe treatmentofclassicHodgkin’s lymphoma(cHL),f30%of
patientsinadvancedstagesmayeventuallydieasresultof thedisease,andcurrentmethodstopredict
prognosisare ratherunreliable.Thus, theapplicationof robust techniquesfor theidentificationofbio-
markers associatedwith treatment responseis essential ifnewpredictive tools are tobedeveloped.
Experimental Design:We used gene expression data from advanced cHL patients to identify
transcriptionalpatterns fromthe tumoralcells and theirnonneoplasticmicroenvironment, associat-
edwith lackofmaintained treatment response.Gene-SetEnrichmentAnalysiswasused to identify
functionalpathwaysassociatedwithunfavorableoutcomethatwere significantlyenrichedineither
theHodgkin’s andReed-Sternberg cells (regulationof the G2-M checkpoint, chaperones, histone
modification,andsignalingpathways)or thereactivecellmicroenvironment(mainly representedby
specificT-cellpopulations andmacrophageactivationmarkers).
Results:Toexplore thepathways identifiedpreviously,weusedaseriesof52 formalin-fixedparaf-
fin-embeddedadvancedcHL samples anddesigneda real-timePCR-based low-density array that
included themost relevant genes. A large majority of the samples (82.7%) and all selected genes
wereanalyzedsuccessfullywith this approach.
Conclusions:The resultsof this assaycanbe combinedina single risk score integrating thesebio-
logicalpathwaysassociatedwithtreatment responseandeventuallyusedinalarger series todevel-
opanewmolecularoutcomepredictor foradvancedcHL.
Classic Hodgkin’s lymphoma (cHL) is considered to be a
monoclonal proliferation of the characteristic Hodgkin’s and
Reed-Sternberg (HRS) cells. It has a defective B-cell immuno-
phenotype and a characteristic paucity of neoplastic cells within
the tumor, diluted in a reactive inflammatory background
composed of nonneoplastic B and T cells, macrophages,
eosinophils, neutrophils, and plasma cells, which comprise
the bulk of the infiltrate. The B-cell origin and monoclonality of
the HRS cells have been clearly established in the last two
decades (1–3). Likewise, progress has been made in recent
years to clarify the particular composition of the enigmatic cell
microenvironment (4, 5). This is commonly made up of a
characteristic TH2 environment (6) that is involved in the
production of survival signals.
Although cHL is usually a curable tumor, f20% to 30% of
patients relapse and eventually die due to progressive disease
or complications of therapy (7, 8). Patients with advanced
disease and clinical indicators of poor prognosis, and those
with disease that persists despite optimized primary treatment,
may need intensified treatment (9). In contrast, another
fraction of patients could benefit from reduced treatment.
Current predictive systems are based on clinical and analytic
variables, such as the International Prognostic Score devel-
oped for advanced cHL (10), but this still fails to identify a
significant fraction of patients with very short failure-free
survival (11).
In this context, the application of robust molecular
techniques to identify molecular events and biological
processes associated with treatment response is a necessary
requisite for developing new predictive tools that enhance the
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accuracy of classic clinical variables. Reliable prognostic
markers could allow subsets of patients to be identified
who might benefit from alternative approaches. Several
biological markers identified in tumor tissues, alone (12–
15) or in combination (16), have been associated with
clinical outcome and treatment response. Not surprisingly,
most of these variables reflect functional characteristics of the
neoplastic cells in tumor tissues, revealed by proteins with
deregulated expression in HRS cells.
The HRS cells and the inflammatory infiltrate secrete
cytokines, creating an elaborate cross-talk that contributes
to the survival, proliferation, and immune evasion of the
tumor cells in many interacting ways (17–20). Recent studies
have indicated that the composition of this background is
also associated with the clinical outcome of the patients
(21–23). Indeed, previous work by our group identified
specific gene signatures associated with treatment response
that are attributable to the nonneoplastic component of the
tumors (24).
In the study reported here, we used gene expression data
from the analysis of advanced cHL samples and Hodgkin’s
lymphoma-derived cell lines (24) to identify specific markers
from the tumoral cells and their nonneoplastic microenviron-
ment that were associated with lack of maintained treatment
response. Gene-Set Enrichment Analysis (GSEA) was used to
recognize specific functional pathways related to outcome that
were significantly enriched in both tumor and microenviron-
ment components. We then assigned the signatures generated
from both tumoral and stroma cells to specific pathways in
an attempt to ascribe a biological significance to these
findings. To investigate these cell subpopulations and chosen
pathways, we selected 64 genes that could be assayed using
quantitative real-time PCR [RT-PCR; TaqMan low-density
array (TLDA) assays] on formalin-fixed, paraffin-embedded
(FFPE) tissues.
Materials andMethods
Samples. The initial gene data set has been generated previously
(24) by gene expression profiling of tumor samples from 29 patients
with advanced cHL, including 14 responders and 15 nonresponders to
doxorubicin, bleomycin, vinblastine, and dacarbazine treatment and 5
Hodgkin’s lymphoma-derived cell lines (L428, L540, L1236, HDLM2,
and HDMYZ; Fig. 1). This data set was used here to define Tumor
Database (TDB) and Microenvironment Database (MDB) and subse-
quently in GSEA analysis.
To validate specific genes to be analyzed in FFPE samples, we selected
an independent series of 52 cHL cases that did not overlap with the
initial series used for expression profiling. Patients were eligible if they
fulfilled the same stringent criteria as described previously: ages between
18 and 65 years, advanced cHL (Ann Arbor stage IV, III, or IIB with bulky
masses), proven HIV-negative status, and receiving a standard chemo-
therapy regimen that included doxorubicin (doxorubicin, bleomycin,
vinblastine, and dacarbazine or variants). All tissue samples consisted of
representative specimens of pretreatment lymph node biopsies and were
collected after revision by the institutional review board.
The endpoint of this study was maintained response to therapy.
Good response (favorable outcome) was considered to be that where
patients sustained complete response (18 months), whereas a bad
response (unfavorable outcome) was concluded for cases without
complete response or in patients with early relapses following
previously published criteria (25). Because the main aim of this study
was to analyze the biological variables associated with response to the
initial therapy, data from second-line and salvage therapies and/or
bone marrow transplantation were not considered.
Supervised analysis and identification of tumoral and microenviron-
ment signatures. The analysis of the initial data set (24) was done
using the GEPAS (26) tool, which is available free at http://
www.gepas.org. To identify genes that are differentially expressed
between tumoral samples and cHL cell lines, we used a supervised
method based on Student’s t test with a correction for multiple testing.
Unadjusted P values were obtained from 100,000 permutations of the
data set and false discovery rates were calculated by the method of
Benjamini and Hochberg (27). Genes with false discovery rate < 0.15
were considered to be differentially expressed and used to construct the
TDB and MDB employed in subsequent analyses.
Gene expression profiles of cHL-derived cell lines and tumor tissues
were compared to facilitate the separation and recognition of the
signatures attributable to both the neoplastic cells and the microen-
vironment, thus making possible the building of two databases (TDB
and MDB) for further analysis and selection of the genes analyzed in
the TLDA assay. We first compared gene expression profiles from the
tumoral samples and from cHL-derived cell lines. Genes overexpressed
in the cell lines were included in the TDB, whereas those genes
overexpressed in the tumor samples were assigned to the MDB. To
avoid loss of information, genes that were not differentially expressed
were included in both databases used in further analyses. This first
analysis was done without consideration of clinical outcomes of the
patients.
Immunohistochemical validation of selected genes in TDB and MDB.
Additionally, we selected a limited number of genes for validation at the
protein level using tissue microarray-based immunohistochemical
techniques on an independent series of 142 cHL cases as described
previously (24). Primary chosen antibodies were as follows: anti-BCL2
and anti-LYZ (DAKO); anti-BCLXL (Zymed Laboratories); anti-CASP3
and anti-CCNA (Novocastra Laboratories); anti-CTSL (Alexis Biochem-
icals); anti-STAT1, anti-SH2D1A, anti-CDK7, anti-HSP70, and anti-
MUM1 (IRF4; Santa Cruz Biotechnology); anti-CCNH (Cell Signaling
Technology); and anti-HIST1H and anti-HISTH2A (Upstate Biotech-
nology). These markers were chosen as representative of the different
signatures and for the availability of reliable antibodies for paraffin-
embedded tissue.
Translational Relevance
Current predictive systems, basedonclinical andanalytic
variables, fail to accurately identify a significant fraction
of advanced Hodgkin’s lymphoma patients with short
failure-free survival. The purpose of this work was the
identification of biological processes underlying treatment
failure in advanced Hodgkin’s lymphoma patients and the
subsequent development of a quantitative real-time
PCR-based assay to be applied to routine formalin-fixed,
paraffin-embedded samples. This study identifies gene
subsets expressed by the tumoral cells and the Hodgkin’s
microenvironment and shows that robust methodologies
based on quantitative real-time PCR are suitable for
expression profiling of tumors and can be easily applied to
paraffin-embedded samples allowing interrogating a
limited number of selected genes in a single sample. In
addition, we have identified functional signatures associat-
ed with treatment response and showed the potential
prognostic capacity of our assay finding a positive correla-
tion between the expression of the proposed genes and
treatment response.
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GSEA and pathway selection. GSEA was done to identify sets of
related genes that might be correlated with therapy resistance. The TDB
and MDB were tested separately. Briefly, this method uses t statistics to
search for predefined lists of gene-sets that are associated with
phenotypic differences. The pathways were selected taking into
consideration the particular cellular heterogeneity of cHL tumors, thus
including all public pathways associated with immune response and
cell-cell interactions. We used Biocarta18 and other public sources
available through the Molecular Signature Database19 to generate the
gene-set databases used for the TDB and MDB analysis. The final gene-
set databases were manually curated and enriched in pathways also
known to be involved in lymphoma pathogenesis and immune
response.
The rank of all genes in the sets was determined and an enrichment
score was calculated as described previously (28). We performed the
analysis with 1,000 random class permutations. Genes with >30% of
missing values were excluded, and only gene-sets meeting the gene-set
size criteria (min = 10, max = 500 genes) were analyzed.
Representative genes were chosen from the most highly enriched
pathways in the TDB andMDB. They were selected based on the strength
of their ability to discriminate patients with a good or bad treatment
response (enrichment score of the genes in each pathway) and the
biological relevance of the pathway. To ensure high quality and fidelity of
TLDA assays, we also considered amplicon length as a selection criterion,
discarding those genes with longer amplicon length.
RNA extraction and cDNA synthesis. Total mRNA was extracted from
three 10 Am FFPE sections as described previously (29), with minor
modifications. Briefly, paraffin sections were deparaffinized by incuba-
tion with 1 mL xylene for 10 min. Samples were then centrifuged and
the supernatant was removed. After an ethanol wash, tissue pellets were
dried, resuspended in 200 AL RNA lysis buffer containing 50 mmol/L
Tris, 0.5 mmol/L EDTA (pH 8.0), and 10% SDS, and incubated
overnight at 65jC with 10 AL proteinase K (20 mg/mL; Qiagen). RNA
was purified by phenol-chloroform extraction followed by precipitation
in an equal volume of isopropanol in the presence of 1 AL lineal
acrylamide (Ambion) at -20jC. The RNA pellet was washed once in
70% ethanol, dried, and resuspended in 30 AL Tris/EDTA (pH 8). For
genomic DNA removal, DNase digestion was carried out by treating the
total RNA with 5 AL DNase I (1 units/AL; Epicentre Biotechnologies).
The final RNA concentration (A260: A280) and purity (A260:A230
ratio) was measured using a NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies).
First-strand cDNA was synthesized from total RNA using the High
Capacity cDNA Archive kit (Applied Biosystems) in 50 AL reactions
using these cDNA samples for TLDA analysis according to the
manufacturer’s instructions.
Limited amounts of tissue and RNA and cDNA were available from
FFPE samples, which restricted the number of genes and cases that
could be analyzed in some samples, so we were able to test the
application of the TaqMan PreAmp Master Mix (T-PreAmp; Applied
Biosystems) in 13 cases and 32 genes. The pooled assays were diluted to
a final concentration of one-fifth that of the PreAmp primer/assay pool.
Initial experiments comparing the volume of PreAmp reaction
recommended by the manufacturer (total PreAmp reaction volume:
Fig. 1. Workflow analysis and enrichment
plots for gene-sets identified by GSEA in
unfavorable outcome group used to design
TLDA assay. After characterization of the
tumor and gene databases, GSEA allowed
us to select the genes included in theTLDA
assay. F, favorable outcome; U, unfavorable
outcome.
18 www.biocarta.com
19 http://www.broad.mit.edu/gsea/msigdb/index.jsp
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50 AL) and a tenth of that volume (5 AL PreAmp reaction volume) gave
identical PreAmp results, so we subsequently used the latter volume for
reasons of cost-effectiveness. The chosen PreAmp reaction involved 14
cycles of preamplification with 15 s at 95jC and 4 min at 60jC. The
preamplified products were diluted at a ratio 1:10 and used as templates
for RT-PCR analysis.
TLDA assays. To explore the different pathways, we designed a
quantitative RT-PCR assay based on TLDA technology (Applied
Biosystems) to measure the expression of each selected gene in
triplicate.
Each cDNA sample (30 AL) was added to 20 AL RNase-free water and
50 AL of 2 TaqMan Universal PCR Master Mix (No AmpErase UNG;
Applied Biosystems). The mixture was then transferred into a loading
port on a TLDA card. The card was centrifuged twice and sealed and
PCR amplification was done using Applied Biosystems Prism 7900HT
Sequence Detection System under the following thermal cycler
conditions: 2 min at 50jC and 10 min at 94.5jC for 40 cycles (30 s
at 97jC and 1 min at 59.7jC).
Reference gene selection. The TLDAs included HMBS, GUSB, TBP,
and 18S as reference genes based on their proven role as housekeeping
genes (30, 31) and their uniform expression in preliminary TLDA assays
in FFPE tumor samples from this series of cHL (data not shown).
To determine the stability of the selected reference genes, the
geNORM Visual Basic application available in RealTime StatMiner
(Integromics), also known as the pairwise approach, was used as
described previously by Vandesompele et al. (32). This tool exploits the
principle that the expression ratio of two perfect reference genes should
be identical in all samples regardless of the experimental condition or
cell type. The program calculates the gene stability measure M by
determining the average pairwise variation between a particular
reference gene and all other control genes. Genes with higher values
ofM have greater variation in RNA expression. By stepwise exclusion of
the least stable gene and recalculation of the M values, the most stable
reference genes are identified. Finally, a normalization factor was
calculated based on the geometric mean of the expression levels of the
best-performing reference genes. The two best candidates, HMBS and
GUSB, were chosen for normalization of gene expression levels.
Statistical analysis and prediction algorithm. Association between
standard clinical variables (age, gender, stage, and International
Prognostic Score) were assessed by the Pearson m2 test.
Fig. 2. Immunohistochemical analyses of selected markers. Proteins identified in the six panels on the left correspond to genes included in theTDB, and their expression is
mainly restricted to tumoral HRS cells (BCL2, MUM1, CDK7, BCL2L1, CASP3, and CCNA2).The four panels on the right correspond to genes included in the MDB, and the
expression of the respective proteins is mainly restricted to fibroblasts, macrophages, and reactiveTcells (CTSL, STAT1, LYZ, and SH2D1A), whereas tumor cells are negative.
The histograms represents the number of postive cHL samples for each marker expressed by the HRS cells of the microenvironment.
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To illustrate the relationship between gene expression data and
treatment response, we derived an integrated risk score, which was
defined as the logarithmic mean of the expression levels of all the genes
included in the analysis.
Associations between gene expression levels and the probability of
treatment response were estimated by logistic regression analysis.
Normalized expression levels were used as independent continuous
variables and phenotype-favorable (responders) versus phenotype-
unfavorable (nonresponders) as the dependent variable. Receiver
operating characteristic curves were used to compare the predictive
sensitivity and specificity of individual genes (33) and to select the best
predictive markers.
All statistical analyses were two-sided and done using SPSS 13.0
(SPSS).
Results
Clinical variables of selected samples. Differences in the
distribution of classic clinical variables (age, gender, and stage)
between the two groups of patients (responders and non-
responders) were not statistically significant (m2 test). Interest-
ingly, the International Prognostic Score did not differ
significantly between the two groups either because the sample
was too small to conclude statistical significance for the
magnitude of the difference measured or because the analysis
was restricted to advanced Hodgkin’s lymphoma cases (data
not shown).
Supervised analysis and identification of tumor and microen-
vironment signatures. Established cHL-derived cell lines are
commonly used as model systems for characterizing the
biology of HRS cells, whereas tumoral samples represent a
complex mixture of tumoral cells and reactive microenviron-
ment (34). To identify genes expressed by either HRS cells or
the microenvironment, we first compared gene expression
profiles from the tumoral samples and gene profiles from cHL-
derived cell lines. We identified 3,463 of the 5,134 genes that
were differentially expressed (false discovery rate V 0.15). Those
genes overexpressed in the cell lines were included in the TDB
(1,705 genes), whereas those overexpressed in the tumor
samples were assigned to the MDB (1,758 genes). Genes that
were not differentially expressed (false discovery rate > 0.15;
1,671 genes) were considered as potentially being expressed by
both populations and were included in both databases.
The gene composition of the two databases confirms this
hypothesis: the TDB contains genes known to be expressed
by HRS cells. These include cell cycle regulators, signaling,
surface receptors, and transcription factors. In addition, genes
reported previously as being expressed by HRS cells in studies
done by other groups (35), such as TNFRSF8 (CD30),
GATA3, the tumor necrosis factor receptor family member
RANK, and the metalloproteinase TIMP1 (36, 37), were
incorporated within the TDB. The MDB is mainly composed
of genes involved in the immune response. We performed an
additional validation by showing that genes attributed to the
TDB (BCL2, BCLXL, CASP3, CDK7, MUM1, and CCNA) were
indeed expressed by the tumoral cells, whereas genes
attributed to the microenvironment (STAT1, LYZ, SH2D1A,
and CTSL) were expressed by macrophages, reactive T cells,
and fibroblasts (Fig. 2). This confirms and extends previous
observations on the expression of ALDH1A1, RRM2, CDC2,
MAD2L1, TOP2A, and PCNA (35).
These gene signatures were used to generate two different
data sets with the gene expression data of the previously
Table 1. GSEA-enriched pathways associated with unfavorable outcome
Normalized
enrichment score
Nominal
probability
Genes included in TLDA assays
Gene-sets enriched in TDB
G2-M pathway -1.67 0.016 AURKA CENPE MAD2L1
BUB1B CENPF MAPRE1
BUB3 CHEK1 NBS1
CCNH CSE1L NUMA1
CDC2 HMMR RSN
Gs pathway -1.50 0.052 RAMP CCNH CDK7
CCNA2 CDC6
CCNE2 CDC2
G1 pathway -1.35 0.145 BCCIP CCNH CDKN2C
Histone pathway -1.26 0.151 H1F0 H2AFX HIST1H3D
Chaperone pathway -1.24 0.269 DNAJA2 HSPA4 HSPA9B
HSP90AA1
Drug resistance pathway -1.23 0.204 DCK RRM2 TYMS
MLH1 TOP2A
Mitogen-activated protein kinase pathway -0.83 0.736 GRB2 MAPK14 MAPK9
MAP3K7 MAPK6
Mitochondrial pathway -0.77 0.883 BCL2 BCL2L1 CASP3
CYCS
Gene-sets enriched in MDB
T-cell pathway -1.50 0.063 CD3D CD8B1 CTSL
SH2D1A IFI16
Monocyte/macrophage -1.39 0.161 ALDH1A1 ITGA4 LCP1
LYZ STAT1
NOTE: The most significantly enriched pathways identified by GSEA in TDB and MDB associated with the unfavorable outcome group and the
highest-scoring genes from each pathway selected for investigation in the TLDA assay.
Hodgkin’s Lymphoma Outcome Prediction
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described 29 cHL patients containing the genes characteristic
of the reactive microenvironment and the HRS cells,
respectively.
GSEA. We hypothesized that response to treatment in cHL
might be associated with concurrent alterations in biological
pathways or coregulated gene-sets rather than with randomly
identified individual genes. However, comparisons made on
the level of gene lists indicated considerable divergence when
different statistical methods or data sets were used. Thus, we
applied GSEA to the two previously generated databases (TDB
and MDB) taking into consideration that group testing
techniques and pathways recurrently identified by this method
are more likely to be reliable than those identified by other
approaches (38).
We used independent gene-sets for each database (the
complete list of gene-sets used in the analysis is presented in
Supplementary Table S1). Taking into consideration the low
number of samples and their uneven phenotypic distribution,
we used GSEA for testing hypotheses and designing the TLDA
assay rather than for final statistical analysis.
GSEA analysis highlighted 15 of the 46 functional path-
ways associated with unfavorable outcome in TDB and 13 of
48 in MDB. The TDB analysis identified two gene-sets (G2-M
and G1-S) that were significantly enriched at nominal
probabilities of <5% in HRS cell signature-containing genes
such as AURKA, MAD2L1, BUB1B, BUB3, CHEK1, and CDK1
(CDC2) associated with the regulation of the spindle
checkpoint, in agreement with previous results (24). Also,
G1 pathway (CCNH, CDKN2C, and BCCIP), histone (H1F0,
H2AFX, and HIST1H3D), chaperones (DNAJA2, HSPA4,
HSPA9B, and HSP90AA1), and other signaling pathways
such as mitogen-activated protein kinase pathway and
mitochondrial signaling were identified as being enriched in
the unfavorable outcome group by GSEA analysis (Table 1;
Fig. 2). Additionally, in TDB, the drug resistance pathway
was enriched in the unfavorable outcome group of patients.
This pathway contains genes such as TOP2A and MLH1,
which are known to be involved in transport and metabo-
lism of doxorubicin.
On the other hand, in the analysis of the MDB, T cells,
monocyte/macrophages, and dendritic cell pathways were the
most enriched gene-sets among those associated with unfavor-
able outcomes. These included genes reporting from specific
T-cell populations, highlighting the important role of the
microenvironment.
TLDA analysis and relationship with treatment response. The
results of GSEA analysis prompted us to design a TLDA assay
with the highest-scoring genes from the previously identified
pathways reporting on functions known to be altered in cHL
disease that might be related to outcome and treatment
response.
The selected genes for the TLDA assays are listed in Table 1.
We selected 56 representative genes from the most enriched
pathways in the TDB and MDB based on the strength of their
performance in discriminating different outcomes and the
biological relevance of the pathway. Three additional genes,
BCL2, IRF4, and FOXP3, were included based on their
published prognostic significance in cHL (12, 23, 39). TNFRSF8
(CD30) was also included because of its common expression in
HRS cells (the complete list of genes is available in Supple-
mentary Table S1).
Fifty-two FFPE tumor samples were analyzed and adequate
RT-PCR profiles (Ct < 35 for endogenous genes; ref. 40) were
obtained for 82.7% of cases (43 of 52) and normalized using
the two most stable endogenous genes (HMBS and GUSB)
identified by geNORM analysis.
Normalized expression levels (DCt) of the individual genes
varied considerably among samples. However, consistent with
previous results (24), most of these genes were, on average,
overexpressed in the unfavorable group. As shown in Fig. 3, the
integrated risk score was significantly higher in the bad
outcome group (P = 0.025), although with some overlap in
the values, probably due to the limited number of cases. This
result confirms that the functional pathways selected by GSEA
are also associated with treatment response in an independent
series of cHL patients.
The area under the receiver operating characteristic curves,
with a cutoff of 0.65, which corresponds to P values < 0.05, was
used to identify the best predictive genes, of which there were
14: BCCIP, CASP3, CCNE2, CSEL1, CTSL, CYCS, DCK,
DNAJA2, HSP90AA1, HSPA4, ITGA4, LYZ, RSN, and TYMS
(Table 2). With this set of genes, the logistic regression model
had an overall 100% predictive accuracy for the whole series
(m2 = 51.049; P < 0.001), indicating that individual genes could
be included in a single model of outcome prediction. Due to
the small number of cases analyzed, leave-one-out cross-
validation gave a value of 69.5% accurate classification. Thus,
these initial results need to be confirmed in a larger series to
develop a predictive model of sufficient accuracy that can be of
general application.
Reanalysis of the caseswith inadequateRT-PCRdata. Although
RT-PCR is a sensitive, precise, and reproducible tool for
determining gene expression in tissues, the quality and amount
of RNA that can be extracted from FFPE tissues are low, which
Fig. 3. Box-plots of the integrated risk score, defined as the logarithmic mean of
expression levels of all genes included in theTLDA assays (metagen), in each patient
outcome group. Black line within the box, median of each group. Box group
values are within the first and third quartiles.Whiskers (error bars) extend from each
end of the box to the adjacent values in the data and represent the most extreme
values within1.5 times the interquartile range from the ends of the box. Symbols,
outliers.
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limits the number cases and target genes that can be analyzed.
PreAmplification techniques (PreAmp) could enhance the
sensitivity and quality of the LDA assay. Thus, we also tested
the application of the TaqMan PreAmp Master Mix technique
in a subset of cases and genes in the study and were thereby
able to recover some missing data and improve the quality of
the assay.
The study of a few cases yielded RT-PCR results considered of
low quality, with Ct < 35. With the aim of increasing the
proportion of analyzable cases in further studies, we tested a
preamplification step in a smaller set of 13 cases, including 2
previously considered to be low quality. This allowed us to
analyze all the genes and cases and yielded a mean improve-
ment of 4.49 cycles (mean Ct value = 25.62 F 4.76 using
PreAmp versus 30.11 F 3.40 without PreAmp), which
represents more reliable and better quality data.
Discussion
The increasing knowledge of Hodgkin’s lymphoma patho-
genesis and the complex relationship existing between the
neoplastic HRS cells and their microenvironment have not yet
been translated into the development of new predictive tools
that could accurately identify Hodgkin’s lymphoma patients
with different risks of treatment response and failure.
Transcriptional analysis of cancer is proving to be a
powerful and increasingly useful tool in biomedical research.
A goal of these studies is to use gene expression patterns
revealed by transcriptional profiling to understand the
pathogenesis of the disease and to predict prognosis and
responsiveness to therapy. Indeed, previous gene expression
analysis studies on Hodgkin’s lymphoma samples (41)
suggested that these techniques could potentially be applied
for outcome prediction. However, the practical applications
of these advances in the routine clinical care of the patients
are still rare mainly due to the limitations arising from the
relatively few cases that can be studied using frozen speci-
mens. Thus, it is essential to simplify experimental methods,
use them for paraffin-embedded samples, and reduce the
gene composition of the predictive signatures to develop new
predictive models of potential clinical application.
In this study, we have shown that robust methodologies,
based on quantitative RT-PCR, are suitable for expression
profiling of tumors and can be applied to routine FFPE tissue
samples and that new platforms such as TLDAs allow the robust
analysis of a limited number of genes. Hundreds of reactions can
be done simultaneously, enabling large numbers of cases to be
rapidly assessed. These technologies would be especially useful
for identifying gene signatures of prognostic significance (42)
and have already been shown to be useful in other tumor types
(43). Thus, we have built a novel TLDA assay that includes genes
known to be involved in Hodgkin’s lymphoma pathogenesis
and that could be related to treatment response. To select the
genes for inclusion in our assay, we applied GSEA to the data
from our previous study using gene expression profiling of cHL
tumor samples to identify a reduced number of genes.
The amount of tissue and RNA and cDNA available from
FFPE samples are limited, which restricts the number of
analyzable genes and cases, so we tested an alternative
approach that could be used in further studies. Preamplifica-
tion techniques (PreAmp) enhance sensitivity of RT-PCR
especially for low-abundance target genes and low RNA quality,
which increases the number of cases and target genes that can
be analyzed. PreAmp maintenance of gene expression profiles
has been already validated (44) in previous studies.
With the present approach, we first identify genes putatively
expressed by the neoplastic HRS cells and the microenviron-
ment by comparing gene signatures from cHL-derived cell lines
and profiles from tumor samples. A similar bioinformatic
approach has recently been adopted with this tumor type (34),
and the gene composition of the two databases confirms that it
yields informative and consistent results.
GSEA identifies functional pathways overrepresented in
specific phenotypes, thus permitting a reduction in the number
of redundant genes and avoiding the loss of information from
important biological processes. The final set of genes includes a
balanced representation of those associated with the tumor
cells and the microenvironment and that are intrinsically
associated with the pathogenetic characteristics of cHL.
Table 2. Summary of the best discriminant genes (14 genes with area under receiver operating characteristic
curve > 0.65) used for the logistic regression analysis
Gene symbol Gene name Area under receiver operating
characteristic curve
P
BCCIP BRCA2 and CDKN1A interacting protein 0.756 0.008
CASP3 Caspase-3, apoptosis-related cysteine peptidase 0.765 0.006
CCNE2 Cyclin E2 0.656 0.051
CSEL1 CSE1 chromosome segregation 1-like (yeast) 0.657 0.050
CTSL Cathepsin L 0.678 0.046
CYCS Cytochrome c, somatic 0.753 0.009
DCK Deoxycytidine kinase 0.747 0.010
DNAJA2 DNAJ (Hsp40) homologue, subfamily A, member 2 0.671 0.049
HSP90AA1 Heat shock protein 90 kDa a (cytosolic), class A member 1 0.662 0.050
HSPA4 Heat shock 70 kDa protein 4 0.659 0.050
ITGA4 Integrin, a4 (antigen CD49D, a4 subunit of VLA-4 receptor) 0.651 0.055
LYZ Lysozyme (renal amyloidosis) 0.674 0.047
RSN Restin (Reed-Sternberg cell-expressed
intermediate filament-associated protein)
0.706 0.033
TYMS Thymidylate synthetase 0.750 0.010
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Selected genes of the tumor signature highlight significant
biological functions that are known to be involved in
Hodgkin’s lymphoma pathogenesis (24) and, more specifically,
cell proliferation, consistent with the increased proliferation
shown by HRS cells (45). The G2-M pathway includes several
important genes associated with the regulation of the spindle
checkpoint, such as AURKA, MAD2L1, BUB1B, BUB3, CHEK1,
and CDK1 (CDC2). Most of these genes are known to be
involved in chemoresistance (46, 47) and could be therapeutic
targets. RSN is another interesting marker of HRS cells in cHL
(48), which is able to multimerize tubulin acting as polymer-
ization chaperones and is probably also associated with the
regulation of the spindle checkpoint (49).
There is also a representation of cell cycle regulators
specifically related with drug metabolism, including
topoisomerase 2a (cellular target of Adriamycin), TYMS,
and RRM2, which have been associated with drug resistance
in different tumor models (50, 51).
Another interesting observation is the presence of the
chaperone pathway in the selected genes. Among the genes
included in the TLDA assay with a significantly higher risk score
in the bad treatment response group, we found histones
(HSP90AA1 and HSPA4), which are frequently overexpressed
in cancer cells and may play a role in malignant trans-
formations (52). HSP90A acting as a chaperone regulates
proteins that promote HRS survival, such as AKT, MEK, and
components of the nuclear factor-nB pathway (53, 54). It is of
note that there are small molecules such as 17-allylamino-17-
demethoxygeldamycin that inhibit HSP90 function (55) and
could offer an alternative approach to the treatment of cHL.
On the other hand, the microenvironment signature is
overrepresented by genes involved in the Th2 immune
response, which has recently been described as being charac-
teristic of Hodgkin’s lymphoma tumors and associated with
tumor survival (20). Other interesting T-cell populations
present in the selected genes are cytotoxic and regulatory T
cells, also associated with outcome in cHL (23). A macrophage
pathway is also included, consistent with the association
between macrophage activation and Th2-type immune
responses. Recent observations also indicate a relationship
between tumor-infiltrating macrophages and length of survival
among patients with follicular lymphoma (56, 57). The
inclusion of these pathways in our gene selection is consistent
with the idea that treatment response and survival in cHL (and
other lymphoma types) correlate with the molecular features of
nonmalignant immune cells present in the tumor at diagnosis.
Although the main aim of this study was the development of
an exploratory tool for this tumor model, the results also
confirm its potential prognostic capacity, because higher-risk
scores were obtained in patients with poor treatment response.
We expect these results to pave the way for a more
comprehensive analysis of a larger series that could allow a
predictive model to be developed in which different genes and
pathways could be integrated with specific scores.
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Appendix A
The following centers and investigators participate and
contribute with the Spanish Hodgkin’s Lymphoma Study
Group: P. Domı´nguez and C. Jara (Fundacio´n Hospital
Alcorco´n); M.J. Mestre, R. Quibe´n, M. Me´ndez, and L. Borbolla
(Hospital de Mo´stoles); M.A. Martı´nez and C. Grande (Hospital
12 de Octubre); M. Garcı´a-Cosı´o, C. Montalba´n, and J. Garcı´a-
Laran˜a (Hospital Ramo´n y Cajal); C. Bellas and M. Provencio
(Hospital Puerta de Hierro); A. Castan˜o and P. Sa´nchez-Godoy
(Hospital Severo Ochoa); C. Martı´n and R. Martı´nez (Hospital
Clinico Universitario San Carlos); J. Mena´rguez, P. Sabı´n, and
E. Flores (Hospital Gregorio Maran˜o´n); J. Gonza´lez-Carrero and
C. Pondero´s (Hospital Xeral-Cies); T. A´lvaro and L. Font
(Hospital Verge de la Cinta); V. Romagosa and A. Ferna´ndez de
Sevilla (Institut Catala d’Oncologia); M. Mollejo and M.A. Cruz
(Hospital Virgen de la Salud); H. A´lvarez-Arguelles and M.
Llanos (Hospital Universitario Canarias); C. Morante (Hospital
Cabuen˜es); F. Mazorra and E. Conde (Hospital Marque´s de
Valdecilla); M.F. Fresno, C. Rayo´n, and C. Nicola´s (Hospital
Central de Asturias); T. Flores and R. Garca-Sanz (Hospital
Universitario de Salamanca); J. Guma (Hospital Sant Joan); P.
Gonzalvo (Hospital Comarcal de Jarrio); G. Ferna´ndez (Hos-
pital Alvarez Buyllas); J. Forteza, M. Fraga, and J.L. Bello (F Med
Santiago de Compostela); J.R. Me´ndez (Hospital Valle de
Nalo´n); and J.F. Garcı´a, M.M. Morente, and M.A. Piris (Spanish
National Cancer Centre).
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Despite improvement in the treatment of
advanced classical Hodgkin lymphoma,
approximately 30% of patients relapse or
die as result of the disease. Current pre-
dictive systems, determined by clinical
and analytical parameters, fail to identify
these high-risk patients accurately. We
took a multistep approach to design a
quantitative reverse-transcription poly-
merase chain reaction assay to be ap-
plied to routine formalin-fixed paraffin-
embedded samples, integrating genes
expressed by the tumor cells and their
microenvironment. The significance of
30 genes chosen on the basis of previ-
ously published data was evaluated in
282 samples (divided into estimation and
validation sets) to build a molecular risk
score to predict failure. Adequate reverse-
transcription polymerase chain reaction
profiles were obtained from 262 of
282 cases (92.9%). Best predictor genes
were integrated into an 11-gene model,
including 4 functional pathways (cell
cycle, apoptosis, macrophage activation,
and interferon regulatory factor 4) able
to identify low- and high-risk patients
with different rates of 5-year failure-free
survival: 74% versus 44.1% in the estima-
tion set (P < .001) and 67.5% versus
45.0% in the validation set (P  .022).
This model can be combined with stage
IV into a final predictive model able to
identify a group of patients with very
bad outcome (5-year failure-free survival
probability, 25.2%). (Blood. 2010;116(8):
e12-e17)
Introduction
Classical Hodgkin lymphoma (cHL) is assumed to be a curable
tumor, but an important fraction of patients with advanced disease
do not respond favorably to the current standard chemotherapy
regimens whose base is adriamycin. The most widely used and
reproducible prognostic score is the product of clinical and
analytical parameters integrated in the International Prognostic
Score (IPS), but it still fails to identify accurately, at the moment of
diagnosis, a significant fraction of patients with very poor progno-
sis.1-3 Thus, the identification of biomarkers that, at diagnosis, may
be consistently associated with nonresponse is essential for the
recognition of patients at high risk of treatment failure to establish a
more rational risk-adapted treatment strategy.
cHL represents a distinctive model of histologic complexity,
with a minor population of the neoplastic Hodgkin and Reed-
Sternberg (HRS) cells diluted in a reactive inflammatory back-
ground composed of nonneoplastic B and T cells, macrophages,
eosinophils, neutrophils, and plasma cells. The complex relation-
ship between the HRS cells and their microenvironment is only
partially understood; however, important, if fragmentary, advances
in our understanding are steadily being made.4 The clinical
outcome of cHL has been found to be related to the expression of
multiple biologic markers alone5-8 or in combination,9 expressed
either by the tumor HRS cells, macrophages, regulatory T cells, or
other nonneoplastic cell subpopulations.10-13
Some of these previous analyses rely on array-based gene
expression analyses, which use frozen tissue and in most cases can
only provide retrospective information. Investigators of other
studies have used immunohistochemical staining, with some
inherent limitations to the reproducibility of the data thus gener-
ated. It is now feasible to apply multigenic predictive molecular
tests in advanced cHL patients in a routine setting by the use of
a quantitative reverse-transcription polymerase chain reaction
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(RT-PCR) assay as we here describe, incorporating a selected
number of genes that capture information from tumor and microen-
vironment cell components, designed for application to routine
formalin-fixed paraffin-embedded (FFPE) samples and that can be
used at the moment of the initial diagnosis.
Methods
Patients and samples
Previous studies allowed us to identify a group of genes whose expression
was associated with the response of patients with advanced cHL to standard
first-line treatment. Thus, the selection of genes to be analyzed was
determined by results previously obtained in 2 independent series of 29 and
52 advanced cHL patients.10,11
The patients included in this study fulfilled stringent, previously
described criteria (ie, age older than 16 years; advanced cHL; Ann Arbor
stage IV, III, or IIB with bulky masses1; proven HIV-negative status) who
have been treated with a first-line standard chemotherapy regimen that
included adriamycin—ABVD (adriamycin, bleomycin, vinblastine, and
dacarbazine) or ABVD variants—and for whom information was available
about the achievement of complete remission (CR) and a follow-up of at
least 12 months thereafter, which is a well-known and accepted surrogate
indication of the course of the disease. With respect to the latter, patients
were considered to have had a favorable course if they had achieved CR and
maintained it for at least 12 months or with an unfavorable course if they
had either not achieved CR or if they had once had it but had relapsed
during the following 12 months. All tissue samples consisted of representa-
tive pretreatment lymph node biopsies collected after revision and approved
by the institutional review board of the participating institutions of the
Spanish Hodgkin Lymphoma Study Group. The study initially included
282 FFPE patients, who were randomly split and assigned to the training
(194 cases) or validation sets (88 cases) on the basis of the minimum
estimated sample size to derive the final model (Table 1).
Additional exclusion criteria were insufficient RNA quality (purity ratio
A260:A230  1.7) or a weak RT-PCR signal (average cycle threshold
 35) for the reference genes or in more than 10 genes of the assay. As a
result, 20 patients were excluded, and the remaining 262 patients (183 in the
training group and 79 in the validation group) meeting these criteria were
included in the statistical analysis (Table 1).
Gene selection
The genes included in the assay initially were selected from 2 preliminary
expression-profiling studies10,11 that rendered a list of genes expressed by
HRS and microenvironment cell subpopulations identified in unfavorable
cHL patients. Selected genes were primarily chosen on the basis of their
prognostic ability and capacity to represent biologic functions identified as
relevant in cHL pathogenesis.11 In addition, the strength and consistency of
primer and probe performance also were taken into account.11 The initial
selection consisted of 30 genes, including genes expressed by the neoplastic
cells involved in the cell cycle (G2/M), apoptosis, histones, chaperones,
drug metabolism, and mitogen-activated protein kinase signatures, and
from microenvironment genes expressed by different cellular or functional
populations of T cells, monocytes, macrophages, and dendritic cells.
Details of the RT-PCR assays are available in supplemental Table 1
(available on the Blood Web site; see the Supplemental Materials link at the
top of the online article).
Analysis of gene expression
Gene expression was analyzed by the use of a customized TaqMan
low-density array platform (Micro Fluidic Cards; Applied Biosystems) on
FFPE as previously described.11,14 A preamplification step (PreAmp;
Applied Biosystems) was used to improve the sensitivity of our assay for
low-abundance target genes available from FFPE samples.15-17 Reactions
were performed by use of the ABI PRISM 7900HT Sequence Detection
system (Applied Biosystems), and we measured the expression of each
gene in triplicate and then normalized it with a set of 2 reference genes
(HMBS and GUSB) whose uniform expression in cHL tumor samples was
tested in previous studies.11 Missing values were imputed using the
K-nearest neighbor algorithm.18
Statistical analysis
Differences in the distributions of standard clinical parameters (age, sex,
stage, IPS, the individual variables contained in IPS, and outcome) in the
estimation and validation datasets were tested by the Pearson 2 test (Table 1).
The first end point of this study was the response to standard first-line
treatment considering favorable response (F) and unfavorable response (U),
as mentioned previously. Data from second-line and salvage therapies
and/or bone-marrow transplantation were not considered.
The selection of the best predictive genes and the logistic regres-
sion model was on the basis only of the data from the training group of
183 patients, without any previous survival analysis that used information
from the validation group. Univariate regression analysis was performed
with treatment response (F vs U) as the dependent variable to identify
genes significantly associated (P  .05) with outcome. In addition, final
gene selection analysis was performed by cross-validation with the use of
3 prediction algorithms (http://tnasas.bioinfo.cnio.es/): diagonal linear
discriminant analysis,19 support vector machines,20 and K-nearest neigh-
bor.21 Cross validation was used to test the classification ability of the initial
set of significant genes to choose the strongest predictor genes, which were
classified into functional groups on the basis of their known biologic
relationship and their coregulated expression as estimated by the Pearson
correlation coefficient. Individual genes from each functional group were
weighted by the use of linear discriminant analysis.22 Finally, these
functional gene clusters associated with cHL outcome were analyzed in a
multivariate logistic regression model with response to therapy (F vs U) as a
dependent variable. In this way, an algorithm was derived that combines
these measurements into a quantitative “molecular risk score” (MRS),
which can be used as a continuous variable to estimate the probability
of treatment response. The MRS cut-off points were prespecified by
the use of an area under the receiver operating characteristic curve (ROC)
analysis to define different risk groups. (See the supplemental Appendix
for details of the statistical analysis and methods.) Finally, performance
Table 1. Clinical characteristics of the cHL series
Characteristic
Estimation,
n (%)
Validation,
n (%)
Total,
n (%) P
Age, y (n  183) (n  79) (n  262)
Younger than 45 133 (72.67) 56 (70.88) 189 (72.14) .883
45 or older 50 (27.32) 23 (29.11) 73 (27.86)
Sex (n  183) (n  79) (n  262)
Male 99 (54.10) 51 (64.55) 150 (57.25) .151
Female 84 (45.90) 28 (35.44) 112 (42.75)
Stage IV (n  182) (n  79) (n  261)
No 132 (72.52) 47 (59.49) 179 .053
Yes 50 (37.87) 32 (40.50) 82
IPS code (n  182) (n  79) (n  261)
Less than 3 109 (59.89) 41 (51.90) 150 (57.47) .288
3 or greater 73 (40.11) 38 (48.10) 111
Outcome (n  183) (n  79) (n  262)
F 132 (72.14) 57 (72.16) 189 (72.14)  .999
U 51 (27.86) 22 (27.84) 73 (27.86)
Clinical characteristics of patients with adequate RT-PCR profiles. Summary
of the clinical characteristics of the patients in the estimation and validation sets
that yielded suitable analyzable data (262 of 282; 92.90%). Differences in distribution
of standard clinical parameters (age, sex, stage, IPS and outcome) between
estimation and validation datasets tested by Pearson chi-square with Yates cor-
rection were not statistically significant (IPS values of 0-2 classified as low IPS; IPS
values 2 classified as high IPS).
cHL indicates classical Hodgkin lymphoma; F, favorable response; IPS, Interna-
tional Prognostic Score; RT-PCR, reverse transcription polymerase chain reaction;
U, unfavorable response.
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of the logistic regression model was tested in the validation group of
patients (n  79).
For graphical representation, survival analyses were performed with the
Kaplan-Meier method and long-rank test separately in the training and
validation series and in the entire series. Because the primary objective of
the study was to identify patients at high risk of treatment failure, we used
failure-free survival (FFS) as the fundamental end point for survival
analysis. FFS was defined as the time interval between treatment initiation
and treatment failure or last follow-up. Failure was defined as either the
failure to achieve CR or the occurrence of progressive disease, irrespective
of whether there had been an initial CR. Overall survival (OS), an end point
whose significance is imperfect because it is conditioned by the effect of
subsequent eventual treatments and complication of treatment, was in-
cluded as a secondary end point in the survival analyses, defined as the time
interval between diagnosis and death caused by the lymphoma.
Finally, in the whole series, a multivariate Cox proportional hazards
model, including the data at diagnosis, the IPS stratified as previously
defined (0-2 vs  3),1 and its 7 individual variables (hemoglobin  1.5 g/
dL; albumin  4 g/dL; leukocytosis  15 000/mm3; lymphopenia  600/
mm3; age  45 years; male sex; stage IV), was applied to test the
independence of the MRS, including the remaining significant variables in a
final integrative model.
All statistical analyses were 2-sided; values of P less than .05 were
considered to be significant. These were performed with SPSS 15.0 (SPSS
Inc). Survival curves were assessed by the Kaplan-Meier method, and risk
groups were compared by the log-rank test. Plots were generated with the
use of GraphPad Prism Version 5 (GraphPad Software, Inc).
Results
Gene selection and development of the predictor model
In training series, univariate regression analysis of the expression
data for the 30 initially selected genes revealed 20 genes to
significantly predict failure to first-line treatment (supplemental
Table 3). When cross validation was applied, the genes most
frequently found in prognostic models consisted of a panel of
11 genes that were included in the final model: BCL2, BCL2L1,
CASP3, HMMR, CENPF, CCNA2, CCNE2, CDC2, LYZ, STAT1,
and IRF4.
To derive the model, we took a 2-step approach, first combining
individual gene-expression patterns into precise functional path-
ways and then subsequently correlating these functional groups
with the clinical outcome by using multivariate logistic regression.
Final selected genes were weighted by the use of linear discrimi-
nant analysis and clustered into their corresponding functional
pathways defined as macrophage activation (LYZ, STAT1), cell
cycle (HMMR, CENPF, CCNA2, CCNE2, CDC2), and apoptosis
(BCL2, BCL2L1, CASP3; Figure 1A). The Pearson correlation
coefficient was significant for the genes included in each of the
signatures (P  .001) apart from IRF4, which was included as an
independent predictive gene because there were neither distinct
functional relationships nor statistically significant correlations
with other genes or pathways (supplemental Table 4). These
functional groups captured information about the tumoral HRS
cells and their nontumoral microenvironment, in agreement with
previous studies.10 The multivariate logistic regression analysis
integrating these pathways showed that cell cycle and apoptosis
terms were associated with an unfavorable outcome of patients,
whereas macrophage activation and IRF4 signatures had protec-
tive effects.
Thus, the optimized final model was determined on the basis of
the relative contributions of each of the 4 functional terms, as
described in the following equation: constant (0.913) 
(0.401  apoptosis)  (0.284  cell cycle)  (0.301  macro-
phage activation)  (0.143  IRF4). The continuous probability
function generated by the logistic regression was defined as the
MRS to treatment failure and ranged from 0.06 to 0.813 (Figure
1B). ROC analysis was used to define a threshold for stratifying
patients, and the largest area under the curve was obtained by the
use of 0.3 as the threshold, thus dividing the series into high-risk
(MRS 0.3) and low-risk (MRS 0.3) cases (Figure 1B-C).
Figure 1. Panel of 11 genes and the molecular risk
algorithm. (A) The molecular risk algorithm is deter-
mined on the basis of the relative contributions of each
of the 4 gene functional groups from the tumoral HRS and
their reactive microenvironment as follows: MRS 
exp (fx)/(1  exp [fx]), where fx  (0.913)  (0.401 
apoptosis)  (0.284  cell cycle)  (0.301  mono-
cyte) (0.143  IRF4). Coefficients were derived from
a multivariate analysis in which positive values indicate
that a greater level of expression is correlated with a
worse outcome, and negative coefficients indicate that a
greater level of expression of the pathways is associated
with a better outcome. (B) MRS as a continuous function
was used to set a threshold for stratifying patients by
ROC analysis. Patients were stratified according to the
levels of the molecular risk score into low-risk ( 0.3) and
high-risk ( 0.3) groups. (C-D) Survival estimates of FFS
in patients from estimation (n  183) and validation
(n  79) sets after classification into risk groups. Kaplan-
Meier analysis and the log-rank test gave significant
results in both estimation and validation sets, indicating
the potential prognostic capacity of the algorithm devel-
oped here.
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Validation of the MRS
The MRS differed significantly between the various outcome
groups (supplemental Figure 2) and predicted treatment response
with an accuracy of 68.9% in the estimation dataset and 70% in the
validation dataset. Because treatment failure was the main end
point used to derive the logistic regression function, FFS as previ-
ously defined, was used for validation of the model and Kaplan-
Meier analysis of survival. Predicted probabilities also identified
2 risk groups associated with FFS in both the estimation and
validation sets (Figure 1C; supplemental Figure 3). FFS probabili-
ties at 5 years were 74.0% versus 44.1% (P  .001) in the training
set and 67.5% versus 45.0% (P  .022) in the validation set.
In addition, the analyses of OS showed different risk groups
identified by the MRS in the estimation group of patients. The
differences were not significant in the validation series, probably
because of the limited number of events (supplemental Figure 3).
There were no significant statistical differences in the MRS
distributions of the 2 histologic subtypes, nodular sclerosis and
mixed-cellularity cHL (P  .186, t test), and the differences in
survival between risk groups identified by the MRS remained
significant in both the estimation and validation sets stratified by
histologic subtype (supplemental Figure 4).
Integrative model using MRS and clinical variables
In the whole series, a multivariate Cox proportional hazards model
with FFS as the dependent variable and including the MRS and the
IPS, we found that only the MRS was significant (Table 2). No
interaction was observed between the IPS or the individual IPS
variables and the MRS low- and high-risk groups (supplemental
Table 5). Thus, to compare the molecular risk algorithm and the
individual IPS components, a backward stepwise selection Cox
model was tested, with FFS as the dependent variable and
including the MRS and the individual components of the IPS in the
global series of samples. Only MRS and stage IV were statistically
significant (Table 2) and so were retained in the final Cox
regression model. Patient stratification into quartiles on the basis of
the Cox model identified a subgroup of advanced cHL patients
(fourth quartile) with a very poor outcome: 5-year FFS of 24.3%
(P  .001; Figure 2).
Discussion
Here we describe, in a series of patients with advanced cHL, a
4-cluster/11-gene model derived from an initial selection of
30 potentially predictive markers that can be detected by RT-PCR
and integrated into a molecular risk algorithm that can identify
patient subgroups with very different probabilities of treatment
failure. This approach is determined on the basis of reliable
quantitative RT-PCR techniques applicable to paraffin-embedded
diagnostic samples and follows similar approaches taken in breast
cancer and other tumor types.23,24 This benefits from previous
expression profiling studies performed in cHL,10 and the improved
knowledge about the role of the tumoral cell and the microenviron-
ment in the pathogenesis and outcome of this disease.13,25,26 This
MRS, calculated in an initial estimation set, was confirmed in an
independent set. Genes included in the score were selected on the
basis of previous gene expression profiling data generated in
independent sets of patients11,27 and can be classified in 4 functional
pathways.
The final 4-cluster/11-gene model can additionally incorporate
one of the well-established clinical variables (stage IV), thus
integrating the main molecular characteristics of the tumors related
with treatment response and tumor burden estimation in a single
scoring system. The multivariate Cox model indicates that most
patients with stage IV cHL and with a high MRS ( 0.3) will have
a very poor outcome, with 5-year FFS probability of 24.3% and
OS probability of 76.3%. Therefore, this combination of stage IV
and high MRS identifies a group of patients with very bad outcome
who could have been initially missed by consideration of the
IPS alone.1,3
It is of note that in the present series the IPS did not show any
significant prognostic influence on FFS. From the individual
components of the IPS, only stage IV disease remained significant
in multivariate analyses. This finding is in agreement with recent
studies in which the authors demonstrated that IPS is of limited
utility in advanced HL cases treated in the modern era, where more
Table 2. MRS and the IPS variables
P Hazard ratio (95% CI)
IPS and MRS (n  262)*
MRS  .001§ 24.362 (6.268-94.691)
IPS .205 1.111 (0.944-1.309)
IPS variables and MRS (n  262)†
MRS  .001§ 24.715 (6.804-89.768)
Hemoglobin  10.5 g/dL .352 1.243 (0.787-1.963)
Albumin  4 g/dL .504 1.157 (0.755-1.772)
Leucocytosis 15 000/mm3 .256 1.312 (0.821-2.095)
Lymphopenia  600/mm3 .555 0.820 (0.425-1.583)
Age 45 y .369 1.227 (0.785-1.916)
Stage IV .041§ 1.552 (1.018-2.360)
Male sex .753 0.936 (0.618-1.416)
PT-BR Integrative Cox model (n  262)‡
MRS  .001§ 23.782 (6.041-94.340)
Stage IV .025§ 1.409 (1.044-1.900)
95% CI indicates 95% confidence interval; IPS, International Prognostic Score;
and MRS, molecular risk score.
*Multivariate Cox regression analysis considering MRS and the IPS.
†Univariate Cox regression analyses considering individual IPS variables and
MRS.
‡Cox regression analysis of the final variables included in the integrative model
(molecular risk plus stage IV) obtained by backward stepwise selection.
§Significant.
Figure 2. Integrative risk model of cHL. The final Cox model integrates the MRS
and clinical variable stage IV. Patients in quartiles 1, 2, and 3 have comparable FFS
rates at 5 years (76.4%, 79.3%, and 69.7%, respectively) whereas patients in quartile
4 show a 5-year FFS of 24.3% (P  .001).
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accurate pathologic diagnosis, improved control of therapy, use of
growth factors, and enhanced supportive care are yielding better
outcomes compared with historic results.3 Thus, deviations from
the standard therapy cannot be justified on the basis of the survival
prediction capacity of the IPS, and identification of high-risk
populations needs to be supplemented with molecular markers.
In the model, the expression of BCL2, BCL2L1, CASP3,
HMMR, CENPF, CCNA2, CCNE2, and CDC2 included in the
apoptosis and cell-cycle pathways, respectively, were correlated
with short FFS. The expression of various antiapoptotic BCL2
family proteins has been repeatedly reported in HRS cells,7,28,29
thereby contributing to the survival of HRS cells. BCL2 and
BCL2L1 (BCL-XL) both frequently are expressed by HRS cells in
cHL, and their levels have been associated with inferior FFS in
patients treated with ABVD or equivalent regimens,5 thus con-
firming the importance of this group of apoptotic regulators for
cHL outcome prediction. The second signature, cell cycle, is
mainly composed of genes coding for regulatory proteins of
the S and G2/M phases of the cell cycle, thus directly related with
cell proliferation. Again, expression of some of these markers has
been previously described at the protein level in cHL,7,30,31 and a
significant prognostic value for CDC2 (CDK1) and CCNA2 (cyclin
A2) protein expression in non-Hodgkin lymphomas was also
found for both disease-free survival and OS. Interestingly, this
aberrant association between increased expressions of antiapop-
totic proteins and growth fraction-associated proteins in HRS
cells provides further evidence that cell cycle and apoptosis
regulation are profoundly disturbed and closely related in the
disease, further justifying the inclusion of these 2 pathways in
the predictive model.
Moreover, pathways involved in cell cycle and apoptosis
regulation are rational therapeutic targets. Indeed, inhibitors of
Cyclin-Cdk complexes (including Cyclin E-Cdk2, Cyclin A-Cdk2,
and Cyclin B-Cdk1 complexes) are currently under preclinical and
clinical investigation in different cancer types,32-34 and these drugs
could be considered for the treatment of advanced and refractory
cHL patients. Likewise, the potential for targeting BCL2-related
proteins in lymphoma is promising. Small molecule inhibitors of
the Bcl-2 family have demonstrated high target affinity and an
improved toxicity profile, and clinical trials of these agents are
yielding interesting results.35
Confirming previous observations about the importance of the
reactive microenvironment for cHL patient outcome,9,11,12 LYZ and
STAT1 genes, expressed at high levels in a subset of tissue
monocytes and activated macrophages, also are included in this
model, and correlated with prolonged FFS and better outcome. The
relevance of the cell composition of the reactive background in
cHL has been reinforced by the data recently reported by Steidl et
al.36 They used gene expression profiling to identify a gene
signature of tumor-associated macrophages that is associated with
treatment failure, in an approach methodologically similar to
previous reports from our group and others.10,37 The discrepancy in
the results concerning the role of macrophages may have arisen
from technical differences (RT-PCR vs microarray gene-expression
and immunohistochemistry) or the selection of markers such as
LYZ and STAT1 in this study, reflecting a specific functional status
of the monocyte-macrophages.38
In addition, IRF4 (MUM1) expression was associated with
longer FFS. This gene is an interferon regulatory factor, lympho-
cyte specific, induced after nuclear factor-	B (NF-	B) activation,
which controls B-cell proliferation and differentiation and has
recently been shown to be up-modulated by CD40 engagement
in HL cells.39 Interestingly, the lack of IRF4 protein has been
previously associated with outcome in cHL,40 representing a
potential adverse prognostic factor. In addition, both IRF4 and
BCL2L1 represent well-known NF-	B target genes41,42 whose
expression is induced after NF-	B pathway activation. Thus, our
final model includes important subrogates from the NF-	B activa-
tion, which is thought to be an essential pathogenetic mechanism in
this disease. It is of note that Bednarski et al43 recently described
how the inhibition of the canonical NF-	B pathway enhances the
proapoptotic effects of adriamycin, thus also identifying NF-	B
inhibition as an interesting therapeutic approach.
In conclusion, we have developed a molecular risk algorithm,
on the basis of feasible and reproducible molecular techniques, that
is capable of stratifying at the moment of diagnosis advanced cHL
patients with different outcome. Moreover, a combination of this
algorithm with the presence of clinical stage IV disease can be used
to identify a group of cHL patients with a very bad outcome who
could benefit from more intensive therapeutic approaches.
These results are promising, but further validation in larger and
independent series of patient is needed for the model to become
established as part of the clinical routine. Also the predictive value
of this model should also be tested in patients treated with modern
intensive chemotherapy.
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Diffuse large B-cell lymphoma (DLBCL)
prognostication requires additional bio-
logic markers. miRNAs may constitute
markers for cancer diagnosis, outcome,
or therapy response. In the present study,
we analyzed the miRNA expression pro-
file in a retrospective multicenter series
of 258 DLBCL patients uniformly treated
with chemoimmunotherapy. Findings
were correlated with overall survival (OS)
and progression-free survival (PFS).
miRNA and gene-expression profiles were
studied using microarrays in an initial set
of 36 cases. A selection of miRNAs asso-
ciated with either DLBCL molecular sub-
types (GCB/ABC) or clinical outcome were
studied by multiplex RT-PCR in a test
group of 240 cases with available formalin-
fixed, paraffin-embedded (FFPE) diagnos-
tic samples. The samples were divided
into a training set (123 patients) and used
to derive miRNA-based and combined
(with IPI score) Cox regression models
in an independent validation series
(117 patients). Our model based on miRNA
expression predicts OS and PFS and im-
proves upon the predictions based on
clinical variables. Combined models with
IPI score identified a high-risk group of
patients with a 2-year OS and a PFS probabil-
ity of < 50%. In summary, a precise miRNA
signature is associated with poor clinical
outcome in chemoimmunotherapy-treated
DLBCL patients. This information improves
upon IPI-based predictions and identifies a
subgroup of candidate patients for alter-
native therapeutic regimens. (Blood. 2011;
118(4):1034-1040)
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common type
of non-Hodgkin lymphoma in adults, accounting for  80% of
aggressive lymphomas.1 DLBCL is a heterogeneous group of
tumors with different genetic abnormalities, clinical features,
responses to treatment, and prognosis.2 This heterogeneity hinders
outcome prediction based on clinical and/or molecular parameters.
Combination therapy that associates CHOP (cyclophosph-
amide, doxorubicin, vincristine, and prednisone) with rituximab
(R-CHOP) has become a standard treatment for DLBCL, leading to
complete remission rates of 75%-80% and a 3- to 5-year PFS of
50%-60%.3-8 Nevertheless, patients who fail to respond to first-line
therapy or relapse continue to pose a challenge, and identification
at diagnosis of poor-outcome cases is crucial for deciding between
alternative treatment schemes.
The International Prognostic Index (IPI) has been the primary
clinical tool for predicting the outcome of patients with aggressive
non-Hodgkin lymphoma.9 Original IPI factors were redistributed in
patients treated with R-CHOP to give a revised score (R-IPI) that
distinguishes 3 prognostic categories, with 4-year survival rates
ranging from 94%-55% for poor-risk patients.7 Nevertheless, the
R-IPI does not discriminate patients with  50% probability of
survival, which restricts its clinical value.7
The biologic heterogeneity of DLBCL has been shown substan-
tially to reflect the cell origin of these tumors from germinal center
or activated B cells. These differences are significant indepen-
dently of IPI stratification, showing that identifying4,8 cell or origin
signatures captures features other than IPI and can refine outcome
prediction.10 These differences between GC and ABC DLBCL
remain significant in patients treated with combined immunoche-
motherapy including rituximab.11 This classification system can
be accurately reproduced using immunohistochemistry against
GCET1, CD10, bcl6, MUM1, and FOXP1 in formalin-fixed,
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paraffin-embedded (FFPE) samples,12 thereby providing a simple
tool for evaluating the protein-expression profile of the tumor at the
time of diagnosis. However, although semiquantitative immunohis-
tochemistry for subclassifying DLBCL is feasible and reproduc-
ible, the concordance rates of the different markers vary.13 Differ-
ent methods of gene-expression profiling based on quantitative
RT-PCR have been developed as alternative or complementary
strategies for patient subclassification.14,15
Recently, miRNAs, small noncoding RNAs that fine-tune the
expression of multiple genes,16,17 have been shown to be excellent
biomarkers for cancer diagnosis and prognosis,18-21 including hemato-
logic malignancies.22-27 Furthermore, recent evidence demonstrates that
they may constitute markers of differentiation stage, malignant transfor-
mation, or sensitivity or resistance to specific drugs.22,28-31
The main goal of the present study was to search for an miRNA
signature associated with clinical outcome in DLBCL patients
treated with R-CHOP using FFPE tissue samples. We also investi-
gated whether miRNA expression profiling can identify particular
miRNA species that are differentially expressed between DLBCL
subtypes according to the cell of origin (COO) classification.10,32
Methods
The experimental procedures are summarized in Figure 1.
Patients and treatments
The study population consisted of a retrospective series of 258 de novo
cases of DLBCL obtained from various centers in Spain, 1 in Italy, and 3 in
the United States. The study was reviewed and approved as being of
minimal/no risk or as exempt by each of the participating institutional
review boards, and the overall collaborative study was approved by the
institutional review board at the Spanish National Cancer Research Center
(CNIO) in Madrid, Spain. The study protocol and sampling methods were
approved by the Instituto de Salud Carlos III institutional review board in
de-identified anonymous format. Cases associated with HIV or HCV
infections or previous immunosuppressive treatments were excluded. All
histologic samples corresponded to initial diagnostic biopsies before
treatment. Histologic criteria used for diagnosis and classification were
those of the World Health Organization.1 All cases positively stained for
CD20. Cases diagnosed as T-cell histiocyte-rich B-cell lymphoma, primary
mediastinal B-cell lymphoma cases, cutaneous LBCL, intravascular LBCL,
and those histologically associated with a follicular lymphoma component
were excluded.
All patients were treated as part of their routine care with standard
treatment protocols using a combination of anthracycline-based regimens
(6-8 cycles in most cases) and immunotherapy including rituximab; the
majority were treated with R-CHOP (n  243). Other regimens included
R-EPOCH and R-MegaCHOP. Responses to treatment were determined by
a computed tomography scan in most cases (as recorded in the clinical
recovery data sheet) and following the response criteria for lymphoma as
defined by Cheson et al.33
Array-based expression analysis and in silico prediction of the
miRNA regulatory network
miRNA and gene-expression hybridization were carried out using Agilent
Technologies microarrays. RNA and DNA extraction methods, details of
microarrays and hybridization procedures, and miRNA and gene-
expression profiling array normalization are described in supplemental
Methods (available on the Blood Web site; see the Supplemental Materials
link at the top of the online article).
The differential miRNA expression profile between DLBCL subtypes
according to the COO signature was studied after GEP-based classification
of the cases32 (for details, see supplemental Methods).
miRNA expression data for all 36 DLBCL cases from the discovery set
of patients were examined in a univariate (gene-by-gene) Cox model using
SignS.34 miRNA and gene-expression data have been deposited in the Gene
Expression Omnibus35 and are accessible through GEO series accession number
GSE21849 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?accGSE21849).
Targets were predicted using available databases (miRBase Version
11.0, MICROCOSM, and TargetScan release 5.1) and a Pearson correlation
test based on gene-expression and miRNA-expression data from cases in
the discovery set (details and additional references are provided in
supplemental Methods).
Real-time PCR for relative miRNA quantification using RNA
from FFPE tissue
miRNA expression in FFPE tissues was analyzed using the Applied
Biosystems 384-well multiplexed real-time PCR assay with 250 ng of total
RNA. Details of the methods, including the selection of endogenous
miRNAs, are described in supplemental Methods.
Figure 1. Flowchart with experimental design. The
whole series of patients was divided into 2 major groups:
a discovery group (36 patients with available frozen
tissue for profiling using array technologies) and a test
group (240 patients with available FFPE tissue from the
diagnostic pathologic sample). The test group was fur-
ther divided systematically into 2 sets of patients: the
training group (123 patients) and the validation group
(117 patients). The clinical characteristics according to
sex, age, stage, extranodal disease, serum lactate dehy-
drogenase levels, electrocorticogram, and IPI score of
the different sets of patients are summarized in Table 1.
miRNAAS PROGNOSTIC MARKERS IN DLBCL 1035BLOOD, 28 JULY 2011  VOLUME 118, NUMBER 4  For personal use only.2011. 
 at Centro Nacional de Investigaciones Oncológicas on August 29,bloodjournal.hematologylibrary.orgFrom 
Immunohistochemistry and tissue microarray construction
All cases of DLBCL with available FFPE tissue were histologically reviewed.
Representative areas were selected to construct tissue microarrays. Immunohisto-
chemical staining was performed after standard automated protocols using
antibodies against CD10, bcl6, MUM-1/IRF4, GCET1, and FOXP1. Immunohis-
tochemical markers were scored on the basis of the cutoffs used by Choi et al12
(see details in supplemental Methods).
Statistics
The statistical analyses are fully described in supplemental Methods. In
brief, outcome-related indices (overall survival [OS] and PFS) were
calculated as defined by Cheson et al.33 Survival distributions were
estimated using the Kaplan-Meier method36 and compared with the
log-rank test.37 The percentage of patients alive at the median follow-up
time (and 95% confidence intervals) were noted. The 2 test was used to
assess differences in the proportions of individual prognostic factors
between series.
Cox regression analysis38 was used to derive 3 independent survival
models based on IPI score, miRNA expression (of 9 selected miRNAs),
and GC-ABC classification based on immunohistochemistry12 for both
OS and PFS in the training set. More complex models composed of
combinations of the 3 individual predictor models were examined. We
assessed the improved model fit using 2 values to check for significant
changes in log likelihood.
Only the combination of miRNAs and IPI score gave a significantly
better fit than the individual models for both OS and PFS (P  .05 in all
comparisons), which justified our fitting a large model with these variables.
In this model, significant variables were determined by backward stepwise
selection using AUC as the criterion. In this way, we derived definitive
combined models for both OS and PFS. These were then validated in the
test series using the (integrated) area under the ROC curve, the concordance
index, and the Brier score (for details, see supplemental Methods).
Both miRNA-based and combined survival models (functions) based on
IPI score and miRNAs after variable selection were applied to the entire test
group of patients. For details, see survival functions hi(t)(OS) and hi(t)(PFS)
in supplemental Methods.
Models were constructed and validated using the R statistical program,
specifically with the packages survival (T. Therneau), pec (T. Gerds), and
survcomp (B. Haibe-Kains, C. Sotiriou, and G. Bontempi). Additional
analyses were conducted with SPSS Version 15.0.0.
Results
Clinical characteristics of the series
A summary of the clinical characteristics of the entire set of
patients used in this study can be found in Table 1. Complete
clinical and histopathologic data were available for all 258 patients.
The median follow-up time for all patients was 21.3 months. The
median follow-up time among patients alive at last follow-up was
27 months (range, 2-105 months). The estimated 2-year OS was
74.7%  3% and the estimated PFS was 67.5%  3% (supplemen-
tal Figure 1). Because the number of events at the median
follow-up time comprised 75% (44 of 58) and 92% (66 of 77) of the
total number of events during follow-up for OS and PFS, respec-
tively, we considered that the series was suitable for further
statistical analysis despite the limited follow-up.
No significant differences were found between the IPI variables
in the training and validation groups of patients in the test set
(240 patients), with the exception of age. All clinical components
of IPI were predictive for OS in the univariate analysis and all but
age for PFS (relative risks and confidence intervals for each
variable are shown in Table 1, and survival estimates according to
IPI in supplemental Figure 1).
Confirmation of the prognostic capacity of COO classification
based on immunohistochemistry
Immunohistochemistry was performed in all 240 cases with
available FFPE tissue. Most cases (232 of 240) could be classified
Table 1. Clinical features of the series
Test set (n  240 patients)
Screening set Training P Validation
Relative risk of death,
OS (95%CI)
Relative risk of progression,
PFS (95% CI)
Number of patients 36 123 117
IPI factors
Age, y .004 2.406 (1.298-4.462); P  .005 1.238 (0.758-2.021); P  .394
 60 13 61 35
 60 23 62 79
Stage .5 2.221 (1.213-4.067); P  .01 3.287 (1.823-5.927); P  .000
I-II 8 55 43
III-IV 28 68 65
Lactate dehydrogenase .112 3.13 (1.53-6.43); P  .001 3.051 (1.66-5.608); P  .000
low 10 56 28
high 26 67 55
Performance status .87 2.265 (1.306-3.929); P  .004 1.956 (1.182-3.238); P  .009
Ambulatory (0-1) 29 90 56
Not ambulatory (2-4) 7 33 22
Extranodal site involvement .49 2.012 (1.135-3.565); P  .017 2.197 (1.315-3.670); P  .003
 1 site 28 96 57
 1 site 8 27 21
IPI score (number of IPI factors) .067 1.690 (1.378-2.073); P  .000 1.479 (1.244-1.758); P  .000
Low risk (0,1) 6 46 33
Low to intermediate risk (2) 10 24 25
Intermediate to high risk (3) 12 29 26
High risk (4,5) 8 22 28
Distribution of IPI factors in the whole series is shown. The 2 test was used to assess differences in the proportions of individual prognostic factors between the training
and validation sets of patients. Relative risk of event (OS and PFS) estimated from univariate Cox regression is shown for each IPI factor in the test set of patients.
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into GC or ABC subtypes according to previously published
algorithms.12 There were 106 cases classified as the GC type (46%)
and 126 as the ABC type (54%). The estimated 2-year OS for
ABC-type DLBCL cases was 69.8%  4.5%, significantly worse
than for GC-type DLCBL patients (81.4%  4.3%; P  .05).
Differences were also found for PFS (60.7%  4.7% for the ABC
type compared with 75.6%  4.6% for the GC type, P  .05;
supplemental Figure 1).
Identification of a COO miRNA signature.
After gene expression–based classification using the gene set classifier
of Wright et al,32 11 cases were classified as the GC type and 18 cases as
the ABC type. Eight miRNAs were found to be differentially expressed
between these subtypes (FDR 0.03; see supplemental Table 2). These
included miR-331, miR-151, miR-28, and miR-454-3p, which were
up-regulated in the GC-type DLBCL, whereas miR-222, miR-144,
miR-451, and miR-221 were up-regulated in the ABC-type DLBCL.
We searched for the putative gene targets of the 8 miRNAs that were
differentially expressed among the subtypes. Selected target pairs were
miR151-5p and miR28-5p targeting FOXP1, miR144 targeting LRMP1,
and miR451 targeting MME (CD10; see supplemental Table 2).
Moreover, Gene Set Enrichment Analysis (GSEA Version 239) demon-
strated that the GC–B-cell pathway was the main target set of genes that
could be modulated by this set of miRNAs (see supplemental Table 2).
Identification of a set of candidate miRNAs associated with
outcome in DLBCL
To search for miRNAs related to outcome but not associated with
the previously described COO signatures, miRNA expression data
for all 36 DLBCL cases from the discovery set of patients were
subjected to a univariate (gene-by-gene) Cox analysis after FCMS
using SignS.34 Fifty-seven human miRNAs were correlated posi-
tively or negatively with OS (P  .05; see supplemental materials).
None of these 57 miRNAs formed part of the COO signature,
suggesting that this method may add some complementary informa-
tion to the previous approach.
After the previously described procedures, a final set of 9 miRNAs
was subjected to relative RT-PCR quantification in the entire test group
of 240 patients for whom FFPE tissue was available (see details in
supplemental Methods). Seven of these miRNAs (miR-221, miR-222,
miR-331, miR-451, miR-28, miR-151, and miR-148a) were identified
using the COO-signature approach and 2 additional miRNAs (miR-93
and miR-491) were obtained from the univariate (gene-by-gene) Cox
analysis using SignS.34
Generation of a miRNA-based predictor model using FFPE
tissue samples
After Cox regression analysis,38 3 independent survival models
based on IPI score, miRNA expression (of 9 selected miRNAs),
and GC-ABC classification based on immunohistochemistry12
were derived for OS and PFS in the training set.
miRNA expression-based models using the expression of
9 miRNAs as a continuous variable were able to predict both OS
and PFS. Their predictive performance in the validation group of
patients was confirmed by 3 different statistical methods including
the (integrated) area under the ROC curve, the concordance index,
and the Brier score (for details, see supplemental Methods). When
evaluating the Brier score, we used a conditional weighting scheme
from a Cox model of the censoring distribution,40 including all
miRNAs and the IPI score as predictors. The results for all tests are
shown in supplemental Tables 2 and 3 and in supplemental
Figure 2.
After confirming the predictive performance in the validation set of
patients, we plotted Kaplan-Meier curves using the whole test group
(training and validation sets) of patients. After median stratification of
the continuous score obtained from the miRNA-based models, all
patients from the test group were classified as having either a low
miRNA score (below median) or a high miRNA score (above median).
Significant differences in OS and PFS were found between the 2 groups
of patients (log-rank test, P .001 for both; Figure 2).
Only the combination of miRNAs and IPI score was signifi-
cantly better than the individual models for both OS and PFS
(2 test for the change in log likelihood, P  .05 for all compari-
sons), justifying our fitting a large model with these variables. The
model was derived by backward stepwise selection using area
under the curve as the criterion. This yielded combined models for
both OS and PFS (details of survival functions can be found in the
supplemental Methods). Because the construction of the combined
models involves a multivariate analysis (variable selection step),
the prediction based on the expression of the miRNAs present in
the combined models was independent of the IPI score (the
miRNAs included in these combined models together with IPI
score and its associated hazard ratios are shown in Figure 3).
Kaplan-Meier estimates for OS and PFS in all test group
series using the combined models were calculated and plotted
according to the distribution of terciles (Figure 4). A high-risk
subgroup of patients with OS and PFS below 50% after a 2-year
follow-up was identified.
Figure 2. Kaplan-Meier representation of the miRNA-based survival model. miRNA-based survival scores were calculated for each patient in the test group according to the survival
function obtained in the training set of patients.After median stratification, Kaplan-Meier estimates were plotted for OS and PFS (log-rank test, P .001 for both OS and PFS).
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The miRNA-regulatory network
To gain a deeper insight into the network of genes that might be
regulated by the set of outcome predictor miRNAs, we interrogated
the current versions of the MiRBase and TargetScan miRNA target
prediction databases. The predicted pairs we found included
miR-222–CDKN1A (p21), miR-93–BCL66, miR-93–MCL1, and
miR-93–MAP3K14 (NIK), among others.
We also examined the correlation between gene expression and
miRNA expression in the data from the 29 samples of the discovery
set. Because down-regulation of the target mRNA41,42 is considered
the main mechanism by which miRNAs modulate protein expres-
sion, significant negative correlation pairs were identified, includ-
ing miR-331–CARD10, miR-331–IRF4, miR-331–PIM2, and miR-
331–AID. The complete correlation grid obtained is shown in
supplemental Table 2. Interestingly, the absence of any significant
negative correlation between many in silico–predicted pairs of
miRNAs and mRNAs in this test suggests that additional mecha-
nisms to mRNA down-regulation, such as translation inhibition, may
explain the protein-expression modulation afforded by miRNAs.41,43,44
Discussion
miRNAs are emergent biomarkers of disease that have proved
useful for cancer diagnosis and prognosis18-21 and in hematologic
malignancies.22-27 They have been demonstrated to reflect accu-
rately the differentiation stage of human lymphoid B cells,22,27,28
providing valuable information for tumor classification19,28 and
prognostication26,27 that may be added to that available from
gene-expression and clinical data.
In the present study, we analyzed miRNA expression profiles in
a series of homogeneously treated DLBCL patients, deriving
miRNA-based models that correlate with OS and PFS, but which
are independent of IPI. We used a 2-step approach to identify a
candidate set of miRNAs and then validated this with multiplex
RT-PCR using RNA from FFPE tissue in 2 independent sets of
patients. This method (real-time PCR) has been found to give
reliable measures of gene and miRNA expression14,15 that are
alternatives to the classic semiquantitative immunohistochemical
approaches.13 Furthermore, the technique can be routinely applied
to FFPE samples, because the small size of miRNAs makes them
relatively resistant to RNAse degradation and because they can be
successfully isolated from routinely processed FFPE tissue.26
After the first step of candidate identification, we found a
signature of miRNAs related to the differentiation stage as defined
by the COO signature.32 Specifically, we found miR-331, miR-151,
miR-28, and miR-454-3p to be up-regulated in the GC-type
DLBCL. Conversely, miR-222, miR-144, miR-451, and miR-221
were up-regulated in the ABC-type DLBCL. Our data from patient
tissue samples classified according to their gene-expression profile
Figure 3. Hazard ratio charts. The interquartile range of the hazard ratios estimated from the models after variable selection is shown for each continuous variable. For each
miRNA, we calculated the log of the hazard ratio, where the difference in that variable was that of the interquartile range (ie, the third to the first quartiles). For example, for
miR-222, the first and the third quartiles are 1.515 and 3.945; the bar shows the hazard ratio. For PFS: exp(0.315 * [3.945-1.515]  2.15) and a 75% and 95% interval. For
IPISCORE, a discrete variable, we show the log hazard ratio comparing each of the values of IPISCORE (except 0) with IPISCORE  0 as a reference.
Figure 4. Kaplan-Meier representation of combined survival model based on IPI score and miRNAs. Survival scores according to IPI and miRNAs were calculated for
each patient in the test group according to the combined survival function obtained in the training set of patients (see “Generation of a miRNA-based predictor model using
FFPE tissue samples”). After tercile stratification, Kaplan-Meier estimates were plotted for OS and PFS (log-rank test, P  .001 for both OS and PFS). Hazard ratios estimated
from the models are shown in Figure 3.
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(using the COO classifier) confirm those from other studies, which
found miR-222 and miR221 to be up-regulated in the well-known
ABC-DLCL cell lines OCI-Ly-10 and OCI-Ly-3.26,27,29,45 Further-
more, our in silico prediction indicates that genes essential as
markers of the COO subtype (mainly GCB genes) are putative
targets of certain differentially expressed miRNAs.
When we compared the classification of patients according to the
miRNA model and the immunochemically based GC-ABC classifica-
tion, the systems were shown to be nonoverlapping and complementary,
thereby establishing different subsets of cases (P .001, supplemental
Table 4 sheet D). These results are particularly interesting because there
is not complete agreement about the best method for stratifying patients
with DLBCL. Different immunohistochemical algorithms are currently
being tested with various results among series of patients, including the
one presented here.46,47
Our results also identify a set of miRNAs in which expression is
associated with poor clinical outcome in R-CHOP–treated DLBCL
patients. miRNA expression–based models using the expression of
miRNAs as a continuous variable were able to predict both OS and
PFS in 2 independent sets of patients. These models predict OS and
PFS and improve IPI-based predictions, which allowed us to
generate combined models identifying a high-risk subgroup of
patients with OS and PFS below 50% after a 2-year follow-up.
This particular signature, which contains some miRNAs previ-
ously shown to be correlated with the outcome of DLBCL
patients27,29 and other hematologic malignancies,23 includes
miRNAs that target pathways commonly deregulated in DLBCL.
These include, for example, genes related to apoptosis (MCL1), the
cell cycle (CDKN1A), MAPK and NFkB signaling (MAP3K14,
MUM1/IRF4, CARD10, and PIM2), somatic mutation during the
GC reaction (AID), and key transcription factors such as BCL6.
Specifically, miR-221 and miR-222 have been found to be essential
growth-regulatory mediators inhibiting p27 (Kip1), a cell-cycle
inhibitor and tumor suppressor.48-51 Other components of the
signature, such as the miR-106b-25 cluster (including miR-93),
have recently been found to interfere with the expression of
CDKN1A (p21) and BCL2L11, thereby impairing the TGFB
tumor-suppressor pathway in other cancers.52 Functional experi-
ments will be required to confirm the candidate interactions
identified here. Transfection experiments (introducing the miRNA
and measuring changes in the target mRNA/protein) and silencing
experiments (using shRNAs to inhibit the constitutive expression
of the miRNAs) might both be performed to address this matter, but
this was beyond the scope of the present study.
It is remarkable that the miRNA signature identified here
predicted survival independently of the COO classification. Al-
though the GC-ABC subclassification has a potentially predictive
role in the identification of patients likely to respond to specific
therapies for ABC-type DLBCL,53 the development of new meth-
ods that can capture a set of DLBCL cases with particularly
aggressive behavior paves the way for the design of trials using
alternative therapeutic strategies (eg, untargeted therapies such as
stem cell transplantation or more refined targeted therapies against
the substrate genes/pathways involved).
The recent observation that c-MYC rearrangements in DLBCL are
associated with poor prognosis in a subset (5%-15%) of rituximab-
treated patients54,55 led us to consider the possible relationship between
MYC status and the miRNA expression classifier. The biologic basis for
such an association might reside in the role of MYC as a transcriptional
regulator of the expression of some miRNAs.56-58 None of the miRNAs
included in the prognostic signatures described here has been found to
be associated with MYC in a wide range of functional studies in
lymphoid cell lines and lymphoma animal models.56-58 However,
because of the possible combinatorial effect of both MYC rearrange-
ments and miRNA deregulation, additional studies on the combination
of MYC and miRNA predictive impact are warranted. Our data
identified a set of miRNAs that could be useful outcome prognostic
markers in DLBCL treated with R-CHOP, and an integrated model with
IPI identified a subset of high-risk patients with a 2-year OS  50%.
Therefore, our approach may serve to refine outcome prediction and to
assign a risk-stratified therapy for DLBCL patients.
Acknowledgments
The authors thank María Encarnacio´n Castillo and CNIO’s Tumor
Bank Unit (María Jesu´s Artiga, Laura Cereceda, and Manuel
Morente) for their skillful retrieval and handling of clinical data
and samples from different clinical institutions and Lorena di Lisio
for fruitful discussions on methodologic issues. They also acknowl-
edge all of the clinical colleagues who kindly completed the
clinical data form, particularly M. Canales, F. Mazorra, M. Cruz, J.
Menarguez, and T. Gerds for discussions about Brier scores.
This study was supported by grants from the Ministerio de
Sanidad y Consumo (PI051623, PI052800, CP06/00002, RTICC),
the Asociacio´n Espan˜ola contra el Cancer (AECC), and the
Ministerio de Ciencia e Innovacio´n Spain (SAF 2008-03871).
Authorship
Contribution: S.M.-M. designed and performed the research, analyzed
the data, and wrote the manuscript; N.M. and B.S.-E. performed the
research and analyzed the data; A.S., C.M., E.G.-B., A.L., M.M., C.G.,
and M.A.M. contributed clinical data; M.E.R. performed the research;
R.D.U., D.G.P., and G.G. analyzed the data; J.F.G. contributed clinical
data and performed the research; C.D., E.D.H., E.C., C.V., and R.S.G.
contributed clinical data and skills; G.B.R., Z.X.-M., and J.C. performed
the data analysis; K.H.Y. analyzed the data and critically revised and
drafted the manuscript; and M.A.P. designed the research, analyzed the
data, and wrote the manuscript.
Conflict-of-interest disclosure: The authors declare no compet-
ing financial interests.
Correspondence: Miguel A. Piris, Pathology Department, Hos-
pital Universitario Margue´s de Valdecilla, IFIMAV, Avenida de
Valdecilla n 25, 39008 Santander, Spain; e-mail: mapiris@cnio.es.
References
1. Swerdlow SH CE, Harris NL, Jaffe ES, et al.
WHO Classification of Tumours of Haematopoi-
etic and Lymphoid Tissues. 4th ed. Lyon, France:
IARC Press; 2008.
2. Lossos IS, Morgensztern D. Prognostic biomark-
ers in diffuse large B-cell lymphoma. J Clin Oncol.
2006;24(6):995-1007.
3. Sehn LH, Donaldson J, Chhanabhai M, et al. In-
troduction of combined CHOP plus rituximab
therapy dramatically improved outcome of diffuse
large B-cell lymphoma in British Columbia. J Clin
Oncol. 2005;23(22):5027-5033.
4. Habermann TM, Weller EA, Morrison VA, et al.
Rituximab-CHOP versus CHOP alone or with main-
tenance rituximab in older patients with diffuse large
B-cell lymphoma. J Clin Oncol. 2006;24(19):3121-
3127.
5. Feugier P, Van Hoof A, Sebban C, et al. Long-
term results of the R-CHOP study in the treat-
ment of elderly patients with diffuse large B-cell
lymphoma: a study by the Groupe d’Etude des
miRNAAS PROGNOSTIC MARKERS IN DLBCL 1039BLOOD, 28 JULY 2011  VOLUME 118, NUMBER 4  For personal use only.2011. 
 at Centro Nacional de Investigaciones Oncológicas on August 29,bloodjournal.hematologylibrary.orgFrom 
Lymphomes de l’Adulte. J Clin Oncol. 2005;
23(18):4117-4126.
6. Coiffier B, Lepage E, Briere J, et al. CHOP che-
motherapy plus rituximab compared with CHOP
alone in elderly patients with diffuse large-B-cell
lymphoma. N Engl J Med. 2002;346(4):235-242.
7. Sehn LH, Berry B, Chhanabhai M, et al. The re-
vised International Prognostic Index (R-IPI) is a
better predictor of outcome than the standard IPI
for patients with diffuse large B-cell lymphoma
treated with R-CHOP. Blood. 2007;109(5):1857-
1861.
8. Pfreundschuh M, Trumper L, Osterborg A, et al.
CHOP-like chemotherapy plus rituximab versus
CHOP-like chemotherapy alone in young patients
with good-prognosis diffuse large-B-cell lym-
phoma: a randomised controlled trial by the Mab-
Thera International Trial (MInT) Group. Lancet
Oncol. 2006;7(5):379-391.
9. A predictive model for aggressive non-Hodgkin’s
lymphoma. The International Non-Hodgkin’s Lym-
phoma Prognostic Factors Project. N Engl J Med.
1993;329(14):987-994.
10. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct
types of diffuse large B-cell lymphoma identified
by gene expression profiling. Nature. 2000;
403(6769):503-511.
11. Lenz G, Wright G, Dave SS, et al. Stromal gene
signatures in large-B-cell lymphomas. N Engl
J Med. 2008;359(22):2313-2323.
12. Choi WW, Weisenburger DD, Greiner TC, et al. A
new immunostain algorithm classifies diffuse
large B-cell lymphoma into molecular subtypes
with high accuracy. Clin Cancer Res. 2009;
15(17):5494-5502.
13. de Jong D, Rosenwald A, Chhanabhai M, et al.
Immunohistochemical prognostic markers in dif-
fuse large B-cell lymphoma: validation of tissue
microarray as a prerequisite for broad clinical ap-
plications—a study from the Lunenburg Lym-
phoma Biomarker Consortium. J Clin Oncol.
2007;25(7):805-812.
14. Malumbres R, Chen J, Tibshirani R, et al. Paraf-
fin-based 6-gene model predicts outcome in dif-
fuse large B-cell lymphoma patients treated with
R-CHOP. Blood. 2008;111(12):5509-5514.
15. Alizadeh AA, Gentles AJ, Lossos IS, Levy R. Mo-
lecular outcome prediction in diffuse large-B-cell
lymphoma. N Engl J Med. 2009;360(26):2794-
2795.
16. Ambros V. The functions of animal microRNAs.
Nature. 2004;431(7006):350-355.
17. Bartel DP. MicroRNAs: genomics, biogenesis,
mechanism, and function. Cell. 2004;116(2):281-
297.
18. Ji J, Shi J, Budhu A, et al. MicroRNA expression,
survival, and response to interferon in liver can-
cer. N Engl J Med. 2009;361(15):1437-1447.
19. Lu J, Getz G, Miska EA, et al. MicroRNA expres-
sion profiles classify human cancers. Nature.
2005;435(7043):834-838.
20. Yanaihara N, Caplen N, Bowman E, et al. Unique
microRNA molecular profiles in lung cancer diag-
nosis and prognosis. Cancer Cell. 2006;9(3):189-
198.
21. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA
expression profiles associated with prognosis
and therapeutic outcome in colon adenocarci-
noma. JAMA. 2008;299(4):425-436.
22. Basso K, Sumazin P, Morozov P, et al. Identifica-
tion of the human mature B cell miRNome. Immu-
nity. 2009;30(5):744-752.
23. Calin GA, Ferracin M, Cimmino A, et al. A Mi-
croRNA signature associated with prognosis and
progression in chronic lymphocytic leukemia.
N Engl J Med. 2005;353(17):1793-1801.
24. Garzon R, Volinia S, Liu CG, et al. MicroRNA sig-
natures associated with cytogenetics and progno-
sis in acute myeloid leukemia. Blood. 2008;
111(6):3183-3189.
25. Marcucci G, Radmacher MD, Maharry K, et al.
MicroRNA expression in cytogenetically normal
acute myeloid leukemia. N Engl J Med. 2008;
358(18):1919-1928.
26. Lawrie CH, Soneji S, Marafioti T, et al. MicroRNA
expression distinguishes between germinal cen-
ter B cell-like and activated B cell-like subtypes of
diffuse large B cell lymphoma. Int J Cancer. 2007;
121(5):1156-1161.
27. Malumbres R, Sarosiek KA, Cubedo E, et al. Dif-
ferentiation stage-specific expression of
microRNAs in B lymphocytes and diffuse large
B-cell lymphomas. Blood. 2009;113(6):3754-
3764.
28. Zhang J, Jima DD, Jacobs C, et al. Patterns of
microRNA expression characterize stages of hu-
man B-cell differentiation. Blood. 2009;113(19):
4586-4594.
29. Lawrie CH, Chi J, Taylor S, et al. Expression of
microRNAs in diffuse large B cell lymphoma is
associated with immunophenotype, survival and
transformation from follicular lymphoma. J Cell
Mol Med. 2009;13(7):1248-1260.
30. Kovalchuk O, Filkowski J, Meservy J, et al. In-
volvement of microRNA-451 in resistance of the
MCF-7 breast cancer cells to chemotherapeutic
drug doxorubicin. Mol Cancer Ther. 2008;7(7):
2152-2159.
31. Zhu H, Wu H, Liu X, et al. Role of MicroRNA miR-
27a and miR-451 in the regulation of MDR1/P-
glycoprotein expression in human cancer cells.
Biochem Pharmacol. 2008;76(5):582-588.
32. Wright G, Tan B, Rosenwald A, Hurt EH,
Wiestner A, Staudt LM. A gene expression-based
method to diagnose clinically distinct subgroups
of diffuse large B cell lymphoma. Proc Natl Acad
Sci U S A. 2003;100(17):9991-9996.
33. Cheson BD, Pfistner B, Juweid ME, et al. Revised
response criteria for malignant lymphoma. J Clin
Oncol. 2007;25(5):579-586.
34. Diaz-Uriarte R. SignS: a parallelized, open-
source, freely available, web-based tool for gene
selection and molecular signatures for survival
and censored data. BMC Bioinformatics. 2008;9:
30.
35. Edgar R, Domrachev M, Lash AE. Gene Expres-
sion Omnibus: NCBI gene expression and hybrid-
ization array data repository. Nucleic Acids Res.
2002;30(1):207-210.
36. Kaplan E, Meier P. Nonparametric estimation
from incomplete observations. Am Stat Assoc J.
1958;53:457-81.
37. Peto R, Pike MC, Armitage P, et al. Design and
analysis of randomized clinical trials requiring
prolonged observation of each patient. I. Intro-
duction and design. Br J Cancer. 1976;34(6):585-
612.
38. Cox D. Regression models and life-tables. J R
Stat Soc. 1972;34:187-220.
39. Subramanian A, Tamayo P, Mootha VK, et al.
Gene set enrichment analysis: a knowledge-
based approach for interpreting genome-wide
expression profiles. Proc Natl Acad Sci U S A.
2005;102(43):15545-15550.
40. Gerds TA, Schumacher M. Consistent estimation
of the expected Brier score in general survival
models with right-censored event times. Biom J.
2006;48(6):1029-1040.
41. Xiao C, Rajewsky K. MicroRNA control in the im-
mune system: basic principles. Cell. 2009;136(1):
26-36.
42. Kim DH, Saetrom P, Snove O Jr, Rossi JJ.
MicroRNA-directed transcriptional gene silencing
in mammalian cells. Proc Natl Acad Sci U S A.
2008;105(42):16230-16235.
43. Baek D, Villen J, Shin C, Camargo FD, Gygi SP,
Bartel DP. The impact of microRNAs on protein
output. Nature. 2008;455(7209):64-71.
44. Selbach M, Schwanhausser B, Thierfelder N,
Fang Z, Khanin R, Rajewsky N. Widespread
changes in protein synthesis induced by
microRNAs. Nature. 2008;455(7209):58-63.
45. Roehle A, Hoefig KP, Repsilber D, et al. Mi-
croRNA signatures characterize diffuse large B-
cell lymphomas and follicular lymphomas. Br J
Haematol. 2008;142(5):732-744.
46. Meyer PN, Fu K, Greiner TC, et al. Immunohisto-
chemical methods for predicting cell of origin and
survival in patients with diffuse large B-cell lym-
phoma treated with rituximab. J Clin Oncol. 2011;
29(2):200-207.
47. Ott G, Ziepert M, Klapper W, et al. Immunoblastic
morphology but not the immunohistochemical
GCB/non-GCB classifier predicts outcome in dif-
fuse large B-cell lymphoma in the RICOVER-60
trial of the DSHNHL. Blood. 2010;116(23):4916-
4925.
48. le Sage C, Nagel R, Egan DA, et al. Regulation of
the p27(Kip1) tumor suppressor by miR-221 and
miR-222 promotes cancer cell proliferation.
EMBO J. 2007;26(15):3699-3708.
49. Visone R, Russo L, Pallante P, et al. MicroRNAs
(miR)-221 and miR-222, both overexpressed in
human thyroid papillary carcinomas, regulate
p27Kip1 protein levels and cell cycle. Endocr
Relat Cancer. 2007;14(3):791-798.
50. Medina R, Zaidi SK, Liu CG, et al. MicroRNAs
221 and 222 bypass quiescence and compromise
cell survival. Cancer Res. 2008;68(8):2773-2780.
51. Fornari F, Gramantieri L, Ferracin M, et al. MiR-
221 controls CDKN1C/p57 and CDKN1B/p27 ex-
pression in human hepatocellular carcinoma. On-
cogene. 2008;27(43):5651-5661.
52. Petrocca F, Visone R, Onelli MR, et al. E2F1-
regulated microRNAs impair TGFbeta-dependent
cell-cycle arrest and apoptosis in gastric cancer.
Cancer Cell. 2008;13(3):272-286.
53. Dunleavy K, Pittaluga S, Czuczman MS, et al.
Differential efficacy of bortezomib plus chemo-
therapy within molecular subtypes of diffuse large
B-cell lymphoma. Blood. 2009;113(24):6069-
6076.
54. Barrans S, Crouch S, Smith A, et al. Rearrange-
ment of MYC is associated with poor prognosis in
patients with diffuse large B-cell lymphoma
treated in the era of rituximab. J Clin Oncol. 2010;
28(20):3360-3365.
55. Savage KJ, Johnson NA, Ben-Neriah S, et al.
MYC gene rearrangements are associated with a
poor prognosis in diffuse large B-cell lymphoma
patients treated with R-CHOP chemotherapy.
Blood. 2009;114(17):3533-3537.
56. O’Donnell KA, Wentzel EA, Zeller KI, Dang CV,
Mendell JT. c-Myc-regulated microRNAs modu-
late E2F1 expression. Nature. 2005;435(7043):
839-843.
57. Sander S, Bullinger L, Klapproth K, et al. MYC
stimulates EZH2 expression by repression of its
negative regulator miR-26a. Blood. 2008;112(10):
4202-4212.
58. Chang TC, Yu D, Lee YS, et al. Widespread mi-
croRNA repression by Myc contributes to tumori-
genesis. Nat Genet. 2008;40(1):43-50.
59. Montes-Moreno S, Martinez N, Saez A, et al. Mi-
croRNA expression in DLBCL: identification of
unique miRNAs signatures related to clinical out-
come prediction in RCHOP treated patients. Mod
Pathol. 2009;22(supp 1):278A(1262).
1040 MONTES-MORENO et al BLOOD, 28 JULY 2011  VOLUME 118, NUMBER 4 For personal use only.2011. 
 at Centro Nacional de Investigaciones Oncológicas on August 29,bloodjournal.hematologylibrary.orgFrom 
 
www.elsevier.com/locate/humpath
Human Pathology (2011) xx, xxx–xxxOriginal contribution
Glioma-associated oncogene homologue 3, a hedgehog
transcription factor, is highly expressed in Hodgkin and
Reed-Sternberg cells of classical Hodgkin lymphoma☆,☆☆
Wesley O. Greaves MDa,1, Ji Eun Kim MDb,1, Rajesh R. Singh PhDa,
Elias Drakos MD, PhDa, Kranthi Kunkalla MS a, Beatriz Sánchez-Espiridión MS c,
Juan F. Garcia MDd, L. Jeffrey Medeiros MDa, Francisco Vega MD, PhDa,⁎
aDepartment of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA
bDepartment of Pathology, Seoul National University Boramae Hospital, 156-707 Seoul, South Korea
cSpanish National Cancer Research Centre (CNIO), Madrid, 28029 Spain
dCentro Oncológico MD Anderson International España, Madrid, 28033 Spain
Received 23 September 2010; revised 22 December 2010; accepted 23 December 2010tr
p
0
dKeywords:
GLI3;
Hedgehog signaling;
Classical Hodgkin
lymphoma;
ImmunohistochemistrySummary The hedgehog signaling pathway has been shown to play a pathogenic role in diffuse large B-
cell lymphoma and anaplastic large cell lymphoma, but has not been assessed in classical Hodgkin
lymphoma. Glioma-associated oncogene homologues 1, 2, and 3 are transcriptional effectors of the
hedgehog pathway. In this study, we first used real-time quantitative polymerase chain reaction to
investigate the expressions of GLI1, GLI2, and GLI3 in 3 classical Hodgkin lymphoma cell lines. GLI1
and GLI2 were variably expressed, but GLI3 was highly expressed in all cell lines. We then used
immunohistochemistry to assess glioma-associated oncogene homologues 1, 2, and 3 in 39 classical
Hodgkin lymphoma patient samples. Glioma-associated oncogene homologues 1 and 2 were weakly to
variably expressed in a subset of classical Hodgkin lymphoma patient samples. In contrast, glioma-
associated oncogene homologue 3 showed strong, uniform nuclear expression in virtually all Hodgkin/
Reed-Stenberg cells. We then performed an immunohistochemical survey of glioma-associated oncogene
homologue 3 expression in 13 cases of nodular lymphocyte predominant Hodgkin lymphoma and 218
non–Hodgkin lymphomas. Most other lymphoma types showed variable or no expression of glioma-
associated oncogene homologue 3, with a minor subset of cases of nodular lymphocyte predominant
Hodgkin lymphoma, ALK-positive and ALK-negative anaplastic large cell lymphoma, and B-cell
lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma and classical
Hodgkin lymphoma showing a glioma-associated oncogene homologue 3 staining pattern indistinguish-☆ This research was supported by funds from the University Cancer Foundation at The University of Texas M.D. Anderson Cancer Center, from a
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2 W. O. Greaves et al.able from classical Hodgkin lymphoma. Our data provide a rationale to further investigate the biologic
significance of glioma-associated oncogene homologue 3 in classical Hodgkin lymphoma biology.
© 2011 Elsevier Inc. All rights reserved.Table 1 Antibodies used for immunohistochemistry
Antibody Clone Manufacturer Dilution Incubation
HH H-160 Santa Cruz
Biotechnology,
Santa Cruz, CA
1:150 RT, 1 h
GLI1 H-300 Santa Cruz 1:200 RT, 1 h
GLI2 NA Abcam,
Cambridge, MA
1:200 RT, 1.5 h
GLI3 H-280 Santa Cruz 1:150 RT, 1 h
CD20 L26 Dako 1:1000 RT, 1 h
CD30 Ab36749 Abcam 1:150 RT, 1.5 h
Abbreviations: NA, not available; RT, room temperature.1. Introduction
Hodgkin lymphoma (HL) represents approximately 30%
of all lymphomas and can be divided into classical HL (CHL)
and nodular lymphocyte predominant (NLPHL) types,
representing 95% and 5% of cases, respectively [1]. CHL
can be further divided into 4 histologic types: nodular
sclerosis, lymphocyte-rich, lymphocyte-depleted, and mixed
cellularity. The pathogenesis of CHL is not well defined, and
recent studies have shown that constitutive activation of
multiple signaling pathways contributes to the survival and
proliferation of Hodgkin/Reed-Sternberg (HRS) cells. In
particular, constitutive activation of the nuclear factor κB
(NFκB), PI3K/AKT, and JAK/STAT pathways have been
implicated [2]. HRS cells also commonly express Bcl-2 pro-
tein, suggesting that evasion of apoptotic mechanisms plays a
role in HRS cell survival [3,4]. In addition, there is evidence
that the microenvironment is essential for survival of HRS
cells. It is difficult to grow HRS cells in culture or to generate
cell lines, and it is rare to find circulating HRS in peripheral
blood. When CHL does disseminate to nonlymphoid organs,
HRS cells are accompanied by a typical microenvironment
[2]. It seems that the composition of the microenvironment is
regulated by a range of cytokines and chemokines produced
by HRS cells and the microenvironment [2].
The Hedgehog (HH) protein family is a group of
secreted signaling molecules critical for normal mammalian
development and homeostasis of adult renewable tissues
[5,6]. Recent studies have shown that secreted HH ligands
protect nonneoplastic germinal center B cells as well as of
low-grade B-cell lymphoma cells from apoptosis [7,8]. The
HH signaling pathway is incompletely understood. Briefly,
the HH ligands, Sonic, Indian, and Desert, interact with a
membrane-bound receptor complex composed of 2 proteins,
patched (PTCH) and smoothened (SMO) [9]. PTCH is the
HH ligand-binding subunit, and SMO is the signal
transduction component. In the absence of HH ligands,
PTCH inhibits SMO. Once HH ligands bind to PTCH, this
inhibition is released, allowing SMO to transduce the HH
signal mediated by the transcription factors glioma-
associated oncogene homologues (GLI) 1, 2 and 3 [10].
Although both GLI2 and GLI3 have transcriptional
activation and repression properties, GLI1 is a strong
positive regulator of HH transcriptional targets and is, itself,
a transcriptional target of HH [11]. GLI3 is a bifunctional
transcriptional regulator that, in the absence of HH, is
proteolytically cleaved to form the truncated GLI3 protein,
which acts as a repressor of target gene transcription
(GLI3R) [12]. On the other hand, in the presence of HHsignals, the full-length form of GLI3 acts a transcriptional
activator (GLI3A). The functions of GLI3 in the hemato-
poietic system are not well characterized.
Inappropriate activation of the HH pathway has been
shown in many cancers [13,14] but has not been assessed in
CHL. In this study, we investigated the expression of HH
transcription factors in a series of CHL patient samples. We
found that GLI3 is highly expressed in CHL and shows a
distinctive immunohistochemical expression pattern in HRS
cells. Expression of GLI3 protein by HRS cells provides a
rationale for further investigation of the biologic role of GLI3
in CHL. Furthermore, as GLI3 is expressed by thymic stroma
and is described to regulate T-cell differentiation, GLI3 may
be involved in regulating the composition of the microen-
vironment in CHL.
2. Materials and methods
2.1. Cell lines
The CHL-derived cell lines used included KMH2 and
HDMYZ (purchased from DSMZ, Braunschweig, Germany)
and L428. We also used a DLBCL-derived cell line, BJAB
(purchased from American Type Culture Collection
[ATCC], Manassas, VA). All cell lines were maintained at
37°C in RPMI 1640 (ATCC) supplemented with 10% heat-
inactivated fetal bovine serum (Sigma, St Louis, MO) in a
humidified atmosphere containing 5% CO2.
2.2. Real-time quantitative reverse transcriptase
polymerase chain reaction
Total messenger RNA (mRNA) from cell lines was
extracted using RNAeasy Minikit (Qiagen, Valencia, CA) as
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Fig. 1 RT-qPCR analysis for GLI molecules in CHL. RT-qPCR analysis in CHL cells shows the presence of mRNAs for GLI1, GLI2, and
GLI3. Overall, there is variable expression of GLI1 and GLI2 mRNAs in the 3 CHL cell lines tested. However, consistently elevated
expression of GLI3mRNA is seen in all 3 CHL cell lines. BJAB, a DLBCL cell line, and 1 CLL patient samples are used as control references.
3Glioma-associated oncogene homologue 3per the manufacturer's protocol. After DNAse digestion,
first-strand complement DNA was synthesized from total
RNA using random primers and SuperScript II Reverse
Transcriptase (Invitrogen, Carlsbad, CA). Gene expression of
GLI3 was analyzed by quantitative reverse transcriptase
polymerase chain reaction (RT-qPCR) assay using respective
primers (Applied Biosystems, Foster City, CA) and Taqman
probes. Reactions were performed using the ABI PRISM
7500HT Sequence Detection system (Applied Biosystems),
and the expression of each gene was measured in duplicate
and then normalized with 18s ribosomal RNA endogenous
gene. Relative quantification of gene expression levels was
assessed by using the delta cycle threshold (CT) method.
BJAB cells were used as a negative reference control.
2.3. Patients samples and immunohistochemistry
The study group included 33 cases of nodular sclerosis and
6 cases of mixed cellularity CHL. Either routine histologic
sections or tissue microarrays were used. We then performed a
survey of 13 cases of NLPHL and 218 non-HLs as follows: 54
DLBCL, not otherwise specified (NOS); 28 follicular
lymphoma (FL); 21 anaplastic lymphoma kinase (ALK)-Fig. 2 Immunohistochemical expression of GLI3 in normal adult thymu
including epithelial cells, histiocytes, and endothelial cells. B, GLI3 immu
including Hassall corpuscles. Thymocytes are negative (original magnifipositive anaplastic large cell lymphoma (ALCL); 16
ALK-negative ALCL; 16 chronic lymphocytic lymphoma/
small lymphocytic lymphoma (CLL/SLL); 13 B-cell lympho-
ma, unclassifiable, with features intermediate betweenDLBCL
and CHL (BCLU); 12 T-cell/histiocyte-rich large B-cell
lymphoma (TCHRLBCL); 12 Burkitt lymphoma (BL); 7
mantle cell lymphoma (MCL); 7 primary mediastinal large
B-cell lymphoma (PMLBCL); 7 marginal zone B-cell
lymphomas (MZL); 10 natural killer/T-cell lymphoma
(NKTCL); 9 peripheral T-cell lymphoma, NOS (PTCL,
NOS); and 6 angioimmunoblastic T-cell lymphoma (AILT).
The cases of FL and DLBCL in this series include those
reported in a previous study plus additional cases of DLBCL
[15]. All cases were diagnosed at The University of Texas MD
Anderson Cancer Center between 1987 and 2009, except for
9 previously reported gray-zone lymphomas provided by the
Centro Oncológico MD Anderson International España
(Madrid, Spain). The clinicopathologic features of the BCLU
cases used in this study were published previously by 1 of the
authors (J.F.G.) [16]. The diagnosis of all the neoplasms was
based on morphologic and immunohistological criteria
according to the World Health Organization 2008 classifica-
tion criteria and reviewed by 4 of the authors (L.J.M., F.V.,s. A, Benign thymus showing cortex and medulla with stromal cells
nostain highlights cortical and medullary stromal cells in the thymus,
cation ×100-200).
Table 2 Expression of HH signaling proteins by
immunohistochemistry in CHL
No. of
cases
Intensity of
expression
Total
positive
% Positive
1+ 2+
HH 24 12 8 20 83
GLI1 25 7 0 7 28
GLI2 17 9 0 9 53
GLI3 39 0 39 39 100
4 W. O. Greaves et al.J.E.K., andW.O.G.). The diagnosis of PMLBCLwas based on
clinicopathologic correlation and included only patients with
an anterosuperior mediastinal mass, with no disease outside
the mediastinum at the time of the diagnosis, and with
morphologic and immunophenotypic features consistent with
PMLBCL. The diagnosis of ALK-negative ALCL was
established for those lymphomas morphologically within the
spectrum of ALK-positive ALCL with strong and uniform
expression of CD30, but lacking ALK protein expression.Fig. 3 Immunohistochemical expression of HH ligands and GLI3 in
Lymphocytes are negative for HH ligands (B and C), GLI3 shows characte
virtually all HRS cells. Note in panel C that the histiocytes and endothe
neoplastic cells are easily recognized by their large size, irregular nu
immunostaining with GLI3 (brown chromogen) and CD30 (red) con
magnification ×100-1000).Immunohistochemical methods were performed using
routinely processed paraffin-embedded tissue specimens as
previously described [17]. Antibodies and staining condi-
tions are listed in Table 1. All tissue sections underwent
heat-induced epitope retrieval in pH 6.0 citrate buffer
(Dako, Carpinteria, CA). Endogenous peroxidase reaction
was blocked by 3% H2O2 solution for 10 minutes. To
avoid nonspecific binding of primary antibodies, serum-
free blocking solution (Dako) was applied for 40 minutes
at room temperature. Detection was performed using the
LSAB plus-streptavidin-HRP system (Dako). For this
study, we analyzed GLI3 protein expression in all 270
cases of lymphoma and 3 thymus specimens. In addition,
other HH signaling proteins (HH, GLI1, and GLI2) were
assessed in a subset of CHL cases that were available
including HH (n = 24), GLI1 (n = 25), and GLI2 (n = 17).
The baseline expression of HH signaling proteins in
normal lymphoid cells was previously assessed and
described [15]. Appropriate external controls were used
for each antibody.HRS cells. A, Cytoplasmic staining for HH ligands in HRS cells.
ristic strong nuclear staining with nuclear membrane accentuation in
lial cells show weaker staining for GLI3 than the HRS cells. The
clear contours, and, in some cases, multinucleation. D, Double
firms the expression of GLI3 in neoplastic HRS cells (original
Table 3 Immunohistochemical expression of GLI3 in lymphoid neoplasms
Diagnosis n Positive
(%)
% Positive tumor
cells per case a,
median (range)
Number of cases with % positive tumor cells
0%-25% 26%-50% 51%-75% 76%-100%
CHL 39 39 (100) 98 (80-100) b 0 0 0 39
NLPHL 13 6 (46) 55 (10-100) 9 1 1 2
CLL/SLL 16 7 (44) 83 (80-90) 9 0 0 7 c
FL 28 2 (7) 10 (10) 28 0 0 0
MZL 4 0 0 4 0 0 0
SMZBCL 3 0 0 3 0 0 0
MCL 7 0 0 7 0 0 0
PMLBCL 7 7 (100) 25 (10-40) 6 1 0 0
DLBCL 54 21 (39) 15 (10-50) 51 3 0 0
Gray zone 13 13 (100) 40 (10-100) 5 3 0 5
TCHRLBCL 12 6 (50) 27 (10-80) 9 2 0 1
BL 12 0 0 12 0 0 0
PTCL, NOS 9 1 (11) 25 9 0 0 0
AILT 6 0 0 6 0 0 0
ALCL, ALK negative 16 12 (75) 20 (10-100) 11 0 0 5
ALCL, ALK positive 21 21 (100) 65 (10-100) 5 3 5 8
NKTCL 10 0 0 10 0 0 0
Total 270
NOTE. Gray zone lymphoma refers to BCLU with features intermediate between DLBCL and CHL.
a Only cases that showed positive staining are used to calculate the median.
b Three cases of CHL showed b100%, but more than 75%, GLI3-positive tumor cells.
c Only CLL/SLL cases with increased large cells showed GLI3 expression.
5Glioma-associated oncogene homologue 3Cases were considered positive if 10% or more of the
tumor cells exhibited cytoplasmic staining for HH or nuclear
staining for GLI1, GLI2, and GLI3 as previously reported
[18]. Protein expression was scored as negative, weakly
positive (1+), and strongly positive (2+) depending on the
staining signal intensity. In addition, the percentage of GLI3-
positive cells was calculated by manually counting at least
200 tumor cells from representative fields in each case. We
performed double immunostaining for GLI3 and CD30 or
CD20 in a subset of cases of CHL, NLPHL, and
TCHRLBCL and for GLI3 and cytokeratin, CD68, or
CD20 in benign thymus using the EnVision G2 System
(Dako) according to the manufacturer's recommendations.
2.4. Statistical analysis
All statistical analyses were 2 sided and performed using
SPSS 16.0 (SPSS Inc, Chicago, IL) considering P values less
than .05 (2-sided) as significant. Comparison of GLI3
expression frequencies among the different lymphoma types
was done by Kruskal-Wallis and Mann-Whitney U non-
parametric tests.
3. Results
3.1. Real-time qPCR analysis of CHL cell lines
Real-time qPCR analysis showed high expression of
GLI3 in all 3 CHL cell lines assessed. In contrast, GLI1 andGLI2 were variably expressed by CHL cell lines (Fig. 1).
BJAB cells, a human germinal center–derived DLBCL cell
line, and CLL cells isolated from the peripheral blood of a
patient were used as control references. Studies in our
laboratory have shown that expression of GLI3 is usually not
detected in DLBCL cell lines and is frequently detected in
circulating CLL cells.
3.2. Baseline expression of GLI3 in normal thymus
and reactive lymph nodes as detected by
immunohistochemistry
In the thymus, GLI3 was expressed by cortical and
medullary stromal cells including epithelial cells, endothe-
lial cells, and histiocytes (Fig. 2). Double immunostaining
for CD68 and cytokeratin confirmed the identity of
histiocytes and epithelial cells. Thymocytes were negative,
and there was no coexpression of GLI3 in CD20-positive
B cells (not shown).
In a previous study, we assessed the baseline protein
expression of HH ligands, GLI1, GLI2, and GLI3 in
benign reactive lymph nodes using immunohistochemistry
[15]. Briefly, HH ligands were expressed by follicular
dendritic cells and macrophages. GLI1 was not detected
in centrocytes or centroblasts, and GLI2 was weakly posi-
tive in paracortical T cells and in a subset of centroblasts
and centrocytes. GLI3 was expressed by histiocytes,
follicular dendritic cells, and endothelial cells but not by
lymphoid cells.
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7Glioma-associated oncogene homologue 33.3. GLI3 is characteristically and distinctively
expressed in CHL
The expression of the HH signaling proteins in CHL as
tested by immunohistochemistry is summarized in Table 2.
HH, GLI1, and GLI2 showed variable expression in HRS
cells. HH ligands were expressed in 20 (83%) of 24 cases
(Fig. 3A). Most positive cases (12 of 20, or 60%) showed
weak HH staining, whereas 8 cases showed strong (2+)
expression. GLI1 was expressed in 7 (28%) of 25 cases and
was weakly positive, and GLI2 was weakly positive in 9
(53%) of 17 cases. In contrast, all 39 CHL tumors showed
strong and uniform expression of GLI3 in virtually 100% of
the tumor cells (Fig. 3B and C). GLI3 in HRS cells was
expressed in a nuclear pattern with nuclear membrane
accentuation. Double IHC with CD30 performed in a subset
of cases confirmed that the CD30-positive HRS cells were
uniformly positive for GLI3 (Fig. 3D).
3.4. Survey of other lymphoma types
We assessed GLI3 expression by immunohistochemistry
in a large series of B- and T-cell non-HLs. The findings are
summarized in Table 3, and examples of the staining pattern
of GLI3 in lymphomas other than CHL are shown in Fig. 4.
Our data show that GLI3 is more frequently expressed in
CHL tumors compared with all other lymphoma types
studied (P b .0001).
Four tumor types showed variable GLI3 expression.
ALK-negative ALCL, ALK-positive ALCL, BCLU with
features intermediate between DLBCL and CHL, and
NLPHL showed heterogeneous GLI3 expression, with a
variable percentage positive tumor cells with a median of
20%, 65%, 40% and 55%, respectively (Figs. 5A-D). In most
of these cases, only a subset of tumor cells were positive for
GLI3; however, a subset of cases showed strong nuclear
staining of GLI3 in 90% or more of tumor cells in a pattern
indistinguishable from that seen in CHL (Fig. 5E-G). These
cases included 2 (15%) of 13 NLPHLs, 5 (31%) of 16 ALK-
negative ALCLs, 8 (38%) of 21 ALK-positive ALCLs, and 3
(23%) of 13 BCLUs with features intermediate between
DLBCL and CHL.
Among B-cell non-HLs, there was no expression of GLI3
in SMZBCL, MZL, MCL, and BL, whereas 2 cases of FL
showed positive staining for GLI3 in a subset of centroblasts.
Large B-cell lymphomas including all 7 PMLBCL, a subsetFig. 5 GLI3 is heterogeneously expressed in cases of ALCL, ALK-pos
DLBCL and CHLs and NLPHL, with most cases showing focal or no ex
negative ALCL (A), BCLU with features intermediate between DLBCL
focally positive staining for GLI3. For those cases with focal positivity
expression than that seen in histiocytes and endothelial cells (black arrow
with features intermediate between DLBCL and CHL (F), and NLPHL (G
is, strong nuclear staining with nuclear membrane accentuation in virtua
increased large cells (H) was characterized by a weak nuclear expression o
without nuclear membrane accentuation. Note the stronger expression ofof DLBCL (NOS), and TCHRLBCL showed relatively low
levels of GLI3 expression (median b30% positive tumor
cells per case). In contrast with CHL, which showed
uniformly strong GLI3 staining in all tumor cells, the
intensity of GLI3 staining in the tumor cells of B-cell non-
HLs, if positive, was always weak and lacked the distinctive
nuclear membrane accentuation seen in CHL. Although the
cytologic features as well as the immunostaining pattern of
GLI3 allowed the distinction between histiocytes and tumor
cells in most cases, we performed double immunostaining
with GLI3 and CD20 in some cases of TCHRLBCL with a
high content of histiocytes to highlight the tumor cells. These
studies confirmed that the tumor cells were predominantly
negative for GLI3 (not shown).
Interestingly, cases of CLL/SLL with significantly
increased large cells showed positive GLI3 staining in the
large cells (median, 83% positive large tumor cells). These
tumor cells showed weak nuclear staining with no nuclear
membrane accentuation, a pattern easily distinguishable
from that seen in CHL (Fig. 4D). Cases of CLL/SLL without
increased large cells did not express GLI3.
Of the T- and natural killer (NK) cell lymphomas,
NKTCL, and AILT showed no GLI3 expression, and 1
(11%) of 9 PTCLs, NOS, showed weak nuclear GLI3
expression in a subset of neoplastic cells.4. Discussion
This is the first study showing high expression of the HH
transcription factor GLI3 in HRS cells of CHL. We also
show that HRS cells express relatively low levels of other
HH-related molecules including HH ligands and the
transcription factors GLI1 and GLI2. GLI3 is universally
expressed in HRS cells and is either not expressed or
significantly less frequently expressed in other lymphomas.
However, a small subset of other lymphomas also express
GLI3 including ALK-positive ALCL, ALK-negative ALCL,
BCLU with features intermediate between DLBCL and
CHL, and NLPHL. A subset of tumors in these 4 categories,
one third of cases or less, showed a pattern of GLI3 staining
indistinguishable from that seen in CHL. The reason for the
expression of GLI3 in some of these cases is unclear;
however, these findings provide further support for the
existence of a subset of lymphomas with intermediate/hybrid
features between CHL and non-HL.itive, and ALK-negative, BCLU with features intermediate between
pression in the tumor cells. The tumor cells in most cases of ALK-
and CHL (B), NLPHL (C), and CLL/SLL (D) show negative or
, GLI3 was expressed in a subset of the tumor cells with weaker
in C). However, a small subset of ALK-negative ALCL (E), BCLU
) show a GLI3 expression pattern indistinguishable from CHL, that
lly 100% of the tumor cells. The pattern of staining in CLL with
f GLI3, as compared with intrinsic histiocytes and endothelial cells,
GLI3 in histiocytes in comparison with the positive tumor cells.
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9Glioma-associated oncogene homologue 3Inappropriate activation of the HH signaling pathway has
been shown in many cancers including ALK-positive ALCL
and DLBCL [18-20]. However, this aberrant activation is
mediated by the transcription factors GLI1 and GLI2 and not
by GLI3. In fact, GLI3 mainly functions in vivo as a
transcriptional repressor. Furthermore, in most systems
studied, GLI3 limits HH pathway activation and absence of
GLI3 causes up-regulation of HH signaling. Thus, the
biologic significance of the expression of GLI3 in HRS is
uncertain at this time.
Constitutive activation of the PI3K/AKT and NFκB
pathways has been implicated in CHL [2], and crosstalk
between these pathways with expression of HH ligands has
been described. It has been shown that some growth factors
such as platelet-derived growth factor, epidermal growth
factor, and insulin-like growth factor 1 increase expression of
HH ligands and that this increase is dependent of PI3K and
AKT activation [21,22]. We and others have shown that
adenoviral delivery of activated AKT up-regulates HH
ligand expression and that recombinant HH induces
activation of PI3K/AKT [18,22,23]. Similarly, it has been
shown that NFκB regulates and contributes to HH ligand
expression [24,25]. The mode of action of HH signaling in
cancers seems to be complex and may be tumor dependent.
Several studies suggest an autocrine action from HH
signaling in some tumors, and others favor a paracrine
model. In the paracrine model, neoplastic cells secrete HH
ligands that may stimulate stromal cells near the tumor
(endothelial cells, fibroblasts, and immune cells) to support
tumor growth through secreting of growth factors. It is
possible that the secretion of HH ligands by HRS contributes
in the interactions between tumor cells and surrounding
stroma in HL. However, the relationship between PI3K/AKT
and NFkB signaling pathways with expression of GLI3 is
uncertain at this time.
One of the historic challenges to a more complete
understanding of the pathobiology of CHL is the lineage
infidelity frequently demonstrated by HRS cells. For
instance, for many years, CHL was thought to be derived
from histiocytic/dendritic cells because they frequently
express histiocytic/dendritic cell markers like fascin [26].
Other lineage-associated markers variably expressed by
HRS cells include inhibitor of DNA binding 2 (ID2)
(dendritic cell marker); CD3 and CD4 (T-cell markers) and
CD15; and colony-stimulating factor 1 receptor (myeloid
markers) [27-29]. Some authors have shown that the unique
phenotype of HRS cells results from disruption or
imbalances in the B-cell lineage transcriptional program
and inhibition of the function of B-cell–determining
transcription factor E protein 2A (E2A) [28,30]. Currently,
HRS cells are considered to be of germinal center B-cell
origin because they undergo B-cell receptor gene rearrange-
ment and express B-cell specific transcription factors like
paired box 5 (PAX-5) [2,31]. We suggest that the
expression of GLI3 in HRS cells is another example of
their lineage infidelity given that GLI3 is normallyexpressed by stromal cells in the lymph node (including
follicular dendritic cells, histiocytes and endothelial cells)
and thymus (histiocytes, endothelial cells, and epithelial
cells), but not by mature or immature lymphocytes.
In addition, CHL is characterized by a rich inflammatory
milieu including T and B cells admixed with variable
numbers of plasma cells, macrophages, eosinophils, and
mast cells [32,33]. Regulatory T cells comprise a consid-
erable fraction of infiltrating T cells in CHL [34,35]. Tanijiri
and colleagues [36] showed that the coculture of CHL cell
lines with naïve CD4+ T cells promotes the bidirectional
differentiation of naïve T cells toward CD25+ Foxp3+ T
cells and CD4+ cytotoxic T cells without the cooperation of
any other factor and without requiring additional cell types.
This would explain, at least in part, the predominance of
regulatory T cells in CHL. Furthermore, Hager-Theodorides
and colleagues [37,38] recently showed that GLI3 in thymic
stromal cells regulates T-cell selection and differentiation.
Whether GLI3 plays a regulatory role in the T-cell
population in CHL remains to be studied, but we think
that it is an interesting hypothesis, and our findings provide
a rationale for further investigation of this potential
regulatory role.
From a practical point of view, our findings are also of
particular interest because we found that a lack of GLI3
staining is a strong negative predictor against the diagnosis
of CHL. Thus, GLI3 can be used in conjunction with the
currently available extensive list of immunohistochemical
markers to help distinguish CHL from possible mimics.
In summary, we have shown that GLI3 is strongly
expressed by virtually 100% of the HRS cells of CHL. These
data provide a rationale for further investigation of the
biologic significance of GLI3 in CHL tumor biology, in
particular, a potential regulatory role in the composition of
the CHL microenvironment.References
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Abstract This study investigates the differential gene expres-
sion profile of JAK2V617F-positive myeloproliferative neo-
plasm (MPN) patients, with and without response to
hydroxyurea (HU) treatment. Twenty-one polycythemia vera,
28 essential thrombocythemia, eight secondary erythrocytosis,
and 30 controls were studied. Thirty-four genes were overex-
pressed in patients who did not respond to HU. Of these,
some participate in proliferative pathways: MAPK, AKT, Src
kinase (SFK), and JAK2 pathway. JAK2 allele burden was
similar between groups of responders and nonresponder. A
molecular fingerprint distinguishes JAK2V617F-positive MPN
patients without response to HU treatment, with overexpres-
sion of JAK2, MAPK14, PIK3CA, and SFK genes.
Keywords Polycythemia vera . Essential
thrombocythemia . Gene expression profile . RT-PCR .
Response to hydroxyurea . JAK2 . Src family kinase (SFK)
Introduction
The discovery of the JAK2V617F point mutation has become a
hallmark in the diagnosis of the classic chronic Philadelphia-
negative myeloproliferative neoplasms (MPN) namely, poly-
cythemia vera (PV), essential thrombocythemia (ET), and
primary myelofibrosis (PMF) [1]. As a result, WHO
diagnostic criteria were revised in 2007, and JAK2 mutations
and MPL mutations were included as major criteria for the
diagnosis of PV, ET, and PMF [2]. Moreover, the JAK2V617F
allele burden has been included in response criteria for PV
and ET by a recent European Leukaemia Net (ELN)
consensus conference [3]. Despite the fact that JAK2V617F
has facilitated the diagnosis of MPN and improved our
knowledge on their pathogenesis, there are still a number of
unanswered questions [4].
Although formerly believed to be a single-step process,
recent evidence has shown that the JAK2V617F mutation is
neither the sole, nor sufficient molecular event, responsible
for MPN. It may also not be the initial one, and other
somatic mutations may precede JAK2V617F [5–7]. There is
evidence of clonal heterogeneity and presence of different
mutations in the same patient [8, 9].
The current first line of treatment for PV and ET patients
with a high risk of thrombosis is still hydroxyurea (HU)
[10]. The cytoreductive activity of HU is based on its anti-
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metabolic role as a cell cycle-specific analog of urea, with
activity in the S-phase. HU inhibits the enzyme, ribonucle-
otide reductase, which converts ribonucleotides to deoxi-
ribonucleotides (critical precursors for de novo DNA
biosynthesis and repair). Up to 15–25% of patients show
resistance or intolerance to HU [11, 12]. The mechanism of
resistance is believed to be the increased expression of
ribonucleotide reductase due to gene amplification, in-
creased transcription, and post-transcriptional mechanisms
[13]. Despite this knowledge, there is still no clear
understanding of the underlying molecular mechanism and
consequences of HU activity.
We aimed to analyze the differential gene expression
profile of JAK2V617F-positive MPN patients with or without
response to HU treatment, to determine possible mechanisms
for a poor response. As a consequence, we hoped to identify
alternative routes for targeted therapy. In addition, we aimed
to correlate these results with clinical and laboratory features.
Design and methods
Patients
Forty-nine patients, diagnosed with MPN (21 PVand 28 ET)
with the JAK2V617F mutation were included in the study, as
well as eight patients with secondary erythrocytosis (SE) to
hypoxemia, and 30 healthy control donors. An MPN
diagnosis was established on the basis of World Health
Organization criteria (WHO) 2001/2008 [2], or the Polycy-
themia Vera Southern Study Group (according to the
standard criteria at the moment of diagnosis). Twenty MPN
patients were studied at diagnosis (as control population) and
29 after treatment.
Clinical and laboratory features at diagnosis and follow-
up features of the JAK2V617F PV and ET patients were
assessed and are shown in Table 1.
Response to treatment with HU in PV and ET was
defined according to update recommendations [10] and to
clinico-hematological response criteria for PV and ET
recently published by the ELN consensus conference [3].
The study was approved by the local ethics committee
and written informed consent was obtained from all
patients, according to the Declaration of Helsinki.
Nucleic acids extraction and JAK2V617F quantification
Peripheral venous blood was collected in EDTA and
immediately processed. Granulocytes were isolated by
Ficoll-Paque (Sigma-Aldrich, Saint Louis, Mi USA) density
gradient centrifugation, as previously described. Erythrocytes
were eliminated by lysis with a commercial buffer (Red Blood
Cell Lysis Buffer, from Roche Applied Sciences, Mannheim,
Germany). DNA was extracted using the Maxwell 16 SEV
automated extraction system (Promega co., Madison, WI,
USA). mRNA was extracted from 1×106 cells, with TRIzol
(R) Reagent (Invitrogen Life Technologies, Inc., Paisley,
UK) according to the manufacturer's instructions, with more
Table 1 The clinical and laboratory features of JAK2V617F-positive PV and ET patients at diagnosis and follow-up
Clinical and laboratory variables PV with treatment ET with treatment PV at diagnosis ET at diagnosis
Patients 10 16 11 12
Gender (M/F) 5/5 6/10 6/5 2/10
Age at diagnosisa 64.5 (37–77) 65 (20–92) 57 (21–74) 56 (39–87)
Splenomegaly at diagnosis 0/10 0/16 1/11 1/12
Hepatomegaly at diagnosis 2/10 2/16 1/11 0/12
Hemoglobin (g/100 mL) at diagnosisa 20.05 (17.5–22.5) 15.2 (12.5–16.4) 15.5 (14.2–21.3) 13.9 (11.9–19.5)
Hematocrit at diagnosisa 58 (51.1–66.4) 45.9 (38.5–49.4) 46.3 (42.7–61) 43 (39.2–59)
WBC (×109/L) at diagnosisa 11.1 (5.91–14.7) 9.61 (5.96–19.2) 8.44 (5.2–14.34) 10.2 (6.9–14.8)
Platelets (×109/L) at diagnosisa 436.5 (305–1328) 821 (552–11580) 582 (215–819) 655 (538–996)
Increased LDH at diagnosis 4/10 3/16 1/11 1/2
Thrombotic events at diagnosis 0/10 3/16 2/11 1/12
Hemorrhagic events at diagnosis 0/10 2/16 0/11 0/12
Thrombotic events after diagnosis 4/10 3/16 – –
Hemorrhagic events after diagnosis 0/10 0/16 – –
JAK2V617F allele burdena 20.53% (1.64–100) 6.95% (0.67–29.52) 36.84% (2.32–128.87) 23.45% (2.32–36.09)
Disease duration in months 60.5 (1–122) 118 (4–216) 0 0
Treatment duration in monthsa 60.5 (1–122) 118 (4–216) 0 0
Response to HU treatment 4/10 7/16 – –
PV polycythemia vera, ET essential thrombocythemia, HU hydroxyurea, M male, F female, WBC white blood cells, LDH lactate dehydrogenase,
NA not applicable
aMedian value (range) is reported
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than 90% granulocytes. Lymphocyte contamination was
assessed in five samples by flow cytometry, and was less
than 2% of the total cell count. DNA and RNA quantity and
quality were assessed on a ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA) for low-
density array experiments, and by nanoelectrophoresis using
the Nano lab-on-a-chip assay for total eukaryotic RNA
(Bioanalyzer, Agilent Technologies, Palo Alto, CA, USA)
for microarrays. Retrotranscription was performed with a
MMLV-modified enzyme, according to manufacturer's
instructions (Applied Biosystems, Palo Alto, CA, USA).
Mutational screening for JAK2V617F was performed with
real-time (RT) PCR using DNA from whole peripheral blood
from the study sample [14, 15].
Microarray analyses
As screening proceeding, 14 samples from JAK2 V617F-
positive patients diagnosed with MPN (3 PV and 11 ET)
were included in the study, as well as 20 samples from
healthy control donors (in four pools from five samples); 11
MPN were under treatment and 3 were under no treatment.
Microarray expression profiles were obtained using the
Whole Human Genome Oligo Microarray Kit (Agilent
Technologies, Inc., Santa Clara, CA, USA). Hybridization
was performed with Stratagene Universal Human Reference
RNA, and a mix of tumor cell lines (Agilent Technologies
Stratagene, Inc., Santa Clara, CA, USA). Briefly, for each
sample, 2 μg of total RNAwas mixed with 2 μL of a 5,000-
fold dilution of Agilent's Two-Color Spike-in RNA control.
The mixture was amplified using the low-input RNA
amplification kit (Agilent Technologies Inc., Santa Clara,
CA, USA). Following amplification and labeling with Cy3,
each sample was assessed on the Nanodrop ND-1000
(NanoDrop Technologies, Wilmington, DE, USA) to
measure yield and specific activity. The amplified and
labeled samples were hybridized in a rotating oven to
Agilent 44K human whole genome microarrays, accord-
ing to the manufacturer's instructions. The images were
scanned with a G2565BA Microarray Scanner System
(Agilent Technologies Inc., Santa Clara, CA, USA). The
data were processed and normalized with the use of
Feature Extraction (v.9.0) software. Each time point was
additionally normalized to time zero. Genes with more
than 10% missing values were discarded. Normalized log2
ratios were scaled between arrays to make all data
comparable, and processed again with pre-processor of
GEPAS 3.1 (http://gepas3.bioinfo.cipf.es/) to purify the
data.
The student's t test was employed as statistical tool in the
gene expression pattern analysis suite (GEPAS 3.1),
Pomelo II (http://pomelo2.bioinfo.cnio.es/) and gene set
enrichment analysis (GSEA) programs, used to interpret
gene expression data and to determine statistical signifi-
cance of differential gene expression, as described [16].
The supervised classification of healthy control donors,
ET and PV samples into categories was performed.
Low-density quantitative array (LDA)
To reassess microarray data, 40 JAK2V617F -positive patients,
diagnosed with MPN were included in the study: 20 MPN
patients receiving HU treatment (10 PV and 10 ET) and 20
MPN newly diagnosed patients (10 PV and 10 ET), used as
control population to assay the influence of phenotype. Eight
SE to hypoxemia as well as ten healthy control donors (in
two pools from five samples) were also included in the study.
Related to the 20 MPN patients with HU treatment, 9 of
them showed response to HU (four PV and five ET) and 11
were non-responders (six PV and five ET). Among the MPN
patients with HU treatment, two PV and three ET patients
had been previously included in the microarray assay
Eighty-four genes were selected for their differential
expression from several different dicothomous analyses in
the microarray study. Another nine genes, though without
differential expression in microarray analysis, were selected
for their key role in erythropoiesis, thrombopoiesis, or
signaling pathways in MPN; and three housekeeping genes
(GADPH, 18 s rRNA, and ABL1) were also included
(Supplementary Table 1: Supplementary Data). All these
genes were assayed by quantitative PCR (using the 96
TaqMan Low Density Arrays platform LDA). Besides, three
individual TaqMan assays were performed with three
additional genes of interest according to other MPN studies,
in the same samples of patients.
Custom-made TaqMan low-density arrays with a setup of
96 different genes were applied for relative mRNA quantifi-
cation. cDNA samples were subjected to RT-PCR in duplicate
in an ABI PRISM 7900HT Sequence Detection System
(Applied Biosystems, Palo Alto, CA, USA). Relative expres-
sion of each gene was quantified by the comparative cycle
threshold (Ct) method, using the Abelson murine leukemia
viral oncogene homolog 1 (ABL1) as an endogenous control.
Gene expression quantification was achieved using the
comparative Ct method for relative quantification, in which
the amount of target is expressed as 2ΔCt [15].
Statistical analyses
Statistical analyses of gene expression results in LDA, and of
the clinical and biological data and their relationship with the
gene expression data were performed using the SPSS15
software (SPSS Inc., Chicago, Illinois, USA). Differences
between non-normally distributed group data were analyzed
using the non-parametric Wilcoxon analysis. Statistical
significance was considered when P value was less than 0.05.
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Results
Microarray results based on biological and functional
pathways analyses
Microarray analysis, used as screening test, showed 84
genes with significant differential expression by GSEA
(conditions required in GSEA analysis/core/enrichment/
YES), related to biological and functional pathways of
GSEA tool (significant different expression by GSEA was
considered when P value was <0.05 and/or the false
discovery rate (FDR) was <0.25).
Genes were selected from different analyses performed
in a dichotomic manner: ET versus PV, ET versus controls,
PV versus controls, and MPN with response to HU against
those without response to HU.
Table 2 Differential gene expression of JAK2V617F-positive polycythemia vera (PV) and essential thrombocythemia (ET) patients
Genes ET vs. PV ET vs. PV (with HU treatment) ET vs. PV (at diagnosis) Response to HU treatment
P value Ratio P value Ratio P value Ratio P value Ratio
ET PV ET PV ET PV Yes No
Number of patients 20/20 20 20 10/10 10 10 10/10 10 10 11/9 11 9
ACSL 0.044a 4.072 4.609 0.000a 3.611 5.602 0.598 4.534 3.617 0.017a 4.235 5.060
ANXA1 0.040a 2.282 2.756 0.000a 1.953 3.275 0.975 2.610 2.209 0.020a 2.320 2.973
BTK 0.0032a 0.467 1.636 0.000a −0.707 1.807 0.729 1.642 1.466 0.016a 0.082 1.121
CASP8 0.003a 2.838 3.459 0.000a 2.210 3.775 1.000 3.466 3.144 0.039a 2.667 3.391
CD44 0.008a 2.422 3.229 0.000a 1.796 3.961 0.424 3.049 2.497 0.005a 2.348 3.527
CXCL1 0.054 2.359 3.156 0.000a 1.214 3.168 0.940 3.504 3.144 0.014a 1.713 2.775
EDN1 0.218 −1.292 −0.679 0.002a −1.990 −0.433 0.598 −0.593 −0.926 0.009a −1.818 −0.471
F2R 0.02a −2.409 −2.308 0.091 −2.404 −1.632 0.452 −2.414 −3.019 0.019a −2.420 −1.526
FCER1G 0.0021a 3.511 4.682 0.000a 2.494 5.415 0.497 4.527 3.950 0.004a 3.295 4.760
FRMD4B 0.001a 1.148 2.579 0.000a 0.104 2.931 0.845 2.191 2.228 0.001a 0.735 2.473
GAPDH 0.011a 2.464 3.167 0.000a 1.719 4.164 0.577 3.208 2.170 0.037a 2.520 3.457
GSK3B 0.094 1.550 2.191 0.000a 0.567 2.650 0.220 2.533 1.733 0.024a 1.176 2.137
HMGB2 0.014a 3.188 3.732 0.000a 2.185 4.375 0.869 4.190 3.089 0.014a 2.754 3.924
IGF1R 0.052 2.417 2.703 0.000a 1.715 3.538 0.798 3.120 1.867 0.026a 2.259 3.076
IKZF1 0.022a 1.102 2.187 0.000a 0.503 2.190 0.752 1.700 2.184 0.024a 0.970 1.807
ITGAM 0.065 2.718 3.384 0.000a 1.905 3.912 0.283 3.532 2.857 0.004a 2.400 3.530
JAK2 0.002a 1.527 2.862 0.000a 0.444 2.995 0.892 2.611 2.729 0.008a 1.096 2.482
LITAF 0.002a 4.366 5.142 0.000a 4.146 6.122 0.497 4.586 4.161 0.016a 4.693 5.673
LRMP 0.007a 2.496 3.532 0.000a 1.558 3.740 0.752 3.434 3.324 0.001a 2.134 3.280
LYN 0.002a 4.535 5.686 0.000a 0.648 1.931 0.616 5.321 5.450 0.017a 4.386 5.372
MAP2K1 0.053 1.070 1.683 0.001a 1.931 0.647 0.598 1.493 1.435 0.045a 0.972 1.677
MAPK14 0.006a 3.606 4.314 0.000a 3.200 5.414 0.460 4.012 3.215 0.007a 3.834 4.885
MMP14 0.000a −4.422 −2.794 0.001a −4.430 −2.759 0.003a −4.414 −2.829 0.106 −3.995 −3.105
PECAM1 0.021 2.641 3.562 0.000a 1.676 3.782 0.869 3.605 3.342 0.030a 2.414 3.114
PIK3CA 0.015a −0.490 0.217 0.000a −1.424 0.434 0.752 0.445 0.000 0.020a −0.881 −0.024
PLA2G4A 0.082 −1.904 −1.446 0.002a −2.609 −1.301 0.798 −1.199 −1.590 0.022a −2.289 −1.547
RAF1 0.005a 2.039 2.954 0.000a 1.352 3.082 0.845 2.726 2.826 0.003a 1.811 2.713
S100A4 0.059 3.779 4.334 0.000a 3.072 4.845 0.478 4.486 3.823 0.037a 3.679 4.301
SEC31B 0.114 −0.260 0.194 0.002a −0.463 0.750 0.346 −0.058 −0.391 0.026a −0.184 0.544
SELL 0.005a 3.681 4.666 0.000a 2.765 5.148 0.892 4.596 4.184 0.014a 3.527 4.482
SELP 0.010a −1.000 0.040 0.002a −1.635 0.166 0.641 −0.365 −0.086 0.019a −1.067 −0.327
SKAP2 0.008a 2.230 3.254 0.000a 1.330 3.675 0.845 3.131 2.832 0.013a 2.053 3.052
SPON1 0.469 −5.401 −5.314 0.030a −5.398 −4.389 0.459 −5.403 −6.239 0.027a −5.269 −4.435
TAP1 0.072 2.677 3.522 0.000a 2.441 3.923 0.684 2.913 3.121 0.042a 2.921 3.500
YWHAH 0.025a 1.650 2.436 0.000a 1.188 2.937 0.660 2.137 1.880 0.034a 1.672 2.538
a Results of the low-density array (LDA) analysis (P<0.05) and results of Wilcoxon analyses between clinical and laboratory features relative to
the gene expression profile are shown
942 Ann Hematol (2011) 90:939–946
Low-density array analysis
Gene expression profile and response to HU treatment
A set of 34 genes were found to be differentially expressed in
MPN patients who either responded or showed no response to
HU treatment, and were significantly overexpressed in those
patients with no response (Table 2; Fig. 1). Interestingly, the
following genes were significantly overexpressed in patients
who showed no response to HU treatment: JAK2 (ER=2.482
vs. 1.096; P=0.008), IGF1R (ER=3.076 vs. 2.259; P=0.026),
MAPK14 (ER=4.885 vs. 3.834; P=0.007), FCRE1G (ER=
4.760 vs. 3.295; P=0.004), LYN (ER=5.372 vs. 4.386; P=
0.017), BTK (ER=1.121 vs. 0.082; P=0.016), and PIK3CA
(ER=4.826 vs. 3.731; P=0.011) (Fig. 1).
JAK2 was overexpressed in patients who did not
respond to treatment; and in patients who did respond to
treatment, JAK2 expression was lowered to equivalent
levels to those of SE patients and healthy controls. A
similar gene expression pattern was observed for MAPK14,
FCRE1G, LYN, BTK, and PIK3CA (Fig. 1).
These differences were not due to disease duration
because when we compared patients with a short disease
duration (below 2 years) and patients with a long disease
duration (over 2 years) no differences in gene expression
profile were found (Supplementary Table 2, Supplementary
Data).
The gene expression profile of the control group was
similar to that of patients who responded to HU treatment.
JAK2 allele burden quantification
In order to assay if the lowering expression of JAK2 gene
was due to a decrease of the JAK2V617F allele burden, it
was measured in patients at diagnosis and under HU
treatment. When measured after HU treatment, JAK2V617F
allele burden diminished in PV, but only in a significant
manner in ET (P=0.003). However, the allele burden
differences between patients who responded, or those who
did not respond to HU, were not statistically significant
(Fig. 1).
Gene expression profile associated with response
is not influenced by phenotypic diversity
To assay whether the different gene expression profile
between responders to HU treatment and the non-responder
group could be due to phenotypical differences, gene
expression of patients under HU treatment was compared
with a balanced population of patients at diagnosis.
Upon separate analysis of samples from PV and ET
patients receiving HU treatment, and those patients at
diagnosis, only one gene, MMP14, was overexpressed in
PV newly diagnosed patients compared to ET at diagnosis.
Moreover, this overexpression was maintained when
comparison was established between treated and untreated
ET patients against PV treated and untreated (ER: expres-
sion ratios=−4.442 vs.−2.794; P=0.000) (Table 2; Fig. 2).
Correlation between clinical and laboratory features
and gene expression profile in PV and ET
Clinical and laboratory variables, referred in Table 1 were
analyzed and compared in a dichotomic manner with gene
expression profile to search correlates: (1) at diagnosis:
gender, age, splenomegaly, hepatomegaly, hemoglobin,
hematocrit, white blood cells, platelets, lactate dehydroge-
nase, thrombotic events, hemorrhagic events, JAK2V617F
allele burden; (2) and in the follow up: disease duration,
treatment duration, thrombotic events after diagnosis,
hemorrhagic events after diagnosis, and response to HU
treatment (Supplementary Table 2: Supplementary Data).
Discussion
Microarray analysis looking for a differential gene finger-
print profile between JAK2V617F MPN different groups
treated with HU resulted in the identification of 84 genes
with significant differential expression. These genes play
Fig. 1 MMP14 gene is differentially expressed in JAK2 V617F
positive polycythemia vera (PV) and essential thrombocythemia
(ET) patients at diagnosis. Box plot of MMP14 expression ratios: Y-
axis: MMP14 ratios; X-axis: from left to right: healthy controls, SE,
PV and ET patients
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key roles as transcription factors (LYN, PIK3CA), in MAP
kinase (MAPK) signaling pathways (MAPK14, RAF1,
RASA1, YWHAH), as tyrosine kinases (JAK2, BTK), in
development and function of the hematological system
(CD44, MAP1B, JARID2, HMGB2, IKZF1), and in other
signaling and apoptotic pathways (SKAP2, PLAUR,
LRMP). Some of these genes have been previously outlined
in other microarray analyses or functional studies [17, 18].
Fig. 2 The differential gene expression profile in polycythemia vera
(PV) and essential thrombocythemia (ET) patients relative to their
response to hydroxyurea (HU) treatment. Box plot of JAK2, MAPK14,
PIK3CA and FCER1G expression ratios: Y axis: ratio; X axis: in every
box plot compared groups: healthy controls, SE, PV and ET
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When we looked at this gene signature with LDA (a
real-time PCR approach), we observed a differential gene
expression profile in MPN patients according to response to
HU. We found 34 genes that were overexpressed in patients
who did not respond to HU treatment. Interestingly, among
these 34 overexpressed genes, some participate in four
important proliferative pathways: MAPK14, MAP2K1,
RAF1 (MAPK pathway), PIK3CA, FRMD4B (AKT path-
way), LYN, FCER1G, BTK, SKAP2 (Src family kinase,
SFK), and JAK2, IGFR1 (JAK2 pathway). Gene expression
did not change with disease evolution but it did with the
response to treatment.
A number of genes in the MAPK pathway were
differentially expressed in MPN patients relative to their
response to HU. An overexpression of genes implicated in
this pathway was shown in the group who did not respond
to HU, notably RAF1, MAP2K1, and MAPK14. In the
group of patients who did respond to HU treatment, MAPK
genes expression was lowered to levels equivalent to those
observed in SE patients and controls. The activation and
overexpression of MAPK14 has been described in PV
pathogenesis [1, 17, 19]. Overexpression of genes in the
MAPK pathway may be involved in the lack of response to
HU treatment, although by yet unknown mechanisms, and
probably related to JAK2 gene expression.
The AKT gene, with a crucial role in the AKT pathway,
has been widely implicated in the pathogenesis of MPN
(PV and ET), by overactivation and overexpression [1, 19,
20]. We found that the PIK3CA gene, an AKT regulator,
was also overexpressed in patients who did not respond to
HU treatment. This overexpression may also be involved in
the lack of response to treatment, and correlate with JAK2
overexpression.
The SFK are also suggested to contribute to signaling by
EpoR [21], although they seem not to be indispensable for
the PV phenotype induced by JAK2V617F, as shown by
bone marrow reconstitution studies in mice deficient for
LYN, FYN, or Fgr kinases [22]. Our results showed that
BTK and other SFK members, such as LYN, FCER1G, and
SKAP2, were overexpressed in patients who did not
respond to HU treatment. Thus, an overexpression of these
genes may be related to a lack of response to HU, while
decreased levels, similar to those observed in SE patients
and controls, may be related to a good response to HU
treatment. These findings could be of great interest, since
those patients with overexpressed SFK genes may benefit
from treatment with SFK inhibitors (such as Dasatinib). In
fact, some groups are testing Dasatinib in cell cultures from
PV patients with some success [22, 23].
In addition, HU treatment in MPN patients showed a
resulting decrease in, not only the JAK2V617F allele burden,
but also in response to treatment in JAK2 gene expression.
Interestingly, while JAK2 was overexpressed in patients
who did not respond to treatment, in those patients who
responded well to HU, JAK2 gene expression was lowered
to levels equivalent to those of SE patients and healthy
controls. We also showed that although the JAK2V617F
allele burden diminished after HU treatment, as reported
by others [24], there was no statistical difference between
the levels of the JAK2V617F allele burden in our different
patient groups, with or without a response to HU.
However, JAK2 gene differential expression between the
same groups of patients with or without a response to HU
treatment was statistically significant. Thus, JAK2 over-
expression may reflect of lack of response to HU, although
the mechanism for this is unknown. The criteria for a lack
of response to HU treatment could thus be expressed,
either by the mutant allele burden, and/or by JAK2
overexpression. To our knowledge, this is the first study
to show these results, and could be useful as an additional
parameter of response.
Finally, we found that this different pattern of expression
was not due to phenotypic differences, as demonstrated
when compared with a control group of patients without
treatment.
Only one gene, MMP14, remained significant between
PV and ET patients at diagnosis. MMP14 is a matrix
metalloprotease involved, among other things, in tumor
metastasis. It has an indirect connection with some
proliferative pathways, such as the MAPK pathway. Some
authors have made reference to the importance of the
MAPK pathway in PV pathogenesis, and its connection
with JAK2 [1, 17]. On the other hand, MMP14 has also
been demonstrated to be overexpressed in PMF, and is
modulated by TIMP2, which has erythroid-potentiating
activity [25, 26]. Thus, the overexpression of MMP14 in
PV, compared with ET, may contribute to the final
myeloproliferative phenotype of PV by enhancing the
commitment to erythropoiesis via MAPK pathway, either
by JAK/STAT, TIMP2, or by alternative routes.
To conclude, our results suggest that a differential
molecular fingerprint of genes distinguishes MPN patients
who either do or do not respond to HU treatment. JAK2,
MAPK14, PIK3CA, and SFK genes are overexpressed in
patients who do not respond to HU. In our group of patients,
the JAK2V617F allele burden decreased with HU treatment;
however, a significant diminution was not observed in
response to treatment. On the other hand, patients with no
response to treatment overexpressed JAK2. These results
need to be confirmed with further functional studies.
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HDAC inhibitors induce cell cycle arrest, activate the apoptotic
extrinsic pathway and synergize with a novel PIM inhibitor in
Hodgkin lymphoma-derived cell lines
Molecular studies have shown that the tumoural component of
classical Hodgkin lymphoma (cHL), Hodgkin and Reed-
Sternberg (HRS) cells, shows a profound disturbance of the
cell-cycle and apoptosis regulation (Ku¨ppers, 2009). Although
cHL is often curable, there remains a group of patients who do
not achieve remission with initial therapy and about 30%
patients will die of the disease. Therefore, novel targeted agents
need to be developed to reduce treatment-related toxicity and
to further patient outcome.
Histone deacetylase inhibitors (HDACi) are new agents with
demonstrable preclinical antitumour activity in a wide range of
malignancies. However, their exact mechanism of action
remains to be fully elucidated.
The rationale for evaluating HDACi in cHL is based on
observations implicating epigenetics in the HRS-phenotype, on
high levels of HDACs in approximately 80% cHL cases
(Gloghini et al, 2009), and on the deregulation in cHL of
pathways that can be restored by HDACi in other cancer types
(Garcia et al, 2003).
In order to test drugs therapeutically useful in cHL, we
used the Connectivity Map (Cmap) program and a gene
expression signature from poor-prognosis cHL-patients,
(Sanchez-Aguilera et al, 2006). Cmap revealed two HDACi,
Trichostatin A and SAHA, to be the most specific drugs able to
reverse the cHL-chemoresistance signature, suggesting that
HDACi might be very efficient in cHL-treatment (Fig S1A).
To demonstrate HDACi efficiency as antitumoral agents in
cHL, four cHL-derived cell lines were treated with two HDACi
(suberoylanilide hydroxamic acid (SAHA) and sodium buty-
rate (SB)). HDACi significantly reduced cell viability in all cHL
cell lines in a dose-dependent manner (Fig 1A), with different
effects on cell-cycle in each cell line. Both HDACi induced a
time-dependent G2/M phase arrest in L428 and KMH2 cell
lines, similar to recent findings with SAHA (Buglio et al, 2008)
and depsipeptide (Hartlapp et al, 2009); while HDLM2 and
L1236 cell lines did not experience cell-cycle arrest (Figs 1B
and S1B). Moreover, a significant and time-dependent increase
in apoptosis in all cell lines was observed after HDACi-
treatment (Fig 1C).
As L428 and KMH2 seemed to respond similarly to HDACi
(G2/M arrest), while the response of HDLM2 and L1236 was
different (no cell-cycle arrest), L428 was used as the sensitive
cell line and HDLM2 as the resistant cell line in further
experiments.
To ensure that HDACi were able to target HDACs we
confirmed histones H3 and H4 hyperacetylation upon
HDACi-treatment (Fig S2A).
The differential sensitivity observed in cHL-cell lines after
HDACi-treatment could be explained by differences in basal
status of acetylated histones and gene expression profile
(Fig S2A,B), because the HDLM2 cell line, with a poor-
prognosis molecular profile compared with L428, and a
inactivating TP53 mutation (Feuerborn et al, 2006), is more
resistant to HDACi-apoptosis. Moreover, overexpression of
antiapoptotic proteins, such as Bcl2, is known to be involved in
resistance mechanisms to HDACi.
Since histone-acetylation is a well-known mechanism of
gene expression regulation, we evaluated genes that showed
modified expression after HDACi-treatment. Data obtained
from three independent hybridizations for each time point
were analysed by a t-test. This approach revealed deregulation
of <5% of the whole genome in each HDACi-treated cHL-cell
line (false discovery rate [FDR]<0Æ1) in agreement with most
of studies performed in HDACi-treated cancer cell lines. Gene
Set Enrichment Analysis (GSEA) identified several pathways
altered by HDACi (Fig 1D). The t-test found 1946 differen-
Fig 1. Effect of HDACi on cHL-derived cell lines. L428, KMH2, HDLM2 and L1236 cell lines were treated with SB or SAHA at several doses and
times, and (A) cell viability, (B) cell cycle, (C) apoptosis, and (D–E) gene expression changes were determined. (A) Cell viability was measured by
ATP intracellular content and calculated as the percentage of DMSO-treated cells; 50% inhibitory concentration (IC50) values for 48 h are shown.
(B) L428 and KMH2 cells were arrested at G2/M phase and underwent cell death in a time-dependent manner. HDLM2 and L1236 cells were not
arrested, but cell death was induced after long treatments. Numbers indicate the percentage of HDACi-treated cells minus percentage of DMSO-
treated cells (mean ± SEM) (*indicates statistically significant differences from the control, P < 0Æ05). (C) Apoptosis was calculated as the percentage
of non-viable cells (AnnexinV+/Propidium Iodide- and AnnexinV+/Propidium Iodide+ cells) in HDACi-treated cells minus the percentage of non-
viable cells in DMSO-treated cells (mean ± SEM) (*indicates statistically significant differences from the control, P < 0Æ05). (D) Altered pathways in
L428 and HDLM2 cell lines after treatment with 1 mmol/l SB and 2 lmol/l SAHA at the indicated times (FDR < 0Æ25). Red, green and white indicate
upregulation, downregulation and no significant deregulation, respectively. Intensity of colours indicates the degree of significance (dark:
FDR < 0Æ05; intermediate: 0Æ05 < FDR < 0Æ1; light: 0Æ1 < FDR < 0Æ25). (E) Hierarchical clustering with all 1946 significantly deregulated genes
(FDR < 0Æ1) in L428 and HDLM2 cell lines after treatment with 1 mmol/l SB and 2 lmol/l SAHA at the indicated times. Data were normalized with
respect to untreated control cells. Highlighted genes indicate the mechanism of action of HDACi in cHL cell lines.
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tially expressed genes (FDR < 0Æ1) from 0 h to at least one
subsequent time point in both cHL-cell lines after treatment
(Fig 1E). In accordance with the functional analysis, a number
of cell cycle (CDKN1A, CDKN2D) and apoptosis genes
(TNFSF9, TNFSF10, TNFRSF12A, BCL2L11 and BCL2L12)
were significantly deregulated. A number of genes associated
with chemoresistance in cHL were consistently downregulated
by HDACi (Fig 1E). This supports that HDACi could be added
to current chemotherapy protocols, given that a number of
evidences have indicated the benefits of the combined treat-
ment (Bhalla et al, 2009). The complete list of significant genes
is available in Table S1.
GSEA analyses identified apoptosis as one of the most
important HDACi-modified pathways. To confirm these
alterations, we measured the key proteins involved in apop-
tosis. Consistent with the results of our GSEA, we observed
subtle HDACi-effects on Bax levels (intrinsic apoptosis) and a
release of Cytochrome-c (Fig S2C). Moreover, there was a
decrease in ProCaspase-8 and Fas levels, indicating extrinsic
apoptotic pathway activation. Surprisingly and in contrast with
many other tumour entities, HRS cells strongly expressed Fas,
activating nuclear factor (NF)-kB transcription factor (Mathas
et al, 2004), and suggesting the importance of death receptor
apoptosis signalling in HRS cells. Furthermore, the extrinsic
apoptotic pathway, alone or in conjunction with the intrinsic
pathway, has already been reported to be induced by SAHA in
other cell types (Gillenwater et al, 2007).
Unexpectedly, we found a strong upregulation of the proto-
oncogene PIM2 in both HDACi-treated cHL-cell lines (Figs 1E
and 2A). Moreover, we have previously observed significant
upregulation of PIM1 (FDR = 0Æ03) and PIM2 (FDR = 0Æ001)
in a series of 29 cHL-patients (Fig S3A) (published data from
Sanchez-Aguilera et al, 2006). These findings prompted us to
hypothesize that HDACi effects could benefit from PIM2
inhibition. We performed cell viability assays with a novel PIM
inhibitor (PIMi) and found it to be efficient in four cHL-cell
lines (Fig 2B). PIMi efficiency was checked by measuring its
target pBAD(Ser112) (Fig S3B).
Finally, we performed experiments with HDACi and PIMi
in cHL-cell lines. The combination SB+PIMi was as efficient
as each single drug in all cell lines but HDLM2, where the
effect was synergistic. However, the combination SAHA+
PIMi enhanced the reduction in cell viability in a synergistic
manner in all four of the cell lines (Combination Index =
0Æ19, 0Æ57, 0Æ73 and 0Æ83 for HDLM2, L428, KMH2 and
L1236, respectively) (Fig 2C). This finding highlights the
importance of SAHA+PIMi combination in cHL therapeutics.
Further studies will be needed to fully understand why PIM2
is upregulated after HDACi-treatment, the underlying mech-
anisms of this drug combination, and the role of PIM1 and
PIM2 in cHL.
In conclusion, we have demonstrated that HDACi exert
antiproliferative and proapoptotic effects on cHL-cell lines by
altering the expression of cell-cycle and apoptosis-genes, with
common and different (cell line-dependent) effects.
Additionally, HDACi can downregulate the expression of
genes associated with chemoresistance in cHL-patients. Impor-
tantly, SAHA acts in a highly synergistic manner with a novel
(A)
(B)
(C)
Fig 2. HDACi have a synergistic effect with a PIM inhibitor. (A) After treatment with HDACi, a significant upregulation of PIM2 was observed in
L428 and HDLM2 cell lines. The expression value of PIM2 was normalized with respect to control untreated cells. (B) Four cHL-derived cell lines
were treated with a novel PIMi for 48 h, and IC50 values were calculated by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay. (C) Cell lines were treated simultaneously with the PIMi and with HDACi (SB and SAHA) for 48 h, using IC50 values of each drug in each cell
line, and cell viability was measured by MTT assay. Data are representative of two independent experiments.
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PIMi in cHL-cell lines. Collectively, our results provide the
proof-
of-principle that justifies the investigation of HDACi in
combination with PIM inhibitors for cHL-treatment.
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Figure S1. (A) Output from Connectivity Map (Cmap). Top
ten pharmaceutical perturbagens identified through the Cmap
that reverse cHL-chemoresistance signature (with negative
enrichment score) in the panel of cell lines included in the
software. Trichostatin A and SAHA, also known as vorinostat,
belong to the HDACi family. (B) Cell-cycle changes induced by
HDACi in cHL-derived cell lines. HDACi induced a time- and
dose-dependent G2/M arrest and cell death in L428 and
KMH2 cells, while no cell cycle arrest but cell death after high
doses/long treatments was induced in HDLM2 and L1236 cells.
Numbers indicate mean ± SEM of at least three independent
experiments.
Figure S2.Molecular alterations induced by HDACi in cHL-
derived cell lines. (A) Effect of HDACi on histone acetylation:
L428 and HDLM2 cell lines were treated with SB (1 mmol/l)
and SAHA (2 lmol/l) at the indicated times, and levels of
acetylated and total histones H3 and H4 were measured by
western blot. Numbers represent the ratio of acetylated/total
histones. (B) Basal differentially expressed genes between L428
and HDLM2 cell lines (FDR < 0Æ05). Highlighted genes could
explain the different sensitivity and response to HDACi
treatment. (C) Effect of HDACi on key proteins involved in
apoptosis: L428 and HDLM2 cell lines were treated with SB
(1 mmol/l) and SAHA (2 lmol/l) at the indicated times, and
levels of whole-cell lysed proteins were measured by western
blot. Numbers represent the ratio of measurements of each
protein relative to a-tubulin levels.
Figure S3. (A) PIM1 and PIM2 expression levels in cHL. Two
sorted centroblasts samples, five lymph nodes and a series of 29
cHL cases (14 with favourable outcome and 15 with unfavour-
able outcome) were profiled for PIM1 and PIM2 expression
levels. (B) Levels of pBAD(Ser112) and BAD were measured
after treatment with IC50 values of PIMi in cHL-cell lines.
Table S1. Expression values normalized with respect to
untreated control cHL cell lines and a brief description
extracted from Feature Extraction software of all 1946
significantly deregulated genes identified by a t-test
(FDR < 0Æ1) in L428 and HDLM2 cell lines after treatment
with 1 mmol/l SB and 2 lmol/l SAHA at the indicated times.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the article.
Keywords: HDAC inhibitors, Hodgkin lymphoma, gene
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CHIC cells: a novel ALK+ cell line derived from a relapsed
anaplastic large cell lymphoma
Since the initial description of anaplastic large cell lymphoma
(ALCL) as a proliferation of large CD30+ lymphoid cells, the
morphological spectrum of ALCL positive for anaplastic
lymphoma kinase (ALCL, ALK+) has expanded, and beyond
the common pattern most frequently encountered, several
variants have been identified, including the lymphohistiocytic
and the small cell patterns (Swerdlow et al, 2008). Recent data
suggest that tumours with variant morphology may carry a
worse prognosis than the common pattern, with a tendency to
more frequent and early relapses (Lamant et al, 2007).
Only ten ALK+ ALCL cell lines are currently available, and
most were derived from tumours demonstrating the common
type morphology (Drexler & MacLeod, 2004). We have
established a novel cell line (CHIC) from the cerebrospinal
fluid of a 32-year-old man with relapsing/refractory ALK+
ALCL whose initial tumour exhibited lymphohistiocytic
features (Table I, Fig 1A–C).
The cell line was derived with no feeder layer or addition of
growth factors and, in contrast to others, did not require prior
passage into immunodeficient animals. CHIC cells proliferated
in permanent uninterrupted suspension culture for more than
12 months as single non-attached cells or in loose clumps.
They were frozen and stored in liquid nitrogen for 1 year, and
recovered after thawing without any loss of cellular features or
cell viability.
CHIC cells are large and pleomorphic, morphologically and
immunophenotypically similar to the patient’s malignancy
(Table I, Fig 1D–E), showing positivity for CD30 and EMA,
with nuclear and cytoplasmic expression of p-ALK. The cells
are negative for T-cell associated markers, express CD43 and
have a cytotoxic phenotype (perforin+, granzyme B+, TIA-
1+). Expanded immunophenotyping demonstrated the expres-
sion of classical activation markers, such as CD25, CD26,
CD45RO and HLA-DR. In situ hybridization confirmed the
absence of Epstein-Barr virus (EBV). Cytogenetics revealed
a complex karyotype including the t(2;5)(p23;q35) trans-
location, inducing NPM1-ALK fusion. The same TRG gene
rearrangement was evidenced in CHIC cells, in xenografts (see
below) and in the patient’s tumour, demonstrating their T-cell
origin and their derivation from one common clone.
Subcutaneous xenografts of CHIC cells were tumourigenic to
non-obese diabetic severe combined immunodeficiency (NOD/
SCID) mice. The tumours growing at the inoculation sites were
histologically and immunophenotypically similar to the pa-
tient’s lymphoma and the cell line (Table I, Fig 1F–H). Autopsy
showed no evidence of metastases. This xenograft mouse model
was optimized by the use of Matrigel, enhancing engraftment of
CHIC cells and allowing the development of tumours in a
reasonable time frame (62% of mice had developed tumours at
2 weeks after injection and 81% at 8 weeks).
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